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Neuroblastoma is a biologically heterogeneous tumour developed from 
neural crest cells. It is the most common extracranial solid tumour in children. 
Conventional therapies include surgery, radiotherapy and chemotherapy have 
been used to treat this malignancy. However, recurrence is frequently occurred in 
primary or metastatic tumour sites. It remains to be one of the greatest challenges 
in pediatric oncology. Upon intensive demand of novel drugs which are 
equivalently or more potent but less cytotoxic and detrimental to normal cells 
than the conventional chemotherapy, scientists have started to investigate the 
possibility of using phytochemicals in cancer treatments. Among them, 
Traditional Chinese Medicine has attracted the attention of many scientists. 
Banlangen is the root of plants such as Polygonum tinctorium, Isatis 
tinctoria and Baphicacanthus cusia. It has been customarily used in the treatment 
of influenza and as an active component in a traditional Chinese recipe, Danggui 
Longhui Wan (當歸育6薈九)，that is used in chronic myelocytic leukemia 
treatment. Tryptanthrin is an indoloquinazoline alkaloid and indirubin-3'-oxime 
(I3M) is an indigo alkaloid that were isolated from Banlangen. These two 
alkaloids were found to possess anti-tumour effects on various kinds of cancer. 




In the present study, tryptanthrin and I3M were investigated for their 
modulatory effects on the proliferation, differentiation and apoptosis of 
neuroblastoma cells. Both tryptanthrin and I3M were found to exert potent 
anti-proliferative effect on the growth of a murine neuroblastoma Neuro-2a BU-1 
cell line in a dose- and time- dependent manner. The estimated IC50 values of 
tryptanthrin and I3M were 1.3 i^M and 0.45 i^M respectively in 48-hour 
treatment. Interestingly, they did not exert significant cytotoxic effects on normal 
cells such as murine peritoneal macrophages, bone marrow cells and rat primary 
cortical neurons. I3M also induced Go/Gi phase arrest in Neuro-2a BU-1 cells. 
The occurrence of DNA fragmentation and chromatin condensation indicates that 
I3M could trigger apoptosis in Neuro-2a BU-1 cells after 24-hour treatment. The 
I3M-induced apoptosis was caspase-dependent as I3M treatment enhanced the 
activities of caspase 3，8, 9 in Neuro-2a BU-1 cells. The intrinsic pathway of 
apoptosis was initiated partly due to the cleavage and activation of Bid as shown 
by the Westem blot analysis. The expression of pro-apoptotic protein Bax was 
increased whereas the expression of anti-apoptotic protein Bcl-xtwas decreased 
in I3M-treated Neuro-2a BU-1 cells. Moreover, the induction of apoptosis by 




On the other hand, tryptanthrin arrested Neuro-2a BU-1 cells in G2/M phase 
of the cell cycle in a dose- and time-dependent manner. The expression of G2M 
phase-regulatory cyclins (cyclin A and cyclin B1) and the corresponding 
cyclin-dependent kinase (CDK1) was down-regulated at the protein level. 
Tryptanthrin also triggered neuronal cell differentiation of Neuro-2a BU-1 cells 
after 48-hour treatment. Characteristics of morphological differentiation such as 
enlargement of cell body and outgrowth of neurites were observed by 
Hemacolor® staining. Functional differentiation of Neuro-2a BU-1 cells was 
shown by the dose-dependent increase in acetylcholine esterase (AChE) activity 
as determined by the colorimetric assay. Mechanistic studies of the 
differentiation-inducing activity of tryptanthrin showed that increased expression 
of the tau protein may be involved in the neurite extension. Up-regulation of 
c-Myc and down-regulation of Ras may also play an important role in the 
tryptanthrin-induced neuronal cell differentiation. 
Collectively, our results clearly demonstrated that both tryptanthrin and 
indirubin-3'-oxime could exhibit potent growth-inhibitory activity on the murine 
neuroblastoma Neuro-2a BU-1 cells. Future studies will further elucidate the 
action mechanisms and signaling pathways that might be involved in the 
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過四十八小時，色胺酮和錠玉紅-3’-膀的估計忙5。値分別爲1.3 ^iM和0.45 . 
^iM。有趣的是，他們對正常細胞如小鼠腹腔巨_細胞、骨髓細胞和大鼠原 













其抑制力是隨時間和劑量而增加的。G2/M期調控細胞週期素（cyclin A 和 
0701丨0 81)和相應的細胞週期蛋白依賴性激酶（CycUn-dependentkinase 1 )的 
蛋白表達皆被下調。經過四十八小時的處理，色胺酮也誘導Neuro-2a B U - 1 
細胞分化°當Neuro-2a BU-1細胞被Hemacolor®染色後，可看到形態分化 
的細胞特徵，即細胞體擴大和經軸突的延伸。在探討功能分化方面，利用比 
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Chapter 1 
1.1 Neuroblastoma 
1.1.1 An overview of neuroblastoma 
Neuroblastoma is the most common extracranial solid tumour among 
children. It is a malignant embryonal tumour developed from the neural crest 
cells. During embryonic development, neural crest cells migrate and differentiate 
into cell lineages such as melanocytes, sensory neurons and sympathetic neurons. 
The course of differentiation is governed and regulated by several genes, e.g. 
MASH1, Id-2 and MYCN. Some of these genes were mapped to the regions of 
genetic aberrations in neuroblastoma and these abnormalities occur during neural 
development may finally lead to neuroblastoma (Nakagawara, 2005). The term 
"neuroblastoma" was first coined by a pathologist named James Homer Wright 
in 1910. He found that tumour cells associated with fibrils shared the same 
morphology as cells developed from the sympathetic nervous system and adrenal 
medulla. He regarded the tumour cells were arisen from migrated primitive nerve 
cells and termed them "rosettes" which means ball-like aggregations of 
neurocytes (Wright, 1910). Over a century, although scientists have gained more 
knowledge in the biology of neuroblastoma, the etiology still remains unclear. 
The event-free survival rate in high-risk patients is still low and it remains to be 
the greatest challenge to clinicians. 
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1.1.2 Epidemiology of neuroblastoma 
According to the International Classification of Childhood Cancer system, 
the epidemiological data under the category of "neuroblastomas" refer to both 
neuroblastoma and ganglioblastoma (Goodman et al., 1999) Therefore, the term 
"neuroblastomas" used in this section refers to neuroblastoma and 
ganglioblastoma. For the epidemiology studies of neuroblastomas, all reported 
cases are limited to age younger than 15-year-old as the occurrence in 
adolescents older than 15 is rare. Every year, there are 650 and 1,500 new cases 
in the United State and Europe respectively. It accounts for about 28% of all 
cancer diagnosed in US and European infants (Gumey et aL, 1997; Spix et al.’ 
2006). A study from the National Cancer Institute showed that neuroblastomas 
accounted for 7.8% of all pediatric cancers in the period of 1975 to 1995 
(Goodman et cd., 1999). Among infancy, the incidence rate of neuroblastomas 
(53.4) was the highest among all infancy cancers including leukemia (51.8). 
However, the occurrence is strongly age-dependent with the incidence rate 
decreased drastically from 64/million in the infancy to 29/million in the second 
year of life (Goodman et aL, 1999). 
For age-specific incidence, there was no significant difference between male 
and female with the incidence rate 9.4/million and 8.9/million respectively. For 
- 3 -
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race-Specific incidence, the Blacks to Whites ratio was 1.7:1 in male and 1.9:1 in 
female (Goodman et al., 1999). A recent study in US showed that the incidence 
rates in Whites, Blacks and Hispanics were 12.8/million, 9.6/million and 
9.9/million respectively. However, it is still not strong enough to support any race 
is predisposed to neuroblastomas as the higher incidence rate in Whites may be 
the result ofhigh medical surveillance among the population (Parkin, 1998). 
Although the etiology of neuroblastomas remains unclear, data from 
epidemiological studies have suggested some possible risk factors involved in 
the cancer. Factors that are positively associated with neuroblastoma include 
medications taken or alcohol consumed during pregnancy, sex hormones (e.g. 
fertility drug) and low birth weight of infants (Goodman et al., 1999). Factors 
that are negatively associated with neuroblastoma include vitamin supplements, 
folic acid supplements and history of asthma and allergies (Heck et al” 2008). 
Unfortunately, all these factors showed contradiction in different studies and thus 
these reports are not strong enough to provide statistically convincing evidences 
for the risk factors ofneuroblastoma. 
Recent advancements in understanding the biology of neuroblastoma and 
treatment efficacy have led to an increase in 5-year-survival rate. The 
5-year-survival rate for infancy was 83% and the rate was halved in children 
- 4 -
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older than one year old under treatment (Goodman et cd., 1999). A similar trend 
has also been observed in a European study. Moreover, the survival rate 
increased from 37% to 66% in the period of 1987-1992 and 1992-1997 
respectively (Spix et al., 2006). It may due to a higher rate of asymptomatic 
cases being diagnosed in infants and treatment improvement. However, the 
likelihood of survival depends on the age, stage of disease, molecular biologic 
and cytogenetic characteristics of the tumour. Although the survival rates for 
certain subtypes of patients have been increased, the long-term survival rate for 
the high-risk group is still lower than 40% (De Bemardi. et al,, 2003; Mathhay et 
al., 1999). The death rate is still high (10.9/0.1 million annually) (US cancer 
statistics working group 2009) and accounts for 15% of death because of 
childhood cancers (Maris et al., 2007). Back to the situation in Hong Kong, the 
incidence rate was 5.8/million, accounting for 4.1% in all childhood cancers 
(Hong Kong Cancer Registry, 2008). Since only a few cases are available, it is 
difficult to carry out a comprehensive epidemiological study in Hong Kong. 
1.1.3 Clinical presentation of neuroblastoma 
Most patients with neuroblastoma are asymptomatic in early stage but 
various symptoms could be shown during disease progression. Thirty percent of 
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patients would feel pain from metastases to bone or abdominal distension 
whereas 11% of them would lose weight or failed in weight gain. For stage 4S 
patients, massive hepatomegaly would lead to respiratory distress and impaired 
functions of kidney and bowel (Berthold et al.’ 1990). Other than these frequent 
symptoms, some rare symptoms could be observed in a lower frequency. Patients 
with transverse myelopathy would have sphincter abnormalities, sensory deficit 
and back pain (De Bemardi et al, 2001). Opsomyoclonus-ataxia syndrome is 
presented as rapid and irregular eye movements (dancing eyes) and myoclonus 
and ataxia of limbs (dancing feet). Homer's syndrome is presented as irises of 
different colors. 
As mentioned at the beginning, neuroblastoma cells are developed from 
neural crest cells during the embryonic development. It is inevitable that primary 
tumours are found in the sympathetic nervous system. In most cases, primary 
tumour site is found in the adrenal gland, followed by connective, subcutaneous 
and soft tissues (Goodman et al., 1999). Moreover, metastatic disease is 
frequently observed in neuroblastoma. The metastatic pattern follows a 
stage-dependent and non-random distribution. The most common site of 
metastasis is bone marrow followed by bone. This non-random distribution could 
be explained by the ‘‘seed and soil" theory proposed by Stephen Paget in 1889 
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and is supported by other studies (Fidler, 2001). The CXCR4-bearing 
neuroblastoma cells would be attracted by stromal derived factor (SDF-1) in 
bone. Meanwhile, immobilized growth factors such as transforming growth 
factor-beta (TGF-p), insulin-like growth factors I and II and fibroblast growth 
factor (FGF) in bone would recruit circulating tumour cells from blood. Lymph 
node, liver and skin are also common metastatic sites (Sohara et al., 2005). For 
stage 4S patients, tumours exclusively metastasize to liver. Patients in stage 4 
would have their tumours metastasized to bone instead of skin (Rothenberg et al., 
2009). 
Although patients with neuroblastoma may show symptoms as described 
above, many of them could remain asymptomatic which is not favorable for 
diagnosis and would result in a low survival rate. Therefore, some tumour 
markers have been identified in neuroblastoma for diagnosis. Catecholamine 
metabolites including vanillylmandelic acid (VMA) and homovanillic acid (HVA) 
are the most sensitive and specific tumour markers when using high performance 
liquid chromatography (HPLC) and mass spectrometry for identification. 
Neuron-specific enolase (NSE) which is synthesized by neuroblastoma cells 
would increase in serum level to 30-100 ng/mL in patients with poor outcome. It 
is less specific than catecholamines but more useful in prognosis (Simon et al.， 
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2003; Zeltzer et al., 1983). Ferritin secreted from neuroblastoma cells is 
biochemically different from that secreted by normal cells. The serum level is 
useful in prognosis but not for diagnosis and it was found to be the highest in 
stage 4 patients with poor prognosis (Hann et aL, 1981; Hann and Bombardieri, 
2000). 
1.1.4 Diagnosis and clinical assessment of neuroblastoma 
Diagnosis of neuroblastoma could be established in two situations. First, an 
unequivocal pathologic diagnosis is made from tumour tissue by light 
microscopy with or without immunohistology, electron microscopy, increased 
serum or urine level of catecholamine metabolites. Another is bone marrow 
aspirate or trephine biopsy which contains unequivocal tumour cells and 
increased serum or urine level of catecholamine metabolites (Brodeur et al., 
1993). After diagnosis of neuroblastoma, patients would receive a set of 
treatments and the effect of treatments on targeted tumours would be assessed by 
various imaging strategies based on the tumour site together with monitoring 
urinary catecholamine. Computed tomography (CT) is used for the assessment of 
tumours in abdomen, pelvis or mediastinum. Paraspinal lesions are assessed by 
using magnetic resonance imaging (MRI). Metastatic diseases in occult bone or 
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soft tissue can be assessed by ^^Tc- diphosphonate scintigraphy or 
metaiodobenzylguanidine (MIBG) scintigraphy which is selectively concentrated 
in >90% neuroblastoma cells and is highly specific for primary and metastatic 
disease (Figure. 1.1) (Geatti et al., 1985; Voute et al., 1985). In addition, 
PCR-based technology has been applied to monitor the neuroblastoma-specific 
transcripts such as tyrosine hydrolase, ganglioside 2 (GD2) synthase and protein 
gene product 9.5 (PGP9.5) in bone marrow or blood samples (Cheung et al., 
2001; Hoon et al.，2001; Seeger et al, 2000). 
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Figure 1.1 Metaiodobenzylguanidine (MIBG) scintigraphy. Neuroblastoma 
was detected in the primary site adrenal and the metastatic sites including bone, 
abdomen and soft tissues (Maris et aL, 2007). 
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1.1.5 Staging of neuroblastoma 
Before 1990s, neuroblastoma disease staging was assessed by image-based 
and surgery-based systems and thus it was difficult to compare results obtained 
in different institutes. In order to facilitate clinical comparison around the world, 
a new staging system known as the International Neuroblastoma Staging System 
(INSS) was published in an international conference in 1986 (Brodeur et al., 
1988; 1993). The m S S takes several factors including age, MYCN amplification, 
DNA ploidy and tumour cell histology into account to classify the stage of 
disease (Table 1). Although INSS is widely adopted in different parts of the 
world, it encounters difficulties in certain circumstances. For example, 
differences in surgical approach among institutes, localized disease without 
surgery and difficulties in assessment of extra-regional lymph nodes, making 
m S S failed in staging (Olivier et aL, 2003; Simon et aL, 2008). To improve the 
existing staging system, the International Neuroblastoma Risk Group Staging 
System (DsfRGSS) has been developed. It is a pre-surgical staging system based 
on the assessment of disease by imaging studies and bone marrow morphology 
(Cecchetto et al., 2005; Monclair et al., 2009). 
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Table 1. International Neuroblastoma Staging System (INSS) 
INSS ^ MYCN INPC DNA Risk Acie 
stage Status Classification Ploidy® group^ 
1 0-21 yr Any Any Any L 
2A/2B <365 d ^ Any Any L 
>365 d—21 yr Nonamplified Any - L 
>365 d-21 yr Amplified Favorable - L 
>365 d-21 yr Amplified Unfavorable - H 
3 <365 d Nonamplified Any Any I 
<365 d Amplified Any Any H 
>365 d-21 yr Nonamplified Favorable - 1 
>365 d-21 yr Nonamplified Unfavorable - H 
>365 d-21 yr Amplified Any - H 
4 <548 d Nonamplified Any Any I 
<365 d Amplified Any Any H 
>548 d-21 yr Any Any - H 
4S <365 d Nonamplified Favorable >1 L 
<365 d Nonamplified Any =1 I 
<365 d Nonamplified Unfavorable Any I 
<365 d Amplified Any Any H 
The staging system is based on the age at diagnosis, MYCN status, JN?C 
(International histopathology classification) classification, DNA ploidy and risk 
group. (Modified from the National Cancer Institute - Children's Oncology 
Group. Neuroblastoma Low-, Intermediate-, and High-Risk Group Assignment 
Schema was used for COG-9641 and COG-A3961 studies). 
'DNA Ploidy: DNA Index (DI) >1 is favorable; DI =1 is unfavorable 
bRisk group: L = low; I = intermediate; H = high 
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1.1.6 Genetic aberrations ofneuroblastoma 
Twenty-two percent of neuroblastoma cases are due to germinal mutation. 
This subset of patients show predisposition to develop the disease. However, 
most neuroblastoma occurs spontaneously because of somatic genetic changes 
include MYCN amplification, chromosome deletion or allelic loss at lp, allelic 
loss o f l l q , tumour cell ploidy and trisomy for chromosome 17q (Brodeur, 2003; 
Knudson and Strong, 1972). 
In 1965, minute chromatin bodies/double minutes (DMs) were discovered 
in neuroblastoma (Cox et al,, 1965). The homogenously staining chromosomal 
region (HSR) was also found in 1976 (Biedler and Spengler, 1976). These are 
cytogenetic manifestations of gene amplification. The region of amplification 
was found to be a novel MYC-related oncogene called MYCN (Schwab et al, 
1983). MYCN is located in chromosome 2p24 in normal cells but it also maps to 
DMs and HSRs in MYCN-amplified cells. There are around 20% of primary 
tumours with MYCN amplification which is strongly associated with advanced 
stage disease and poor outcome (Figure 1.2), making it a powerful predictor for 
poor prognosis (Schmidt et al, 2000). However, there are still knowledge gaps to 
be filled for the association between MYCN amplification and a more aggressive 
phenotype (Brodeur et al, 1984; Seeger et al., 1985). 
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Figure 1.2. Kaplan-Meier event-free survival (EFS) for infants with stage 4 
neuroblastoma from the Children's Cancer Group study (CCG 3881). The 
3-year EFS for infants with stage 4 neuroblastoma. The patients without MYCN 
amplification (<10 copies) have 3-year EFS probability higher than 90%, 
whereas those with MYNC amplification (>10 copies) have only 10% (Schmidt 
et al., 2000). 
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Chromosome deletion or allelic loss at lp occurs in 25 to 35% of 
neuroblastoma. The loss of heterozygosity (LOH) was mapped to chromosome 
lp and was highly associated with MYCN amplification (White et aL, 1995; 
2005). Although it seems to correlate to advanced stage disease, its use as an 
independent prognostic indicator is still controversial. Moreover, several studies 
indicated that the allelic loss occurred in lp36 was predictive to increased risk of 
relapse in patients with localized tumours (Gehring et al., 1995). Another LOH is 
allelic loss o f l l q which occurs in 35 to 45% of primary tumours and is the most 
common deletion detected so far (Guo et al., 1999; Plantaz et al., 2001; Spitz et 
al., 2003). It is rarely associated with MYCN amplification. From the study of 
Children's Oncology Group (COG), allelic loss of l l q is independently 
prognostic for outcome in a multivariate analysis and thus it is a useful predictor 
of outcome. It is associated with decreased event-free survival rate in high-risk 
patients lacking MYCN amplification (Guo et al., 1999). 
Neuroblastoma is usually hyperploidy in DNA content. It can be either 
near-diploid (45%) or hyperdiploid (55%) due to defective spindle formation 
during mitosis. Kaneko and Knudsone hypothesized that both near-diploid and 
hyperdiploid (often near-triploid) cells arise from the same genetic event as 
suggested by familial cases (Knudson and Strong, 1972; Kushner et al., 1986). 
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Tetraploidization and subsequent multipolar division of a diploid cell which is 
heterozygous for a mutation would result in an unfavorable diploid tumour cell 
without normal allele and genetically unstable (stage 4) or a clinically favorable 
triploid tumour cell with at least one normal allele (Stage 1，2 and 4S). DNA 
polyploidy is a prognostic marker for patients younger than 2-year-old while it loses 
the prognostic value in older patients. It may due to structural rearrangements in 
near-triploid tumours in older patients (Kaneko and Knudson, 2000). 
Other than deletion of chromosome, allelic gain was also observed in 
neuroblastoma. Trisomy for 17q due to unbalanced translocation with 
chromosome 1 or 11 occurs in more than half of all neuroblastoma patients and is 
the most prevalent genetic abnormality among them. The allelic gain leads to 
overexpression of survivin, an anti-apoptotic protein. It also correlates with more 
aggressive neuroblastoma (Bown et al,, 1999). 
1.1.7 Therapies of neuroblastoma 
Due to highly biological heterogeneity and broad spectrum of clinical 
behaviour, different strategies should be applied for the treatment of 
neuroblastoma. Neuroblastoma patients are stratified into different risk groups 
including low, intermediate and high-risk group. The risk stratification system of 
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the Children's Oncology Group is based on age at diagnosis, DSfSS stage, tumour 
histopathology, DNA index and MYCN amplification. 
Low-risk patients account for around 40% of all neuroblastoma patients. 
The disease is curable with no or minimal cytotoxic therapy and is strongly 
associated with spontaneous regression. Therefore, non-aggressive tumour can be 
treated with surgery alone. Localized tumours regress spontaneously would be 
observed safely without any treatment. However, chemotherapy would be 
conducted in low-risk patients who belong to stage 1, 2A or 2B if they are 
suffering from life-threatening symptoms, recurrent or progressive disease. On 
the other hand, patients in stage 4S with large tumour and massive hepatomegaly 
should receive chemotherapy or low-dose radiotherapy (Park et al., 2008). 
Intermediate-risk neuroblastoma accounts for 15% of all neuroblastoma. It 
is a clinically and biologically heterogeneous entity. Patients would receive 
moderately intensive chemotherapy to facilitate subsequent surgical resection 
(Kushner et al., 2005). 
High-risk neuroblastoma accounts for 40% of all neuroblastoma. Patients 
are primarily children older than one-year-old with MYCN amplification and 
unfavorable histology in stage 3 and 4 while a minority is a subset o f4S patients 
with MYCN amplification and rapid tumour progression. Kaplan-Meier survival 
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analysis (Figure 1.3) showed that the event-free survival rate of high-risk group 
remained low (< 30%) even with intensive multimodality therapy (Kushner et al., 
2005; Maris et al., 2007; Schmidt M.L. et aL, 2000). Therefore, it remains to be 
the greatest challenge for treatment with high-risk group, especially those older 
patients with stage 4 disease. The therapy for high-risk neuroblastoma is 
categorized into four phases, including induction therapy, local control, 
myeloablative consolidation therapy and management of minimal residual 
disease. The aim of intensive induction treatment is to maximize the reduction of 
tumour burden within a time frame and thus to minimize the risk of developing 
resistant tumour clone and clinical progression. It is achieved by prescription of a 
combination of cisplatin, etoposide, doxorubicin, cyclophosphamide and 
vincristine in cycle (Cheung et al., 2001;Park et al., 2006). After the clearance of 
circulating tumour cells and reduction of bone marrow tumour, peripheral blood 
stem cells (PBSC) are collected and saved for later recovery. Followed by that, 
surgical resection of primary tumour cells which are resistant or inaccessible to 
chemotherapy would be carried out. Adkins et al (2004) showed that a slight 
improvement in event-free survival rate among high-risk patients with complete 
gross resection of primary tumour. It also reduced local relapse and prolonged 
long-term survival over 20 years. In addition, as neuroblastoma is one of the 
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most radiosensitive solid tumours of childhood, local control on primary tumour 
can also be conducted by extemal-beam radiotherapy with 2160 cGy in daily 180 
cGy fractions (Bradfield et al., 2004; Haas-Kogan et al.’ 1980; Kushner et al., 
2001). After local control, consolidation therapy is included to overcome residual 
and potentially resistant tumour with high-dose chemotherapy followed by 
autologous hematopoietic stem cell support (Wagner and Danks, 2009). 
Anti-cancer drugs used in this phase usually include carboplatin, etoposide and 
melphalan (CEM). A randomized phase III cooperative study by the Children's 
Oncology Group demonstrated that event-free survival could be improved with 
autologous transplantation (Matthay et al., 1999) A German study also showed 
that consolidation therapy successfully improved 3-year event-free survival in 
patients compared to those who received maintenance chemotherapy alone. The 
last phase of the treatment is a maintenance therapy in which minimal residual 
disease is treated with agents that intervene the biology of neuroblastoma. 
Relapse frequently occurs after autologous transplantation, and majority of 
relapsed patients would die from disease progression eventually (Lau et al., 
2004). Therefore, it is essential to eliminate readily identifiable persistent 
tumours remained with biological therapy. Conventionally, retinoids such as 
13-cis-retinoic acid are used to induce terminal differentiation in neuroblastoma. 
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Fenretinide, a synthetic retinoid analogue, has been shown to produce multi-log 
cell killing in multiple neuroblastoma cell lines which are resistant to other 
retinoids (Maurer et al., 1999; 2000). Other strategies like immunotherapy using 
anti-GD2 monoclonal antibody in phase III trials (King et al., 2004; Kushner et 
al., 2001; Neal et al,, 2004)，engineered cytolytic T lymphocytes (Gonzalez et al., 
2004)，angiogenesis inhibitors (Erdreich-Epstein et aL, 2000; Klement et al., 
2000) and tyrosine kinase inhibitors are under different phases of clinical trials 
(Evans et a/.,2001). 
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Figure 1.3. Kaplan-Meier event-free survival (EFS) for infants with stage 4 
neuroblastoma from the Children's Cancer Group study (CCG 3881). The 
3-year EFS for infants with stage 4 neuroblastoma. The patients with favourable 
Shimada pathologic classification have 3-year EFS probability around 90%, 
whereas those with unfavourable one have only 30% (Schmidt M l . et aL, 2000). 
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1.2 Banlangen alkaloids 
1.2.1 An overview ofBanlangen alkaloids 
In historical time, different civilizations began to use different medicinal 
plants in treatment of diseases. Alkaloid, a class of chemicals that are extracted 
from plants, may be the most frequently used drugs derived from medicinal 
plants in form of potions, medicines, teas, and poisons for 4,000 years. Alkaloid 
is a group of secondary metabolites that can be found in a variety of plant species. 
Secondary metabolites are believed to defend plants against herbivores, parasites, 
viruses and other microorganisms (Wink, 1988). Other than plants, many 
alkaloids have been isolated from animals, marine invertebrates, insects and 
microorganisms. To date, more than 50,000 natural products are known with over 
12,000 are alkaloids (Wink, 1998). 
Among the medicinal plants worldwide, traditional Chinese medicine (TCM) 
plays an important role. The Chinese practitioners have used natural resources as 
drugs to treat various kinds of diseases for thousands of years. Among 5,500 
natural resources, around 82% are plants (Hoessel et al, 1999). In the past, the 
world of medicine was led by the Westem medicine and no one place any effort 
for the investigation of TCM. However, since the 20^ ^ century, the curing effects 
of various TCM preparations on diseases have attracted the interest of scientists 
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to elucidate the underlying pharmacological properties on individual components 
in a recipe. One of the most attractive pharmacological properties of TCM is 
their anti-cancer properties. Well-known examples include Camptotheca 
acuminate with camptothecin, a quinoline alkaloid and Cephalotaxus spp. with 
harringtonine alkaloid as the anti-cancer component respectively. Danggui 
Longhui Wan (當歸育|薈九）is a TCM recipe used customarily in the treatment 
of chronic myelocytic leukemia (CML). The preparation contains a mixture of 11 
herbal medicines. It was until 1966，the active factor has been isolated and 
identified as indirubin, an indigo alkaloid found in Qing Dai (青驚）(Indigo 
naturalis) (Han, 1994; Li, 1987). Qing Dai is dried powder or mass prepared 
from the leaves or the stem and leaves of Isatis indigotica, Polygonum tinctorium 
and Baphicacanthus cusia. Indirubin is an isomer of indigo which gives the 
dark-blue color of the powder. Both indigo and indirubin are derived from 
oxidation and spontaneous, non-enzymatic dimerization of indoxyl and isatin 
(Hurry, 1930; Balfour, 1998). Indigo naturalis has also been included in TCM 
preparations for hemostatic, anti-pyretic, anti-inflammatory, sedative, 
anti-bacterial and anti-viral purposes (Li, 1987). 
Other than Qing Dai, Daqingye (大青葉）and Banlangen (板藍根）are the 
other two plant products derived from the same plant species as Qing Dai. 
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Daqingye is derived from leaves of Isatis indigotica, Indeigofera tinctoria, 
Polygonum tinctorium and Baphicacanthus cusia while Banlangen is derived 
from roots of Isatis indigotica, Isatis tinctoria (Beibanlangen) and 
Baphicacanthus cusia (Nanbanlangen) (Zhao et al., 2001). Banlangen has been 
included in different TCM preparations and was prescribed for anti-influenza 
during the outbreak of severe acute respiratory syndrome (SARS) in 2003. 
However, there was no concrete medical evidence to support the efficacy. More 
than thirty different chemicals have been isolated and identified from Banlangen. 
Alkaloid, a class of weak bases has also been found in Banlangen including 
indole alkaloids, quinazoline alkaloids, benzoxazine alkaloids, purine bases and 
steroid alkaloids. Among these alkaloids, indirubin (Figure 1.4)，an indole 
alkaloid, and tryptanthrin (Figure 1.5), a quinazoline alkaloid have been shown to 
exhibit various pharmacological effects (Ding et al., 2001; Li and Zeng ,2005; 
Liu et a/.,2001;2003). 
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1.2.2 Pharmacokinetics of indirubin, tryptanthrin and their derivatives 
1.2.2.1 Bioavailability of indirubin and its derivatives 
Tritium-labeled indirubin was orally injected into mice and the radioactivity 
was measured. It was found that radioactivity signal can be detected in blood 
after 10 minutes of injection and peaked after 12 hours. The half-life of 
absorption was 5.9 hours. It was still detectable in blood after 3 days. Indirubin 
was found to be distributed in different organs including stomach, intestine and 
liver. It could also be detected in bile and bone marrow. Indirubin was able to 
pass the blood-brain barrier (BBB) due to its hydrophobic nature. It was found 
that 44% of the indirubin input was eliminated in faeces and 12% in urine. The 
half-life of elimination was 21 hours. The degree of bioavailability was 46.5%. 
(Zhao et a/.,2001) 
Adachi et al. (2001) had identified indigo and indirubin as aryl hydrocarbon 
receptor (AhR) inducers using a yeast-based AhR system with a lac reporter. 
Both indigo and indirubin are chemicals found in Danggui Longhui Wan. The 
study showed that indirubin was 50 times more potent than 
2,3,7,8-tetrachlorodibenzo[p]dioxin (TCDD) as the agonist of AhR. A recent 
study using human cell culture and animal models, which are considered to be 
more relevant to human condition, was conducted by Guengerich et al. (2004). 
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Both indirubin (EC50= 0.1 |uM) and indirubin-3'-oxime (EC50= 0.5 ^iM) were 
capable to induce AhR response in human hepatoma HepG2 cells. For in vivo 
study, rat liver microsome was collected from Sprague-Dawley rat fed with 
indirubin or I3M at a dose of 1.5-50 mg/kg. Induction of hepatic cytochrome 
P450 1A1 was detected and was NADPH-dependent. The amount of indirubin 
and I3M decreased and several new metabolites were detected in HPLC profiles 
but the identities were not characterized. 
1.2.2.2 Toxicity of indirubin and its derivatives 
Since alkaloids are usually have multiple biological properties and thus they 
may be expected to interact with different systems of human body when they are 
used as drugs. In an acute toxicity study, indirubin was orally injected to rat at a 
dose of 5g/kg daily for 5 consecutive days and no subjects were found dead or 
with obvious toxicity. A 3-day-treatment of rats with indigo or I3M at 5 
mg/kg/day had no effect on the weight of liver but indirubin reduced the liver 
weight by 36%. Moreover, the other study using dogs as the model, indirubin at a 
dose of 200 mg/kg was given daily for three months and one died out of three 
dogs. In a chronic toxicity study, no bone marrow toxicity and hematotoxicity 
were observed in rats given indirubin at a dose of 60-160 mg/kg/day (Ji et al” 
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1981; Wang et al., 1981). A 6-month chronic toxicity study using dogs as the 
animal model showed that reversible diarrhoea and slight hepatotoxicity could be 
observed at a dose of indirubin 25 times higher than that used for human therapy. 
Moreover, no changes in hematopoiesis, renal functions or electroencephalogram 
activity were observed (Chang, 1985). Chronic toxicity study had been 
conducted among 314 chronic myelocytic and chronic granulocytic leukemia 
patients who orally received 150-450 mg indirubin daily. The study demonstrated 
that indirubin could be well-tolerated without major side effects. Among the 
patients, 29.51% showed no toxicity and 40% showed slight diarrhoea and 
abdominal pain. Serious hepatotoxicity occurred in two cases only. 
Microscopically, alterations of membrane of endoplasmic reticulum and cell 
surface ofwhite blood cells of chronic granulocytic leukemia patients could also 
be observed after treatment with indirubin (Lee et al., 1979). 
1.2.2.3 Bioavailability of tryptanthrin 
There are no reports on the bioavailability of tryptanthrin itself. PA-505 
which is a 2-aza-8-isooctyl analog of tryptanthrin was found to be absorbed fairly 
well (~ 45%) in mice after given a dose of 50 mg/kg. A maximal plasma drug 
level of 3 to 6 mg/L was achieved in an hour. The plasma level decreased to 1 
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mg/L in 7.5 hours. PA-505 was also detected at peak levels in plasma, lung and 
spleen with 2 to 3.5 mg/L, 2 to 3 mg/L and 0.5 to 1 mgyTcg at two hours 
respectively and the level reduced by 50% after 7.5 hours (Mitscher and Baker, 
1998). In rat liver microsomes, tryptanthrin was converted to 
8-hydroxytryptanthrin. The conversion is NADPH-dependent and mediated by 
cytochrome P450 (Lee et al, 2007). Therefore, both indirubin-3'-oxime and 
tryptanthrin share the same route, at least for the involvement of NADPH and 
cytochrome P450, of metabolism. Similar to indirubins, tryptanthrin and its 
derivatives were found to be agonists of the aryl hydrocarbon receptor (AhR). 
Tryptanthrin induced mRNA and protein expression of cytochrome P4501A1 in 
rat hepatocytes in vitro, and induced the activity of 7-ethoxyresorufm 
0-deethylase (EROD) with EC50 at 6.1 ^iM. The derivatives oftryptanthrin were 
also shown to be active and more potent inducers than tryptanthrin itself 
(Schrenk etal., 1997). 
1.2.2.4 Toxicity of tryptanthrin 
In a study of anti-bacterial effect of tryptanthrin on Helicobacter pylori, 5 
mg tryptanthrin was administered to each gerbiL No acute toxicity or significant 
loss of body weight was observed. In addition, no marked changes in internal 
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organs were found by macroscopic observation alone (Kataoka et al,, 2001). 
1.2.3 Pharmacological effects of indirubin, tryptanthrin and their 
derivatives 
Plant extracts from indirubin or tryptanthrin-containing plants such as Isatis 
indigotica and Polygonum tinctorium have been used customarily for various 
purposes. In Europe, the plant extracts are used in treatment of wounds, ulcers, 
snake bites and hermorrhoids. In Japan, tryptanthrin is the active component in a 
Japanese herbal remedy for fungal infections (Honda and Tabata, 1979). In China, 
the roots (Banlangen) and the leaves (Daqingye) have been used in preparations 
for anti-inflammatory, anti-pyretic and detoxifying purposes (Chinese 
Pharmacopoeia Commission, 2005). In Korea, Chun-Dae, a pigment extracted 
from Polygonum tinctorium, has been used for latent-heat-clearance and 
treatment ofinfantile convulsion and epilepsy due to fever. It can also be used for 
the management of asthma and allergic disorders (Chang and But, 1986). The 
multiple pharmacological activities of the plant extracts have attracted 
researchers to investigate different pharmacological activities of the active 
compounds in the extracts, namely, indirubin and tryptanthrin. 
Broadly speaking, the pharmacological activities of indirubin and 
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tryptanthrin can be classified as selective inhibitors on kinases, anti-inflammatory, 
anti-tumour, anti-viral and anti-microbial activities. 
1.2.3.1 Selective inhibitors on kinases 
Indirubin was first described by Hoessel et al (1999) as a cyclin-dependent 
kinase (CDK) inhibitor. Other indirubin derivatives such as indirubin-3'-oxime 
(I3M) and indimbin-5-sulphonic acid are also potent CDK inhibitors. Indirubin 
and I3M inhibit the activities of CDKs selectively with IC50 ranged from 0.1 to 
10 i^M without inhibiting other kinases such as mitogen-activated protein kinase 
kinase (MAPKK), c-Jun NH2-terminal protein kinase (JNK), protein kinase C 
(PKC) at a concentration lower than 100 ^M. The IC50 value of indirubin and 
I3M on CDKl/cyclinB was found to be 10 ^M and 0.18 ^M respectively. From 
the data of X-ray crystallography, the action mechanism of inhibition could be 
attributed to the occupying of indirubin at the ATP-binding pocket of CDKs. As 
CDKs play an important role in cell cycle progression, I3M was found to inhibit 
cell proliferation and arrest various cell lines, including breast epithelial 
HBL-100, breast cancer MCF-7, lung fibroblast CCL-39, colon cancer HT-29, 
pheochromocytoma PC-12, lymphocytic leukemia L1210, myelogenous 
leukemia K-562 and promyelocytic leukemia HL-60 cells, in G2/M phase at 
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higher concentrations (10 - 20 ^M). At lower concentrations, I3M arrested Jurkat 
cells and MCF-7 cells in Gi phase with inhibition of CDK2 and phosphorylation 
of retinoblastoma protein (Hoessel et al., 1999). 
Since Hoessel's report on the CDKs inhibitory effect of indirubin and 
its derivatives, many subsequent studies showed that CDKs are not the only 
group of kinases inhibited by indirubins. Kinetic analysis showed that 
indirubin-5-sulphonate inhibited both glycogen phosphorylase a and glycogen 
phosphorylase b, and acted with glucose synergistically in the inhibition 
(Kosmopoulou et al., 2004). Indirubins can bind to the ATP-binding pocket of 
glycogen synthase kinase-3p (GSK-3p) in a similar fashion to that in CDK and 
thus inhibit GSK-3p with IC50 ranged from 5 to 50 nM. The IC50value of I3M 
was found to be 22 nM (Leclerc et al., 2001). I3M was also shown to be a potent 
inhibitor of JNK with IC50 value of 0.8 ^iM, 1.4 ^iM and 1 ^iM on JNK, JNK1 
and JNK3 respectively. The inhibition of JNK via blockade of c-Jun 
phosphorylation prevents apoptosis in cerebellar granule neurons (Xie Y. et aL, 
2004). A recent study has demonstrated on the specific inhibition of 
autophosphorylation of fibroblast growth factor receptor 1 (FGFR1) in NIH/3T3 
and KG-la cells via inhibition o fFGFRl kinase activity by I3M (Zhen et al., 
2007). Furthermore, serum- and glucocorticoid-induced kinase (SGK), 
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AMP-activated protein kinase (AMPK) and leukocyte-specific protein tyrosine 
kinase (LCK) were also shown to be inhibited by indirubin (Bain et al., 2003). 
1.2.3.2 Anti-inflammatory activity 
A chemokine called regulated on activation, normal T cell expressed and 
secreted (RANTES) is produced by human bronchial epithelial cells to promote 
inflammation in airway during infection. The inhibition of RANTES mRNA 
expression and its production by indirubin and I3M was demonstrated in 
influenza-infected cells. The inhibition was possibly due to the inhibition of 
virus-induced phosphorylation of IKBa and p38 MAPK. Therefore, indirubins 
can be used to relieve virus-induced bronchial asthma during respiratory tract 
infection (Mak et al., 2004) Indirubin extracted from Polygonum tinctorium Lour 
exhibited inhibitory effect on the production of interferon-y (IFN-y) and 
interleukin-6 (IL-6) in human myelomonocytic HBL-38 cells and murine 
splenocytes. Indirubin also inhibited 2,4,6-trinitro-1 -chlorobenzene 
(TNCB)-induced delayed-type hypersensitivity in mice (Kunikata et al., 2000). 
An in vitro study on the effect of tryptanthrin on cytokines production upon 
staphylococcal endotoxin B (SEB) stimulation demonstrated that tryptanthrin 
inhibited the production of IFN-y and IL-2 in mouse spleen cells and Peyer's 
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patch lymphocytes. The anti-inflammatory action of tryptanthrin was confirmed 
in vivo by inhibiting SEB-induced IFN-y production in BALB/c mice. Therefore, 
tryptanthrin might be effective in treatments of intestinal disorders in which SEB 
from Staphylococcus aureus causes food poisoning or even toxic shock 
syndrome (Takei et al., 2003). Macrophages can produce inflammatory 
mediators such as nitric oxide (NO) and prostaglandin E2 by activating the 
inducible nitric oxide synthase (/NOS) and cyclooxygenase (COX) respectively 
in response to infection. Tryptanthrin was demonstrated to inhibit the production 
of prostaglandin E2 by inhibiting COX-2 activity at a concentration lower than 
2.5 ^iM. Tryptanthrin also inhibited NO production in LPS-stimulated murine 
macrophage-like RAW 264.7 cells. At a higher concentration (20 ^iM), the 
expression of /NOS was completely suppressed by tryptanthrin (Ishihara et al., 
2000). The production of prostaglandin and leukotriene was found to be inhibited 
in LPS-stimulated human acute monocytic leukemia Mono Mac 6 cells by 
tryptanthrin (Danz et al., 2002). 
1.2.3.3 Anti-tumour activity 
1.2.3.3.1 Anti-leukemic activity 
In China, Danggui Longhui Wan has been used customarily in chronic 
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myelocytic leukemia (CML) treatment. However, the active ingredients were not 
identified until 1966 and the active compound was later isolated and identified as 
indirubin, an isomer of blue dye indigo (Institute of Haematology, Chinese 
Academy of Medical Sciences, 1979; Han, 1994). Later studies showed that 
indirubin promoted neutrophilic differentiation of human promyelocytic 
leukemia HL-60 cells with typical neutrophilic properties, deformed nuclei and 
granules. The action mechanism may involve inhibition of CDK2 and activation 
of transcription factor PU.1 which govems the expression of leukocyte proteins 
during differentiation (Suzuki et al.’ 2005). In clinical trials against chronic 
myelocytic and chronic granulocytic leukemia, complete remission and partial 
remission in patients with CML were 26% and 33% respectively (Hoessel et al., 
1999). Other than indirubin, tryptanthrin also exhibited anti-leukemic activity by 
the induction of terminal differentiation at low concentrations in monocytic and 
promyelocytic leukemia cells. At higher concentrations, cytoplasmic vacuolation 
and destruction of mitochondria with depolarized membrane potential were 
observed in tryptanthrin-treated leukemia cells. Mechanistic studies showed that 
the mode ofcell death was apoptosis with increases in the Fas expression and the 
caspase 3 activity (Kimoto et al., 2001). 
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1.2.3.3.2 Apoptosis-inducing activity 
In addition to leukemia, indirubins and tryptanthrin have been demonstrated 
to inhibit cell proliferation and cause cell death, mostly apoptosis, in different 
cancer cell lines. I3M induced apoptosis in cervical cancer HeLa cells, hepatoma 
HepG2 cells and colon cancer HCT116 cells in a time- and dose-dependent 
manner. Induction of extrinsic and intrinsic pathways was involved in 
I3M-induced apoptosis. Both the activities of caspase 3，8 and 9 and the 
expression of death receptors DR4 and DR5 were increased. The cleavage of 
Bid and conformational change in Bax were also detected (Shi and Shen, 2008). 
Serum-deprived human breast cancer MCF-7 cells were arrested in Go/Gi phase 
by 2 |iM I3M. At higher concentrations, the cells were arrested in G2M phase 
followed by apoptosis (Marko et al., 2001). Recently, more derivatives from 
indirubin have been synthesized chemically with comparable or higher potency 
in the induction of apoptosis in cancer cells. 5'-nitro-indirubinoxime, 
5'-fluoro-indurubinoxime and 5-trimethylacetamino- indirubinoxime were 
demonstrated to exhibit anti-proliferative activity on human lung carcinoma 
A549 cells, stomach carcinoma SNU-638 cells and fibrosarcoma HT-1080 cells. 
Activation of casapse 7 was found in indirubin derivatives-treated oncogenic 
RK3E-ras rat kidney cells. In vivo study also showed that the indirubin 
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derivatives inhibited the growth of tumour in Sprague-Dawley rats bearing 
RK3E-ras-induced tumours (Kim et al., 2007). Indirubin-5'-nitro-3‘-monoxime 
induced apoptosis in A549 human lung cancer cells with the up-regulation of p53 
and p21 proteins and the release of cytochrome c. (Lee et al., 2005). Indirubin 
derivatives E604, E728 and E804 were potent inhibitors on Stat3 signaling 
pathway. They induced apoptosis via down-regulation of anti-apoptotic proteins 
Mcl-l and survivin in human breast cancer MDA-MB-468 cells (Nam et al,, 
2005). Other than the induction of apoptosis, other modes of cell death were also 
induced by indirubin derivatives. I3M induced necrosis in 
nocodazole-synchronized HBL-100 cells (Damiens et al, 2001). It was reported 
that the nuclei of 7-bromoindirubin-3 ‘-oxime-treated SH-SY5Y cells showed no 
characteristic features of apoptosis but appeared as large pycnotic nuclei. There 
was no cytochrome c release or caspase activation. The non-apoptotic cell death 
was categorized as necroptosis or autophagy by Ribas et al. (2006). In a recent 
study, tryptanthrin was found to inhibit the growth of murine myeloid leukemia 
WEHI-3B JCS cells in a dose- and time-dependent manner. The growth of 
tumour was also suppressed in an in vivo study. The anti-tumour effect was 
suggested due to the cell cycle arrest and cell differentiation induced by 
tryptanthrin (Chan et al., 2009). 
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Tryptanthrin was found to reverse doxorubicin resistance in multi-drug 
resistance (MDR) breast cancer cell line MCF-7/adr by suppressing the activity 
o fMDRl gene promoter. The protein expression of mutant p53 was decreased in 
tryptanthrin-treated MCF/adr cells due to the decrease in protein stability. Since 
MDR1 is the target gene of p53, the decreased expression of mutant p53 would 
lower the protein expression of MDR1 gene and thus the multi-drug resistance 
property in the cells (Yu et al” 2007). 
Indirubins were demonstrated to interact with some important cellular 
signaling mediators in cancer cells in vitro. Indirubin was found to suppress 
TNF-induced NF-KB activation in a dose and time-dependent fashion, leading to 
a down-regulation of gene products involved in anti-apoptosis (survivin, IAP1, 
IAP2, Bcl-2, Bd-XL)，cell proliferation (cyclin D1 and c-Myc) and cell invasion 
(MMP-9 and COX-2) in different cancer cell lines (Sethi et al., 2006). Recently, 
a study reported that I3M inhibited autophosphorylation of FGFR1 and 
stimulated extracellular signal-regulated kinase (ERK) 1/2 activity via p38 
MAPK in fibroblast NIH/3T3 cells. I3M was also shown to inhibit the 
proliferation of myeloid leukemia KG-la cells through inhibition o f the activity 
ofFGFRl tyrosine kinase (Zhen et aL, 2007). 
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1.2.3.4 Anti-viral properties 
Human immunodeficiency virus (HIV) is one of the most widespread 
and persistent viruses in human population. Over 33 millions of people are living 
with HrV by 2007 (UNAIDS, 2008). I3M was demonstrated to inhibit kinase 
activity of CDK9, the catalytic subunit of positive transcription elongation factor 
b (P-TEFb). Since P-TEFb acts as Tat cofactor and is essential in viral replication, 
its inhibition by I3M suppressed HIV-1 replication in peripheral blood stem cells 
(PMSC) and macrophages with IC50 values of 1 i^M and 0.5 i^M respectively. 
Both wild-type and drug-resistant strains of HIV-1 are vulnerable to 
I3M-mediated inhibition of viral replication (Heredia et al., 2005). 
1.2.3.5 Anti-microbiaI properties 
Tryptanthrin but not indirubins was found to exhibit anti-microbial 
properties in different microorganisms. Tryptanthrin inhibited the 
colony-forming ability of Helicobacter pylori in vitro. In an in vivo study, the 
growth of H. pylori colonies in the stomach of gerbils was inhibited in a 
dose-dependent manner (Kataoka et al., 2001). Trypanosoma brucei is a 
flagellated protozoon that causes sleeping sickness in humans with 
meningoencephalitis among African population. Tryptanthrin was shown to exert 
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anti-trypanosomal activity with an EC50 value of 23 ^M. A more potent 
derivative, 4-aza-8-bromotryptanthrin, was identified with an EC50 value of 0.4 
[xM (Scovill et al., 2002). Tryptanthrin is also active in suppressing the growth of 
multi-resistant Mycobacterium tuberculosis strains (Mitscher and Baker, 1998), 
Plasmodium falciparum (Pitzer et al., 2001)，and oral pathogenic bacteria 
including Porphyromonas gingivalis and Prevotella intermedia (Iwaki et al” 
2006). Tryptanthrin isolated from the aerial parts of Isatis tinctoria L. was found 
to possess insecticidal, fungicidal and anti-feedant activities (Seifert and Unger, 
1994). 
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1.3 Aims and Scope ofThis Study 
Since tryptanthrin and indirubin-3'-oxime (I3M) have been isolated and 
identified from Banlangen, their biological and pharmacological activities have 
been studied extensively. However, their modulatory effects and action 
mechanisms on neuroblastoma cells remain unclear. In the present study, the 
modulatory effects of tryptanthrin and I3M on the proliferation, apoptosis and 
differentiation of the murine neuroblastoma Neuro-2a BU-1 cells were examined. 
The project first examined the anti-proliferative activity of tryptanthrin and 
I3M on the murine neuroblastoma Neuro-2a BU-1 cells, using tritiated thymidine 
incorporation assay. Two human neuroblastoma cell lines including SH-S-Y5Y 
and LA-N-1 were included for comparison. The Neuro-2a BU-1 cells were 
chosen for detailed mechanistic studies. The kinetic and reversibility studies 
were conducted using tritiated thymidine incorporation assay and MTT reduction 
assay respectively. The effects tryptanthrin and I3M on the colony-forming 
efficiency of the Neuro-2a BU-1 cells were determined by double-layered 
soft-agar method. The cytotoxicity on neuroblastoma cells and primary normal 
cells was examined by MTT reduction assay and trypan blue exclusion test. The 
cell cycle profile of the Neuro-2a BU-1 cells was studied by flow cytometry. The 
protein expression of cyclins and cyclin-dependent kinases was examined by the 
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Westem blotting technique. 
Induction of apoptosis by I3M was measured by DNA fragmentation assay 
using DNA agarose gel electrophoresis and quantified by the Cell Death 
ELISAPLUS kit. Studies on the chromatin condensation in I3M-treated Neuro-2a 
BU-1 cells fluorescence microscopy served as a confirmatory test. The 
underlying mechanisms of apoptosis were elucidated by Westem blot to examine 
for the up- or down-regulation of Bcl-2 family proteins and other • apoptosis 
regulators. The involvements of reactive oxygen species (ROS) and caspases 
were determined by flow cytometry and fluorometric measurement respectively. 
Induction of differentiation of Neuro-2a BU-1 cells by tryptanthrin was 
elucidated by observing the changes in cell size and internal complexity using 
flow cytometry. Morphological and functional differentiation of 
tryptanthrin-treated Neuro-2a BU-1 cells were determined by Hemacolor® 
staining and measurement of acetylcholine esterase (AChE) activity respectively. 
The underlying mechanisms of cell differentiation were elucidated by Westem 
blot to examine the protein expression of different cell differentiation mediators. 
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2.1 Materials 
2.1.1 Cell lines 
1. Neuro-2a (BU-I) 
The Neuro-2a cells were originally established from a spontaneous tumour 
of a strain A albino mouse (Kelbe and Ruddle, 1968). BU-1 cells were a 
subclone obtaining from the Neuro-2a cell line (ATCC CCL-131) by 
limiting dilution method (Mak et aL, 2000) and the cell line was a generous 
gift ofProfessor N.K. Mak, Department ofBiology, The Hong Kong Baptist 
University, HKSAR, China. 
2. SH-SY5Y 
SH-SY5Y (ATCC CRL-2266), purchased from ATCC, is a thrice cloned 
(SK-N-SH •> SH-SY ^ SH-SY5 ^ SH-SY5Y) subline of the 
neuroblastoma cell line SK-N-SH which was established from a metastatic 
tumour in bone marrow. The cell line was purchased from American Type 
Culture Collection (ATCC), USA. 
3. LA-N-1 
LA-N-1 (RCB0483) is a human neuroblastoma cell line established from 
the metastatic tumour in the bone marrow of a 2-year-old boy. The cell line 
was purchased from RIKEN BioResource Center Cell Bank, Japan. 
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2.1.2 Cell culture media, reagents and buffers 
Cell culture media 
1. Liquid RPMI 1640 medium (IX) 
The liquid RPMI 1640 medium (Gibco BRL Life Technologies, Inc., USA) 
containing L-glutamine and phenol red but lacking HEPES buffer and 
sodium pyruvate was used for subculture of the Neuro-2a BU-1 cells. The 
medium was stored in dark at 4°C until use. 
2. Liquid Dulbecco's Modified Eagle's Medium/F12 (DMEM/F12) 
medium (IX) 
The liquid DMEM/F12 medium (1:1) (Gibco BRL Life Technologies, Inc., 
USA) containing 15 mM HEPES buffer, L-glutamine and pyridoxine HC1 
was used for subculture of SH-SY5Y cells. The medium was stored in dark 
at 4°C until use. 
Cell culture reagents 
Serum supplements 
Fetal bovine serum (FBS) (Gibco BRL Life Technologies, Inc., USA) was 
stored as 50 ml aliquots in sterile universal bottles. FBS was warmed in 
water bath at 56°C for 30 minutes with occasionally shaking to obtain 
heat-inactivated FBS. The aliquots were then kept frozen at -20°C until use. 
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Antibiotic mixture solution 
Penicillin-Streptomycin-Neomycin (PSN) antibiotic mixture (lOOx) stock 
solution (100 mL) containing 5 mg/mL penicillin G (sodium salt), 5 mg/mL 
streptomycin sulphate, and 10 mg/mL neomycin sulphate in 0.85% (w/v) 
saline and Antibiotic-Antimycotic (PSF, 100x) stock solution (100 mL) 
containing 10,000 units/mL penicillin G (sodium salt), 10,000 ^g/mL 
streptomycin sulphate, and 25 ^ig/mL amphotericin B in 0.85% saline were 
purchased from Gibco BRL Life Technologies, Inc., USA. The stocks were 
stored as 5 mL aliquots at -20°C until use. PSN or PSF 100x stock solution 
was added to culture medium to give 1% antibiotics to minimize any 
possible contamination of cell culture. 
MEM non-essential amino acids 
MEM non-essential amino acid (NEAA) 100X solution was purchased from 
GIBCO BRL Life Technologies, Inc., USA. The 100X solution was added 
to DMEM/F12 medium to a final IX solution for subculture of SH-SY5Y 
cells. The solution was stored at 4°C until use. 
Sodium pyruvate solution 
Sodium pyruvate 100 mM (lOOX) solution was purchased from GIBCO 
BRL Life Technologies Inc., USA. The 100X solution was added to 
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DMEM/F12 medium to a final IX solution for subculture ofSH-SY5Y cells. 
The solution was stored at 4°C until use. 
Complete culture media 
RPMI 1640 or DMEM medium supplemented with 1% (v/v) antibiotics is 
called "Plain Medium". Complete culture media ofRPMI 1640 and DMEM 
were prepared by supplementing the plain medium with 10 and 15% (v/v) 
FBS or HI-FBS respectively. Complete culture media supplemented with 
FBS were used in subculturing of cell lines while complete culture media 
supplemented with heat-inactivated FBS were used for assay. 
Trypsin-EDTA solution 
Trypsin-EDTA solution (without Ca?+ and Mg2+) was purchased from 
Gibco BRL Life Technologies, Inc., USA and containing 0.25% (w/v) 
trypsin and 1 mM EDTA- tetrasodium in Hanks' balanced salt solution 
(HBSS). It was stored as 20 mL aliquots at -20°C until use. 
ThiogIycollate (TG) broth 
TG broth (3% w/v) was prepared by dissolving 3 g anhydrous thioglycollate 
powder (Difco Lab, USA) in 100 mL deionized water with continuous heating 
until complete dissolution. It was sterilized by autoclaving at 121°C for 20 
minutes and stored in dark at room temperature for a month before use. 
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Cell culture buffer 
Dulbecco's Phosphate-Buffered Saline (PBS) 
PBS in powdered form was purchased from Gibco BRL Life Technologies, 
Inc., USA. PBS solution was prepared by dissolving the powdered salt (8 g 
sodium chloride, 0.2 g potassium chloride, 0.2 g monobasic potassium 
phosphate and 1.15 g dibasic sodium phosphate) in one litre of deionized 
water until dissolved with the help of a spinning magnetic bar. The pH of 
the solution was adjusted to 7.4 by 1 M HC1 or NaOH solution. It was then 
sterilized by autoclaving at 121°C for 20 minutes. 
2.1.3 General staining solutions 
1. Hemacolor® staining solutions 
Hemacolor® staining solutions (Diagnostica Merck, Germany) consist of 
solution 1 (methanol), solution 2 (a buffered color reagent red) and solution 3 
(a buffered color reagent blue). The solutions were stored in light-protective 
brown glass bottles at room temperature. 
2. Trypan blue staining solution 
Trypan blue solution was purchased from Gibco BRL Life Technologies, Inc., 
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USA. It contains 0.4% (w/v) trypan blue dissolved in 0.85% saline. 
2.1.4 Drugs and chemicals 
1. Tryptanthrin 
Tryptanthrin was purchased from Wako Pure Chemical Lidustries, Ltd., 
Japan. Stock solution of tryptanthrin (10 mM) was prepared by dissolving 
the powdered form of tryptanthrin (with molecular weight of 248.24 and > 
97% purity) in 100% DMSO. The stock solution was aliquoted into 1 mL 
fractions and stored in dark at -20°C until use. 
2. Indirubin-3'-oxime (I3M) 
Indirubin-3'-oxime (I3M) was purchased from Sigma Aldrich Co., USA. 
Stock solution o f I3M (10 mM) was prepared by dissolving the powdered 
form of I3M (with molecular weight of277.28 and > 98% purity) in 100% 
DMSO. The stock solution was aliquoted into 200 uL fractions and stored in 
dark at -20°C until use. 
3. Doxorubicin 
Doxorubicin (DOX) with -98% purity was purchased from Alexis 
Biochemicals, USA. Stock solution of Dox (0.1 M) was prepared by 
dissolving DOX in plain RPMI 1640 medium and stored in dark at -20°C 
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and used within one month after preparation. 
2.1.5 Reagent for primary cultures preparation 
1. Ammonium chloride-potassium (ACK) buffer 
ACK buffer solution contains 150 mM NH4Cl, 1 mM KHCO3 and 0.001 
mM EDTA in deionized water and was sterilized through a 0.2 i^m filter. It 
was stored at 4 °C until use. 
2.1.6 Reagents for cell proliferation assays 
1. 3-(4,5-DimethyI-2-thiazolyl)-2,5-diphenyl-2H-tetrazoiium bromide 
(MTT) 
Powdered MTT was purchased from USB Corporation, USA. It was 
dissolved in sterile PBS as a 4 mg/ml stock solution and stored in an 
aluminium foil-wrapped container at 4°C until use. Thirty microlitres of 
stock solution was added to each well in 96-well flat-bottomed microplate for 
MTT reduction assay. 
2. [Methyl-3H] Thymidine ([^]-TdR) 
The stock solution was purchased from Amersham Life Science Ltd, USA. 
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and was kept at 4°C as 500 uL aliquots. The radioactive concentration of 
stock was 1 mCi/ml and the specific activity was 2 Ci/mmol. The working 
solution of 25 ^Ci/mL was freshly prepared by diluting the stock solution 
with complete RPMI. Twenty microlitres of working solution was added to 
each well of 96-well flat bottomed microplates in tritiated thymidine 
incorporation assay. 
3. Liquid scintillation cocktail 
The OptiPhase "Hisae" 2 liquid scintillation cocktail was purchased from 
Perkin-Elmer Co., USA. It contains diisopropyl naphthalene isomers, 
sodium dioctyl sulphosuccinate, polymer based on alkylphenolethoxylate, 
diethanolaminephosphoric acid ester, polymer based on 
alkylphenolethoxylate, 2-(2-butoxyethoy)ethanol, 2,5-diphenyloxazole and 
1,4-bis-(2-mrthylstyryl)- benzene. It was stored in dark at room temperature. 
4. Agar for colony forming assay 
Agar powder was purchased from Sigma-Aldrich Co., USA. Agar solutions 
(0.6% and 1% w/v) were prepared by dissolving the powder in deionized 
water with heating in boiling water. The homogenous agar solutions were 
stored at 4°C and melted in water bath before use. 
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2.1.7 Reagents for DNA extraction 
1. IGEPAL CA-630 lysis buffer 
The lysis buffer was prepared with 3% non-ionic detergent IGEPAL CA-630 
((Octylphenoxy) polyethoxyethanol) in 50 mM Tris [hydroxymethyl] amino 
methane (Tris)-HCl of pH 7.5. It was stored at room temperature. 
2. Proteinase K 
Proteinase K is a highly active subtilisin kind of protease that was isolated 
from Tritirachium album Limber. Stock solution of 20 ug/uL was prepared 
by dissolving proteinase powder (USB Corporation, USA) in autoclaved 
deionized water and stored at -20°C as 500 uL aliquots. 
3. Sodium dodecyl sulphate (SDS) 
SDS powder was purchased from USB Corporation, USA. The SDS solution 
(5%, w/v) was prepared by dissolving 5g of SDS powder in 100 mL 
deionized water. It was stored at room temperature. 
4. TioEo.i buffer 
The buffer was made up with 10 mM Tris-HCl and 0.1 mM EDTA in 
deionized water (pH 7.5). It was stored at room temperature. 
5. RNaseA 
Lyophilized RNase A powder isolated from bovine pancreas was purchased 
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from USB Corporation, USA. Stock solution of lO^ig/uL was prepared by 
dissolving RNase A powder in TioEo.i buffer with boiling for 15 minutes to 
remove any contaminated DNase. The stock solution was stored at -20°C as 
500 ^L aliquots. 
6. Sodium acetate (NaOAc) 
NaOAc powder was purchased from Sigma-Aldrich Co., USA. The 3 M 
stock solution was prepared by dissolving 24.61 g NaOAc powder in 100 mL 
deionized water (pH 5.2). The solution was sterilized by autoclaving at 
121°C for 20 minutes and stored at room temperature. 
2.1.8 Reagents for geI electrophoresis of nucleic acids 
1. Tris-borate-EDTA (TBE) buffer (5X) 
The 5X buffer stock was prepared by dissolving 54 g Tris, 27.5 g boric acid 
and 20 mL 0.5 M EDTA in one litre deionized water with pH 8.0. All 
chemicals were purchased from USB Corporation, USA. 0.5X working 
buffer was prepared by diluting the stock solution by 10-fold with deionized 
water. Both stock and working buffers were stored at 4°C. 
2. Gel loading buffer (5X) 
The gel loading buffer contains 0.05% (w/v) bromophenol blue, 0.5% (w/v) 
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SDS，40% (w/v) sucrose and 0.1 M EDTA. The buffer was used in 
non-denaturing agarose gel electrophoresis of nucleic acids. The volume of 
buffer to the volume of DNA sample was 1:4 for each well. The buffer as 
stored at 4°C. 
3. 100 bp DNA ladder 
The DNA ladder (1 ug/uL) was purchased from Invitrogen Life Technologies, 
USA. Working solution (0.1 ug/uL) was prepared by diluting- the stock 
solution by 10-fold using TioEo.i buffer The stock and working solutions 
were stored at -20°C and 4°C respectively. 
4. Agarose gel 
Agarose-LE powder was purchased from USB Corporation, USA. (w/v) 
Agarose gels (1% and 2% w/v) were prepared by dissolving 10 g and 20 g of 
agarose powder in one litre 0.5X TBE buffer respectively. The solution was 
heated up to 70°C with continuous stirring until a clear solution was obtained. 
The agarose gel was stored at room temperature and was melted in 
microwave oven before use. 
5. Ethidium bromide (EtBr) 
The EtBr powder was purchased from Sigma-Aldrich Co., USA. The stock 
solution (10 mg/mL) was prepared by dissolving the powder in deionized 
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water. Working solution (1 ^ig/mL) was prepared by diluting the stock 
10,000-fold using deionized water. Both stock and working solutions were 
stored in dark at room temperature. 
2.1.9 Reagents and buffers for flow cytometry 
1. Propidium iodide (PI) DNA staining solution 
The PI DNA staining solution was freshly prepared by mixing 20 uL PI (40 
ug/mL) (Sigma-Aldrich Co., USA), 1 uL RNase A (8 ug/mL) (USB 
Corporation, USA) and 979 uL PBS to 1 mL before use. The PI stock 
solution was stored in dark at 4°C. 
2. Dihydroethidium (Hydroethidine, DHE) 
DHE is a superoxide indicator purchased from Molecular Probes. It exhibits 
blue fluorescence in cytosol while it is oxidized to red fluorescent ethidium in 
the presence of superoxide. The stock solution (10 mM) was freshly prepared 
by dissolving 1.577 mg in 0.5 mL DMSO and kept in dark at -20�C. Working 
solution (10 uM) was freshly prepared by diluting the stock solution in PBS. 
3. EthanoI (70% v/v) 
Absolute ethanol of analytical grade was purchased from Merck Biosciences, 
Germany. Ethanol (70%) was prepared by diluting 70 mL absolute ethanol 
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with 30 mL deionized water. It was used for cell fixation in cell cycle 
analysis and stored at 4°C. 
2.1.10 Reagents and buffers for measuring caspase activity 
1. Cell lysis buffer 
The buffer was made up with 1% (v/v) IGEPAL CA-630 (Sigma-Aldrich Co., 
USA), 150 mM NaCl, 50 mM Tris-Hcl, 1 mM EDTA and a tablet of 
Complete Protease Inhibitor Cocktail (Roche Diagnostics) in 50 mL 
deionized water at pH 7.5. The buffer was stored at 4°C. 
2. DithiothreitoI (DTT) 
DTT was purchased from GIBCO BRL Life Technologies Inc., USA. Stock 
solution (1 M) was prepared by dissolving DTT in deionized water. It was 
added to the 2x reaction buffer just before use with a final concentration of 
10 mM. It stabilizes enzymes with free sulfhydryl groups and thus enzymes 
can work in full activity. The stock solution was stored at -20°C. 
3. Bovine serum albumin (BSA) 
BSA was purchased from Sigma-Aldrich Co., USA. Stock solutions (2 
mg/mL and 10 mg/mL) were prepared by dissolving BSA in deionized water. 
Stock solution (2 mg/mL) was used to construct the protein standard curve 
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for protein quantification. Stock solution (10 mg/mL) was added to 2X 
reaction buffer to a final concentration of 100 ^g/mL. The stock solutions 
were stored at -20°C. 
4. Reaction buffer (2x) 
The 2X reaction buffer was made up with 20 mM HEPES-KOH (pH 7)，80 
mM P-glycerophosphate, 100 mM NaCl, 4 mM MgCl2, 10 mM EGTA, 0.2% 
CHAPS. The buffer was stored at 4°C. DTT (10 mM) and BSA (100 ^igAnL) 
were added to the buffer right before use. 
5. Bradford reagent 
The Bradford reagent was purchased from Sigma-Aldrich Co., USA. The 
reagent was used in protein quantification based on complexing of proteins 
with Brilliant BlueG. A 1:1 volume ratio of diluted protein sample and 
Bradford reagent was mixed in the assay. The reagent was stored in a 
light-exclusive container at 4°C. 
6. Caspase 3 substrate (Ac-DEVD-AMC) 
Acetyl-Asp-Glu-Val-Asp-7-Amido-4-methylcoumarin (Ac-DEVD-AMC) is 
a fluorogenic substrate for caspase 3 that was purchased from Sigma-Aldrich 
Co., USA. The 2 mM stock solution was prepared by dissolving the powder 
in DMSO and stored in dark at -20°C. 
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7. Caspase 3 inhibitor (Ac-DEVD-CHO) 
Acetyl-Asp-Glu-Val-Asp-aldehyde (Ac-DEVD-CHO) is a highly specific, 
potent and reversible inhibitor of caspase 3 that was purchased from ALEXIS 
Biochemicals, USA. The 10 mM stock solution was prepared by dissolving 
the lyophilized powder in DMSO and was stored at -20°C. 
8. Caspase 8 substrate (Ac-IETD-AMC) 
Acetyl-Ile-Glu-Thr-Asp-7-Amido-4-methylcoumarin (Ac-IETD-AMC) is a 
specific fluorogenic substrate for caspases 6, 8 and 10 and granzyme B. It 
was purchased from ALEXIS Biochemicals, USA. The 1 mM stock solution 
was prepared by dissolving the powder in DMSO and stored in dark at -20°C. 
9. Caspase 8 inhibitor (Ac-IETD-CHO) 
Acetyl-Ile-Glu-Thr-Asp-aldehyde (Ac-IETD-CHO) is a reversible inhibitor 
of caspases 6，8 and 10 and granzyme B. It was purchased from ALEXIS 
Biochemicals, USA. The 10 mM stock solution was prepared by dissolving 
the powder in DMSO and stored at -20°C. 
10. Caspase 9 substrate (Ac-LEHD-AMC) 
Ac-Leu-Glu-His-Asp-7-Amido-4-methylcoumarin (Ac-IEHD-AMC) is a 
fluorogenic caspase 9 substrate that was purchased from ALEXIS 
Biochemicals, USA. The 5 mM stock solution was prepared by dissolving the 
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powder in DMSO stored at -20°C. 
11. Caspase 9 inhibitor (Ac-LEHD-CHO) 
Acetyl-Leu-Glu-His-Asp-aldehyde (Ac-LEHD-CHO) is a reversible inhibitor 
of caspase 9 that was purchased from ALEXIS Biochemicals, USA. The 10 
mM stock solution was prepared by dissolving the powder in DMSO and 
stored at -20°C. 
12. 7-Amido-4-methyIcoumarin (AMC) 
AMC was purchased from Sigma-Aldrich Co., USA. It was used as the 
standard for the quantification of caspase 3 activity. The 50 mM stock 
solution was prepared by dissolving AMC in DMSO. The 100 i^M working 
solution was prepared by dissolving the stock in lysis buffer. Both the stock 
and working solutions were stored in dark at 4°C. 
13. Caspase family inhibitor (Z-VAD(OMe)-FMK) 
Z-Val-Ala-Asp(OMe)-fluoromethylketone (Z-VAD(OMe)-FMK) is an 
irreversible and cell permeable broad-spectrum inhibitor of caspases that was 
purchased from ALEXIS Biochemicals, USA. The 10 mM stock solution was 
prepared by dissolving the powder in DMSO and stored at -20°C. 
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2.1.11 Reagents, Buffers and Materials for Western Blot Analysis 
1. Cell Iysis buffer 
The lysis buffer was made up of 1% (v/v) LGEPAL-CA 630 (Sigma-Aldrich 
Co., USA), 150 mM NaCl, 50 mM Tris-HCl (pH 7,5) and a tablet of 
Complete Protease Inhibitor Cocktail (Roche Molecular Biochemicals, USA) 
in 50 mL deionized water. The tablet yielded a mixture of several protease 
inhibitors with a broad spectrum of activity on serine, cysteine and 
metalloproteases and calpains. The buffer was stored at 4°C until use. 
2. Bradford reagent 
The Bradford reagent was purchased from Sigma-Aldrich Co., USA. The 
reagent was used in protein quantification based on complexing of proteins 
with Brilliant BlueG. A 1:1 volume ratio of diluted protein sample and 
Bradford reagent was mixed in the assay. The reagent was stored in a 
light-exclusive container at 4°C. 
3. 30% Acrylamide / bisacrylamide solution 37.5:1 (w/v) 
Acrylamide / bisacrylamide solution at a concentration of 30% was 
purchased from Bio-Rad Laboratories, USA. The ready-to-use solution 
contains 146.1 g acrylamide and 3.9 g N,N'-methylene-bisacrylamide. The 
total monomer to crosslinker ratio is 37.5:1. The solution was stored in a 
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light-exclusive container at 4°C. 
4. Ammonium persulfate (APS) 
Ammonium persulfate was purchased from Bio-Rad Laboratories, USA. The 
working solution (10%, w/v) was prepared by dissolving 0.1 g APS powder 
in 1 mL deionized water. The solution was stored at -20°C and warmed to 
37°Cjust before use. 
5. N,N,N',N'-tetra-methyIethylenediamine (TEMED) 
TEMED was purchased from Bio-Rad Laboratories, USA. It was used in the 
catalysis of polymerization of acrylamide/ bisacrylamide solution in the setup 
of SDS-polyacrylamide gel. It was stored in a light-exclusive container at 
4 � C . 
6. Sodium dodecyl sulphate (SDS) 
SDS powder was purchased from USB Corporation, USA. The SDS solution 
(10%, w/v) was prepared by dissolving 10 g of SDS powder in 100 mL 
deionized water. It was stored at room temperature. 
7. Bovine serum albumin (BSA) 
Bovine serum albumin was purchased from Sigma-Aldrich Co., USA. The 2 
mg/mL stock solution was prepared by dissolving the powder in deionized 
water. The stock solution was subjected to serial dilution in deionized water 
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to obtain the protein standard curve in Bradford assay. The powder was 
stored at 4°C and the stock solution was stored at -20°C. 
8. Lower buffer 
The 1.5 M lower buffer (pH 8.8) was prepared by dissolving 18.15 g Tris in 
100 mL deionized. It was used to prepare the resolving gel. The buffer was 
stored at 4°C. 
9. Upper buffer 
The 0.5 M upper buffer (pH 6.8) was prepared by dissolving 6 g Tris in 100 
mL deionized water. It was used to prepare the stacking gel. The buffer was 
stored at 4°C. 
10. Sample loading buffer (4X) 
The loading buffer (8 mL) was prepared by mixing 2 mL glycerol, 2 mL 10% 
(w/v) SDS, 2 mL upper buffer, 0.4 mL 0.05% (w/v) bromophenol blue, 0.2 
mL 2-mercaptoethanol and 1.4 mL deionized water. The buffer was stored in 
a light-exclusive container at 4°C. 
11. Novex® Sharp pre-stained protein standard 
The protein standard was purchased from Invitrogen Corporation, USA. It 
contains 12 proteins that resolve into 12 sharp and tight bands in the range of 
3.5 to 260 kDa upon electrophoresis. The standard is ready-to-use and stored 
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at -20�C. 
12. SDS running buffer (lOX) 
The 10X running buffer was prepared by dissolving 30.3 g Tris base (pH 8.6), 
144 g glycine and 10g SDS to one litre deionized water. The IX running 
buffer was prepared by diluting 10X stock solution with deionized water by 
10-fold. All the chemicals were purchased from USB Corporation, USA. The 
solutions were stored at 4°C. 
13. Transfer buffer (lOX) 
The 10X buffer was prepared by dissolving 30.3 g Tris-base (pH 8.6) and 
144 g glycine in 1 L deionized water. The 1 X transfer buffer was prepared 
by diluting 10X stock solution with deionized water by 10-fold followed by 
adding 1/5 volume of methanol (Fisher Scientific, USA). The solutions were 
stored at 4°C. 
14. Immobilon-P poIyvinylidene fluoride (PVDF) membrane 
PVDF membrane purchased from Millipore Corporation (USA) was made 
from hydrophobic PVDF with 0.45 ^m pore size. It was stored at room 
temperature and cut to desired size for Westem blotting. 
15. Blotting paper 
Blotting paper (3mm chromatography sheet) was purchased from Whatman, 
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USA. The paper with thickness of 0.34 mm was made of pure cellulose. It 
was stored at room temperature and cut to desired size for Westem blotting. 
16. TBS-Tween washing buffer (lOX) 
The washing buffer contains 100 mM Tris (pH 7.5)，1 M NaCl and 1% (v/v) 
Tween 20 (Sigma-Aldrich Co., USA) in deionized water. The IX buffer was 
prepared by diluting the 10X buffer with deionized water by 10-fold. The 
solutions were stored at 4°C. 
17. Non-fat milk solution (5%, w/v) 
The 5% non-fat milk solution was prepared freshly by dissolving 0.25 g 
Nestle (Hong Kong) non-fat milk powder in 5 mL IX TBS-Tween washing 
buffer. It was used as the blocking solution. The powder was stored in a can 
at room temperature. 
18. Primary antibodies 
i Mouse anti-p-actin monoclonal antibody 
This mouse IgG2a antibody was derived from the AC-74 hydridoma 
from the fusion of mouse myeloma cells with splenocytes from an 
immunized mouse. The antibody recognizes an epitope located on the 
N-terminal end of the p-isoform of actin, The antibody cross-reacts 
with p-actin expressing cells in human, bovine, sheep, pig, rabbit, cat, 
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dog, mouse, rat, guinea pig, chicken, carp, leech and fruitfly tissues, 
but not in amoeba. The antibody labels p-actin and gives a band of 42 
kDa in immunoblotting. The antibody was in a form of ascites fluid 
containing 0.1% sodium azide. It was stored at -20°C for long-term 
storage and at 4°C for continuous use. 
ii Mouse anti-human cycIin B1 monoclonal antibody 
This mouse IgGl antibody was derived from GNS-1 clone. The 
antibody recognizes an epitope between amino acids 1-21 of human 
cyclin B1. It cross-reacts with hamster and mouse cyclin B1 proteins. 
The antibody labels cyclin B1 and gives a band of 62 kDa in 
immunoblotting. The antibody was purified from ascites or hybridoma 
tissue culture supernatant. It was supplied as 0.1 mg antibody in 50 
mM Tris-HCl, pH 8.0，with 150 mM NaCl and 0.09% (w/v) sodium 
azide. It was stored at 4°C. 
iii Rabbit anti-human Cdc2 p34 polyclonal antibody 
This rabbit IgG antibody was raised against a peptide mapping at the 
C-terminus of Cdc2 p34 of human origin. The antibody cross-reacts 
with Cdc2 p34 of mouse, rat and human. The antibody labels Cdc2 and 
gives a band of 34 kDa in immunoblotting. It was supplied as 200 ^g 
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IgG in 1.0 mL ofPBS with < 0.1% sodium azide and 0.1% gelatin. It 
was stored at 4°C. 
iv Rabbit anti-human cyclin A polyclonal antibody 
This rabbit IgG antibody was raised against amino acids 1-432 
representing full length cyclin A of human origin. The antibody 
cross-reacts with cyclin A and cyclin A1 of mouse, rat and human 
origin. The antibody labels cyclin A and gives a band of 54 kDa in 
immunoblotting. It was supplied as 200 i^g IgG in 1.0 mL ofPBS with 
<0.1% sodium azide and 0.1% gelatin. It was stored at 4°C. 
V Rabbit anti-human Bcl-Xs/L polyclonal antibody 
This rabbit IgG antibody was raised against a peptide at the carboxyl 
terminus of Bcl-xt of human origin and the peptide is identical to the 
corresponding sequence in mouse. The antibody cross-reacts with 
Bcl-xs and Bcl-XL of mouse, rat and human origin. The antibody labels 
Bcl-xs and Bcl-XL and gives a band o f l 8 kDa and 30 kDa respectively 
in immunoblotting. It was supplied as 200 ^g IgG in 1.0 mL of PBS 
with 0.1% sodium azide and 0.2% gelatin. It was stored at 4°C. 
vi Rabbit anti-human Bid polyclonal antibody 
This rabbit IgG antibody was raised against amino acids 1-195 ofBid 
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ofhuman origin. The antibody cross-reacts with mouse, rat and human 
origin. The antibody labels Bid and gives a band of 22 kDa in 
immunoblotting. It was supplied in 1.0 mL ofPBS with < 0.1% sodium 
azide and 0.1% gelatin. It was stored at 4°C. 
vii Mouse anti-mouse Bax monoclonal antibody 
This mouse IgG2b antibody was raised against amino acids 1-171 of 
Baxa of mouse origin. The antibody labels Baxa and Baxf of mouse, 
rat and human origin and gives a band of 22kDa in immunoblotting. It 
was supplied in 1 mL of PBS with < 0.1% sodium azide and 0.1% 
gelatin. It was stored at 4°C. 
viii Mouse anti-human c-Myc monoclonal antibody 
This mouse IgGl antibody was raised against the full length c-Myc of 
human origin. The antibody cross-reacts with mouse, rat, human and 
chicken c-Myc. The antibody labels c-Myc and gives a band of 67 kDa 
in immunoblotting. It was supplied in 1.0 mL of PBS with < 0.1% 
sodium azide and 0.1% gelatin. It was stored at 4°C. 
ix Rabbit anti-human ICAD polyclonal antibody 
This rabbit IgG antibody was raised against the amino acids 1-331 
representing full length of ICAD of human origin. The antibody 
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cross-reacts with mouse, rat and human. The antibody labels ICAD and 
gives bands of 45 and 35 kDa in immunoblotting. It was supplied in 
1.0 mL of PBS with < 0.1% sodium azide and 0.1% gelatin. It was 
stored at 4°C. 
X Mouse anti-human Ras monoclonal antibody 
This mouse IgGl antibody was derived from 18/Ras clone. The 
antibody recognizes an epitope between amino acids 1-190 of human 
Ras. It cross-reacts with human, chicken, dog, rat and mouse Ras 
proteins. The antibody labels Ras and gives a band of 21 kDa in 
immunoblotting. The antibody was purified from ascites or hybridoma 
tissue culture supernatant. It was supplied as 50 i^g antibody in 50 
aqueous buffered solution containing BSA, glycerol and < 0.09% (w/v) 
sodium azide. It was stored at 4°C. 
xi Rabbit anti-human c-Jun polyclonal antibody 
This rabbit IgG antibody was raised against the amino acids 1-79 of 
c-Jun of human origin. The antibody cross-reacts with mouse, rat, 
human. The antibody labels c-Jun and gives a band of 43 kDa in 
immunoblotting. It was supplied in 1.0 mL ofPBS with < 0.1% sodium 
azide and 0.1% gelatin. It was stored at 4°C. 
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xii Rabbit anti-human tau polyclonal antibody 
This rabbit IgG antibody was raised against the peptide near the 
C-terminus of tau of human origin. The antibody cross-reacts with 
mouse, rat, human. The antibody labels tau and gives bands between 
43 kDa and 55 kDa in immunoblotting. It was supplied in 1.0 mL of 
PBS with < 0.1% sodium azide and 0.1% gelatin. It was stored at 4°C. 
19. Secondary antibodies 
i Sheep anti-mouse IgG-HRP and donkey anti-rabbit IgG-HRP 
ECL™ mouse IgG, horseradish peroxidase (HRP)-linked whole 
antibody (from sheep) and ECL™ rabbit IgG horseradish peroxidase 
(HRP)-linked whole antibody (from donkey) were purchased from 
Amersham Biosciences. The antibodies were in phosphate buffered 
saline (sodium phosphate 0.1 M，NaCl 0.1 M) at pH 7.5 containing 1% 
(w/v) bovine serum albumin and an anti-microbial agent. They were 
stored at 4°C. 
ii Donkey anti-goat IgG-HRP 
The horseradish peroxidase conjugated secondary antibody was 
purchased from Santa Cruz Biotechnology Inc., USA. It was supplied 
at 200 fig in 0.5 mL volume. It was stored at 4°C. 
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20. Western blotting luminol reagent 
The reagent was purchased from Santa Cruz Biotechnology Inc., USA. It 
contains solution A and solution B in separate, light-exclusive containers. 
The solutions contain dimethylsulfoxide, luminol, p-coumaric acid and 
hydrogen peroxide. Solution A and solution B were mixed in equal volume 
and incubated with the PVDF membrane. HRP-mediated oxidation of 
luminol in the presence of hydrogen peroxide and an iridescent light was 
produced for image development. The solutions were stored at 4°C. 
21. X-ray films 
The medical X-ray films were purchased from Fujifilm Corporation, Japan. 
The films were stored in a light-exclusive box at 4°C. 
2.1.12 Reagent for Hoechst staining 
1. Hoechst 33342 (trihydrochloride, trihydrate) 
Hoechst 33342 (10 mg/mL, 16.2 mM solution in deionized water) was 
purchased from Molecular Probes Inc., USA. The Hoechst 33342 dye is a 
cell-permeable blue fluorescent dye that stains nucleic acid with selectivity 
towards AT. The 10 ^ig/mL working solution was freshly prepared by 
diluting 10 mg/mL stock solution in PBS. The stock solution was stored in a 
light-exclusive container at 4°C. 
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2.2 Methods 
2.2.1 Culture of cell lines 
The murine neuroblastoma cell line Neuro-2a BU-1 and the human 
neuroblastoma cell line LA-N-1 were cultured in complete RPMI 1640 medium 
supplemented with 10% FBS and 1% antibiotics as continuous adherent cultures. 
The human neuroblastoma cell line SH-SY5Y was cultured in DMEM/F12 
medium supplemented with 15% FBS, 1% antibiotics, 1 mM sodium pyruvate 
and MEM NEAA. All cell lines were cultured in 150 cm^ tissue culture flask and 
incubated at 37�C in a 5% CO2-saturated and humidified incubator. The cell lines 
were subcultured every 2 to 4 days depends on the doubling time of the cell line. 
Cryopreservation was done at early passage of the culture. The cryopreservation 
medium was made up of50% FBS, 40% RPMI and 10% DMSO. The cryo-vials 
were stored in a tank ofliquid nitrogen for long-term storage. 
For subculture of Neuro-2a BU-1 cells and SH-SY5Y cells, the culture 
medium was discarded and the adherent cells were washed with warm sterilized 
PBS. The cells were then incubated with 1 mL 0.25% warmed trypsin-EDTA 
solution for 1 minute at 37�C incubator. Complete medium was used to quench 
the process of trypsinization. For subculture of LA-N-1 cells, the cells were 
detached by gentle pipetting. The cell suspension was centrifuged at 600 x g for 
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3 minutes and cells were seeded into a new tissue culture flask with warm 
complete medium at appropriate cell density. 
2.2.2 Determination of cell viability 
MTT reduction assav 
Cells were seeded into 96-well flat-bottomed microplates and cultured 
ovemight. The cells were then incubated with different concentrations of 
alkaloids for 24，48 or 72 hours in a 5% CO2-saturated and humidified incubator 
at 37 T . DMSO was included as the solvent control. At the end of incubation, 
plates were centrifuged at 300 x g for 10 minutes. Removal of the supernatant by 
suction was followed by solubilization of purple formazan with 50 i^L DMSO. 
The plates were subjected to horizontal shaking for one minute before the 
measurement of absorbance at 540 nm by a BENCHMARK microplate reader 
(Bio-Rad Laboratories). The results were expressed as average percentage 
cytotoxicity 土 standard error (S.E.) of quadruplicate cultures. The percentage 
cytotoxicity was calculated as follows: 
0/0 Cytotoxicity = [(OD540 of control - OD540 of test sample/ OD540 ofcontrol)] x 
100% 
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Trypan blue exclusion assay 
Trypan blue exclusion assay was used to determine the number of viable 
and dead cells in the cultures and hence the percentage viability. Trypan blue is a 
viable dye that only stains the cells with compromised cell membrane integrity 
but not viable cells with intact plasma membrane. The cells were treated with 
different concentrations of alkaloids for 24, 48 and 72 hours in a 5% 
CO2-saturated and humidified incubator at 2>TC. At the end of incubation, cells 
were collected similar to the procedure of subculture and the cell pellets were 
collected by centrifugation at 600 x g for 3 minutes. The pellets were 
resuspended in ice-cold PBS. Ten microlitres of cell suspension was mixed with 
an equal volume of trypan blue dye by pipetting up and down. Then, 10 i^L of the 
mixture was filled in each chamber of a hematocytometer. The number of both 
bright viable cells and blue dead cells were counted under a light microscope at 
100X magnification. The percentage cell viability was calculated as follows: 




2.2.3 Determination ofcell proliferation by tritiated thymidine ([^]-TdR) 
incorporation assay 
Cells were seeded into 96-well flat-bottomed microplates and cultured 
ovemight. The cells were then incubated with different concentrations of 
alkaloids, doxorubicin and DMSO up to 72 hours in a 5% CO2-saturated and 
humidified incubator at 37T . At the end of incubation, the cells were pulsed 
with 0.5 ^iCi [^H]-TdR in 20 i^L of assay medium for 6 hours in the incubator at 
37�C. The microplates were then frozen in a -20�C freezer ovemight. The 
microplates were thawed at 37�C for 2 hours before harvesting the cells onto 
UniFilter 96 GF/C using a cell harvester (Packard FilterMate™). The filter plates 
were allowed to dry in air ovemight. The bottom of filter plates was sealed with 
adhesive backseal. OptiPhase "Hisafe" 2 liquid scintillation cocktail (30 ^iL) was 
added into each well of the plate. A microplate scintillation and luminescence 
counter (TopCount® NXT™) was used to measure the radioactivity which was 
expressed in counts per minutes (cpm). The results were expressed as the average 
percentage of inhibition of [3H]-TdR incorporation 土 S.E. of quadruplicate 
cultures compared to the control group (solvent-treated cells). The percentage 
inhibition o f [ ^ ] - T d R incorporation was calculated as follows: 
% Inhibition = [(cpm of control-cpm of test sample)/ cpm ofcontrol] x 100% 
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2.2.4 Isolation, culture and cytotoxicity test of murine peritoneal 
macrophages 
Female BALB/c mice were injected intraperitoneally with 1 mL sterile 3% 
thioglycollate broth using a 3 mL syringe and a 25-gauge needle for the 
recruitment of macrophages in the peritoneal cavity. After three days, mice were 
sacrificed by cervical dislocation. A tiny cut was made using a pair of scissors, 
followed by tearing the abdominal skin apart until the abdominal wall could be 
clearly seen. Ice-cold plain RPMI medium (3 mL) and an equal volume of air 
were injected into the peritoneal cavity using a 5 mL syringe fitted with a 
20-gauge needle. The injected air inflated the cavity and the medium washed the 
cavity. The cell-suspended medium was collected using the same syringe and 
needle. The washing step was repeated three times. The collected 
thioglycollate-elicited peritoneal cells were centrifuged at 600 x g for 3 minutes 
to pellet the cells which were then treated with ice-cold ACK buffer for 5 
minutes to facilitate the lysis of contaminated red blood cells. Afterwards, the 
cell suspension was centrifuged at 600 x g for 3 minutes. The pellet was 
resuspended with RPMI medium supplemented with 10% HI-FBS at a 
concentration of 10^ cells/mL. The cells were seeded to the wells in 96-well 
flat-bottomed microplates and incubated at 37°C for 2 hours before washing 
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away the non-adherent cells. Different concentrations of alkaloids were added for 
cytotoxicity test on the murine peritoneal macrophages. 
2.2.5 Isolation, culture and cytotoxicity test of murine bone marrow cells 
Female BALB/c mice were sacrificed by cervical dislocation. A tiny cut was 
made using a pair of scissors, followed by tearing the abdominal skin. The 
femurs of the back legs were cut out with intact patella. A 5 mL syringe fitted 
with a 25-gauge needle was used to flush the bone marrow out with 3 mL plain 
RPMI medium. The washing step was repeated twice at both ends of the femurs. 
The collected bone marrow cells were centrifuged at 600 x g for 3 minutes to 
pellet the cells which were then treated with ice-cold ACK buffer for 5 minutes 
to facilitate the lysis of red blood cells. Afterwards, the cell suspension was 
centrifuged at 600 x g for 3 minutes. The pellet was resuspended with RPMI 
medium supplemented with 10% HI-FBS at a concentration of 10^ cells/mL. The 
cells were seeded to the wells in 96-well flat-bottomed microplates. Different 
concentrations of alkaloids were added for cytotoxicity test on the murine bone 
marrow cells. 
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2.2.6 Cytotoxicity test of primary cortical neurons from SD rats 
The primary embryonic cortical neurons were a kind gift from Professor K.F. 
Lau, Department of Biochemistry, The Chinese University of Hong Kong, 
HKSAR, China. The culture medium containing minimum essential medium 
(MEM) supplemented with 5% heat-inactivated fetal bovine serum, glucose 
(18 mM), L-glutamine (2 mM), insulin (5 p-g/ml), progesterone (0.02 ^iM), 
putrescine (100 ^iM), selenium (30pM), penicillin (50 U/ml) and streptomycin 
(50 p.g/ml). The cells (30,000/well) were seeded in a tissue culture 96-well 
flat-bottomed microplate. After 5 days, different concentrations of alkaloids were 
added and incubated at 37"C for 48 hours. 
2.2.7 Determination of colony forming ability 
Double-layered soft agar assay was used to determine the colony forming 
ability of murine neuroblastoma Neuro-2a BU-1 cells. The bottom layer was set 
in the wells of 6-well culture plate with a 1 mL mixture of semi-solid agar (1%) 
and RPMI medium supplemented with 15% HI-FBS. The bottom layer was 
allowed to solidify at room temperature for 30 minutes. The upper layer was set 
with a 1 mL mixture of semi-solid agar (0.6%), RPMI medium supplemented 
with 15% HI-FBS, 10VmL Neuro-2a BU-1 cells and the drug. The plates were 
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incubated in a 5% CO2-saturated and humidified incubator at 37°C. Visible 
colonies with >50 cells were counted after 10 — 14 days of incubation using an 
inverted light microscope. The colony forming ability was expressed as 
percentage colonies relative to control and was calculated as follow: 
Percentage colonies = (Average number of colonies in drug-treated group / 
average number of colonies in solvent control group) x 
100% 
2.2.8 Analysis of cell cycle profile/DNA content by flow cytometry 
Neuro-2a BU-1 cells (10VmL) were seeded into 100 mm culture dishes and 
incubated in a 5% CO2-saturated and humidified incubator at 37�C ovemight. 
The cells were then synchronized in plain RPMI medium for 24 hours in the 
incubator. The RPMI medium was replaced by RPMI supplemented with 10% 
HI-FBS after synchronization. Cells were incubated with different concentrations 
of alkaloids up to 72 hours. At the end of incubation, the cells were collected 
after trypsinization as mentioned in "Culture of cell lines". Cells (1 x 10^) were 
washed by ice-cold PBS once at 425 x g for 3 minutes. The cells were then fixed 
with 1 mL 70% ethanol at 4 T for 30 minutes. The ethanol was removed after 
centrifugation at 425 x g for 10 minutes. The cells were washed with PBS once 
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and stained by 1 mL of propidium iodide staining solution in the dark at 37 ®C 
with occasional shaking. The fluorescence intensity of stained cells was 
measured by a flow cytometer (Becton Dickinson FACSCanto). Cells (lxlO^) 
were analyzed for each sample using the BD FACSDiva software. The 
percentage of cells in Go/Gi, S and G2/M phase of cell cycle were calculated by 
the Modfit 3.0 program (Verity Software House). 
Measurement of apoptosis 
2.2.9 Detection of DNA fragmentation by agarose gel electrophoresis 
c ^ 
Neuro-2a BU-1 cells (10 cells/mL) were seeded in 150 cm tissue culture 
flask and incubated in a 5% CO2-saturated and humidified incubator at 37°C 
ovemight. Different concentrations of alkaloids were added and the cells were 
incubated at 37°C up to 48 hours. The cells were trypsinized and centrifuged at 
600 X g for 3 minutes to pellet the cells. The cell pellets were then washed with 
ice-cold PBS once and lysed by adding 200 |iL IGEPAL CA-630 lysis buffer for 
20 minutes at 37�C，followed by centrifugation at 7500 x g for 5 minutes. 
Supematants were transferred to new microfuge tubes and 50 ^iL 5% SDS was 
added. Then 10 ^iL RNase A (10 mg/mL) was added to each sample and 
incubated for 1.5 hours at 56"C. Afterwards, 20 ^iL proteinase K was added and 
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incubated for 1.5 hours at 56�C. RNase A was used to remove any contaminated 
RNA and proteinase K was used to remove proteins in the samples. DNA was 
then precipitated in the presence of 0.1 volume of 3 M sodium acetate and 2.5 
volume of 100% ethanol at 18,000 x g for 30 minutes at 4�C. The DNA pellet 
was then washed with 70% ethanol and 100% ethanol at 18,000 x g for 5 minutes 
respectively. After air dried the DNA pellet, 20 i^L TioEo.i buffer was used to 
resuspend and dissolved the pellet at 37�C for 30 minutes. The DNA samples 
were heated at 65�C for 5 minutes before loading them into the wells of a 2% 
agarose gel. A 100bp DNA marker was run parallel to the samples at 100 volts. 
At the end of electrophoresis, the gel was stained with ethidium bromide for 5 
minutes and destained in deionized water for 10 minutes. The DNA bands were 
visualized with UV illumination and the image was captured by using Bio-Rad 
Gel Doc 2000. 
2.2.10 Quantitative detection ofDNA fragmentation by CeII Death 
ELISAPLUS kit 
Cell Death Detection ELISA^^^^ is a photometric enzyme-immunoassay kit 
that purschased from Roche Applied Science. It allows both in vitro qualitative 
and quantitative determination of cytoplasmic histone-associated DNA fragments 
- 7 8 -
Chapter 2 
(mono- and oligonucleosomes) after cell death induction. It is a sandwich-ELISA 
using two different mouse monoclonal antibodies targeted against DNA or 
histones. Briefly, the Neuro-2a BU-1 cells (7,500/well) were seeded and 
incubated in a 96-well flat-bottomed microtiter plate in a 5% CO2-saturated and 
humidified incubator at 37°C ovemight. Indirubin-3'-oxime was incubated with 
the cells for 16 hours. At the end of incubation, the plate was centrifuged at 200 x 
g for 10 minutes. The supernatant containing any DNA fragments attributed to 
necrosis was removed. The adherent cells were treated with 200 i^L lysis buffer 
at 37"C for 30 minutes with constant shaking at 300 rpm. After that, the cell 
lysate was centrifuged at 200 x g for 10 minutes. Then 20 fiL supernatant was 
transferred into the streptavidin-coated microplate stripes and 80 ]xL of the 
immunoreagent containing anti-histone-biotin-labeled antibodies and 
anti-DNA-peroxidase-conjugated antibodies were added to each well. The 
content was allowed to mix for the binding and the formation of 
antibody-antigen-antibody sandwich in the microplate stripes with constant 
shaking at 300 rpm for 2 hours. The microplate stripes were aluminium 
foil-wrapped during the incubation period. Positive control and negative control 
were included in the assay. After the incubation, the solution in each well was 
removed by tapping and washed 3 times with the washing buffer provided. For 
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the last wash, the solution was removed completely by suction, followed by the 
addition of substrate ABTS. Negative control containing 20 i^L incubation buffer 
and 80 i^L immunoreagent per well was used to set blank. The colour developed 
immediately and the reading of absorbance (A405nm 一 A490nm) was measured by 
using a Bio-Rad microplate reader Benchmark and the software "Microplate 
Manager® Version 5.2". The results were expressed as enrichment factor which 
can be calculated as follows: 
Enrichment factor = Absorbance of samples / Absorbance ofsolvent control 
2.2.11 Detection of intracellular reactive oxygen species (ROS) generation 
Neuro-2a BU-1 cells (10^ cells/mL) were seeded in 100 mm culture dishes 
ovemight. The cells were treated either with different concentrations of 
indirubin-3'-oxime or 0.01% DMSO (solvent control) at 37�C up to 4 hours. The 
cells were collected and washed with PBS once. Dihydroethidium (DHE) was 
used to stain the cells at 37�C for 30 minutes in dark. The fluorescence intensity 
of stained cells was measured by a flow cytometer (Becton Dickinson 
FACSCanto). Cells (lxlO^) were analyzed for each sample using the BD 
FACSDiva software. WinMDI ver.2.9 software was used for analysis. 
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2.2.12 Measurement of caspase activity 
Cell treatment and harvest 
Neuro-2a BU-1 cells (10^ cells/mL) were seeded in 150 cm^ tissue culture 
flask and incubated in a 5% CO2-saturated and humidified incubator at 37°C 
ovemight. Different concentrations of indirubin-3'-oxime and 0.01% DMSO 
(solvent control) were added and the cells were incubated at 37�C up to 24 hours. 
The cells were trypsinized and were centrifuged at 600 x g for 3 minutes. The 
cell pellets were washed with ice-cold PBS once. 
Extraction and quantification of protein 
The cell pellets were treated with cell lysis buffer (50 ^iL/10^ cells) on ice 
for 10 minutes. Afterwards, the cell lysates were vortexed vigorously and then 
subjected to centrifugation at 20,800 x g for 3 minutes at 4 T . The supematants 
were transferred into new microcentrifuge tubes and kept on ice before next step. 
Bradford assay was used to measure the protein concentration in the cell 
lysates. First, a standard curve was constructed using 2 mg/mL bovine serum 
albumin (BSA) in deionized water. The standards were prepared by two-fold 
dilution. Equal volume of standard solutions and Bradford reagent were mixed in 
polystyrene cuvettes (Sarsted Ref # 67.742). A mixture of deionized water and 
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Bradford reagent was used for zero adjustment for the blank. The absorbance 
was measured at 595 nm using a BioPhotometer (Eppendorf). The concentrations 
ofproteins in samples were measured similarly as the standards. After calculating 
the protein concentration in each sample, cell lysis buffer was used to dilute the 
cell lysates into desirable concentration for fluorometric measurement of caspase 
activity. 
Fluorometric measurement of caspase activity 
Diluted cell lysates (50 |iL) were mixed with an equal volume of 2X 
reaction buffer and incubated with 1 i^L of caspase inhibitor at 37 °C for 30 
minutes with occasional shaking. Another set of sample was kept on ice without 
the caspase inhibitor in parallel. At the end of the incubation, specific caspase 
substrate was added to each sample and incubated at 37°C for a further one hour. 
The samples were transferred into a NUNC fluorescence 96-well flat-bottomed 
microplate. A standard was included in the assay. The fluorescence intensities of 
the standards and the samples were measured by a fluorescence plate reader 
(TECAN polarion). The caspase activity was calculated using the standard curve 
constructed. The results were expressed as fold change of AMC release to 
control. It was calculated as follows: 
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Fold change of AMC release = Fluorescence intensity in treated group / 
fluorescence intensity in solvent control group 
2.2.13 Hoechst 33342 staining 
Neuro-2a BU-1 cells (10^ cells/well) were seeded in the wells of a 24-well 
tissue culture plate ovemight. The cells were then incubated with different 
concentrations of I3M and 0.01% DMSO (solvent control) for 24 hours in a 5% 
CO2-saturated and humidified incubator at 37"C. The culture medium was 
discarded and the cells were washed with ice-cold PBS once, followed by 
fixation with 4% para-formaldehyde for 20 minutes. The fixed cells were washed 
with PBS and stained with Hoechst 33342 staining solution (10 ^g/ml) for 15 
minutes in dark. The fluorescence signal from the stained cells was observed 
under a fluorescence microscope (Nikon TE2000) and images were recorded. 
Measurement ofneuronal cell differentiation 
2.2.14 Cell morphological study 
Neuro-2a BU-1 cells (4000 cells/well) were seeded onto the thermanox 
plastic 13 mm coverslips (Nalge Nunc International) in a 24-well tissue culture 
plate ovemight. The cells were then incubated with different concentrations of 
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tryptanthrin and DMSO (solvent control) for 48 hours in a 5% CO2-saturated and 
humidified incubator at 37 °C. At the end of incubation, culture medium was 
discarded and the cells were washed once with ice-cold PBS, followed by 
fixation with methanol. The cells were allowed to be air-dried. Hemacolor® 
staining solutions (Diagnostica Merck) were used to stain the nucleus and 
cytoplasm of the cells differentially. Deionized water was used in the destaining 
step. The coverslips were air-dried and mounted on glass slides. The morphology 
ofthe stained cells was observed under a Zeiss Axioskop light microscope. 
2.2.15 Analysis of morphological changes by flow cytometry 
Neuro-2a BU-1 cells (10VmL) were seeded onto 100 mm culture dishes and 
incubated in a 5% CO2-saturated and humidified incubator at 37�C ovemight. 
The cells were then incubated with different concentrations of tryptanthrin or 
0.02% DMSO (solvent control) up to 96 hours at 3TC. The cells were then 
harvested and washed with ice-cold PBS once. The cell size and internal 
complexity of the cells were measured by the BD FACSCanto flow cytometer. 
The signals from forward light scatter (FSC) and side scatter (SSC) represent the 
cell size and internal complexity respectively. The data were analysed using the 
WinMDI Ver.2.9 software. 
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2.2.16 Assay for acetylcholine esterase (AChE) activity study 
c ^ 
Neuro-2a BU-1 cells (10 /mL) were seeded in 150 cm tissue culture flask 
and incubated in a 5% CO2-saturated and humidified incubator at 37®C ovemight. 
Different concentrations of tryptanthrin and DMSO (solvent control) were added 
and the cells were incubated at 37�C for 48 hours. At the end of incubation, the 
cells were harvested by trypsinization and were washed with PBS by 
centrifugation at 600 x g for 3 minutes. Cells (3 x 10^) were lysed in 600 i^L 
ice-cold cell lysis buffer for 10 minutes. Afterwards, the cell lysates were 
vortexed vigorously and then subjected to centrifugation at 20,800 x g for 3 
minutes at 4 °C. The protein concentration of each sample was measured by 
Bradford assay as described in "Extraction and quantification of protein" under 
"Measurement of caspase activity". Then 500 i^L supernatant of each sample was 
incubated with 50 i^M tetraisopropylpyrophosphoramide (Iso-OMPA), an 
inhibitor of non-specific cholinesterases. Standards of known concentration were 
prepared from bovine erythrocyte acetylcholine esterase by two-fold dilution in 
PBS. The samples were treated with reaction mixture containing sodium 
phosphate buffer (pH 8.0)，0.5 mM acetylthiocholine iodide (substrate) and 0.3 
mM 5,5 ‘ -dithio(bis)nitrobenzoic acid. Yellow colour was developed in the 
reaction mixture and the absorbance was measured at 412 nm using 
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BENCHMARK microplate reader (Bio-Rad Laboratories). The enzymatic 
activity was calculated with the construction of a standard curve. 
2.2.17 Protein expression study 
Treatment and harvest of cells 
Neuro-2a BU-1 cells (10^ cells/mL) were seeded in 150 cm^ tissue culture 
flask and incubated in a 5% CO2-saturated and humidified incubator at 37°C 
ovemight. Different concentrations of alkaloids and DMSO (solVent control) 
were added and the cells were incubated at 37�C up to 48 hours. The cells were 
trypsinized and were centrifuged at 600 x g for 3 minutes. The cell pellets were 
washed with ice-cold PBS once. 
Extraction and quantification of protein 
The cell pellets were treated with cell lysis buffer (50 ^L/10^ cells) on ice 
for 10 minutes. Afterwards, the cell lysates were vortexed vigorously and then 
subjected to centrifugation at 18,000 x g for 3 minutes at 4 °C. The supematants 
were transferred into new microcentrifuge tubes and kept on ice before next step. 
Bradford assay was used to measure the protein concentration in the cell 
lysates. First, a standard curve was constructed using 2 mg/mL bovine serum 
albumin (BSA) in deionized water. The standards were prepared by two-fold 
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dilution. Equal volume of standard solutions and Bradford reagent were mixed in 
polystyrene cuvettes. Mixture of deionized water and Bradford reagent was used 
for zero adjustment for the blank. The absorbance was measured at 595 nm using 
a BioPhotometer (Eppendorf). The concentrations of proteins in samples were 
measured similarly as the standards. After calculating the protein concentration 
in each sample, cell lysis buffer was used to dilute the cell lysates into 20 ^g/^L. 
SDS-Polvacrvlamide gel electrophoresis (SDS-PAGE) 
Polyacrylamide gels of different percentages were set up by mixing 
deionized water, upper/lower buffer, 30% acrylamide / bisacrylamide solution, 
ammonium persulfate, TEMED and SDS. The resolving gel was set first with a 
cover of deionized water at the top to exclude air. After 30 minutes, water was 
removed and the stacking gel was set with the insertion of a comb at the top for 
well formation. Then 20 i^g of protein was mixed with 4X SDS gel loading 
buffer and boiled in a hot plate for 5 minutes. The mixtures were loaded into 
wells of stacking gel ofSDS-PAGE. Novex® Sharp Pre-stained Protein Standard 
(10 ^L) was loaded in parallel. The gel was run under constant voltage of 100 
volts for 2 hours in a Mini-PROTEAN® 3 cell (Bio-Rad Laboratories). 
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Semi-dry Western blotting 
At the end ofelectrophoresis, the stacking gel was discarded and the gel was 
washed in deionized water. The gel and the blotting papers were then 
equilibrated with transfer buffer for 5 minutes. The PVDF membrane was soaked 
and activated in methanol just before the Westem blotting. After that, three 
pieces of soaked blotting paper were placed onto the semi-dry electroblotter 
(Bio-Rad Laboratories), followed by the activated PVDF membrane, the gel and 
three pieces of soaked blotting paper again. Air bubbles were avoided by rolling 
a glass tube on the surface of blotting paper. The proteins were transferred onto 
the PVDF membrane under 16 volts for 45 minutes. The membrane was washed 
with IX washing buffer and incubated with 5% non-fat milk blocking solution in 
a 50 mL centrifuge tube for 30 minutes with rotation. 
Enhanced chemiluminescence (ECL) detection 
The membrane was probed with primary antibody at dilution 1:500 to 
1:1,000 in non-milk fat solution with constant rotation at 4 � C ovemight. The 
membrane was washed with IX TBS-Tween washing buffer 5 minutes each for 
three times to remove the non-specifically bound or unbound primary antibody. 
After that, horseradish-conjugated secondary antibody at dilution 1:1,000 in 5 
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mL washing buffer was added to probe the primary antibody at constant rotation 
for an hour. The membrane was washed with IX TBS-Tween washing buffer 5 
minutes each for three times. The membrane was wiped off the excess buffer and 
placed in contact with a mixture of luminol solution (Santa Cruz Biotechnology) 
for 1 minute. The excess mixture was wiped off and wrapped by a piece of cling 
wrap. The membrane was fixed in a film cassette. In the dark room, a sheet of 
medical X-ray film (Fujifilm) was placed onto the membrane for 10 seconds to 5 
minutes, followed by image fixation and development in an X-ray film processor 
(Kodak). The intensity of the visualized band of target proteins was measured by 
using a MP180 scanner (Canon Inc.) and was analysed using ImageJ 1.40g 
software. 
2.2.18 Statistical analysis 
Each experiment was repeated at least three times with consistent results. 
Unless otherwise stated, the results shown are representative of at least three 
independent experiments. The data were expressed as arithmetic mean 士 standard 
error and were processed in Microsoft Excel program. The Student's t-test 
(upaired, 2-tailed) was used for the determination of statistically difference 
between the treated group and the control group. 
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CHAPTER 3 
IN VITRO STUDIES ON THE 
ANTI-PROLIFERATIVE EFFECT OF 
INDIRUBIN-3'-OXIME AND 
TRYPTANTHRIN ON NEUROBLASTOMA 
CELLS 
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3.1 Introduction 
Folk medicines have been used to treat various kinds of diseases in different 
civilizations with long historical experiences of people by trial-and-error. In 
China, the two valuable and important encyclopedias on Traditional Chinese 
Medicine (TCM), Shen Nong Ben Cao Jing (神農本草經）and Ben Cao Gang 
Mu (本草綱目)，have included more than a thousand of medicinal plants found 
in China. According to the Pharmacopeia of People's Republic of China 2010， 
over 4,000 Chinese material medica have been included in its contents (Chinese 
Pharmacopoeia Commission, 2010). Since the last few decades, scientists have 
attempted to investigate of biological and pharmacological activities of TCM. 
However, TCM are formulated in preparations containing multiple materia 
medica. It would be difficult to undergone mechanistic studies without dissecting 
out the active components in the preparations. Therefore, the modem approach to 
investigate TCM is to identify the active components in the preparation, followed 
by isolating a single chemical compound that exhibits the pharmacological 
properties (Han 1988). 
In our studies, a derivative of indirubin (indirubin-3'-oxime) and 
tryptanthrin were chosen for the investigation of their anti-tumour effect on 
neuroblastoma cells. Indirubin is an indole alkaloid and is the active compound 
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found in the traditional Chinese medicine recipe called Dang Gui Lu Hui Wan. 
The recipe has been used for purging the hepatic substantial fire in human body. 
It contains 11 medicinal herbs and indirubin was isolated from one of the herbs 
called Indigofera tinctoria. The root of Indigofera tinctoria is known as 
Banlangen. Indirubin had been demonstrated to prolong the lifespan of rats 
bearing Walker carcinosarcoma 256 cells. Phase I and II clinical studies also 
showed that indirubin was effective in the treatment of CML (Han, 1994). 
Indirubin is a potent cyclin-dependent kinase (CDK) inhibitor and exhibits 
potential anti-tumour activities. Indirubin-3'-oxime (I3M) is a more 
water-soluble analog of indirubin. Both were found to exhibit potent anti-tumour 
activities towards breast cancer, lung cancer, colon cancer, pheochromocytoma 
and leukemia (Hoessel et al., 1999). Tryptanthrin is a quinazoline alkaloid found 
in Banlangen. Recent researches have shown that tryptanthrin also exhibits 
anti-tumour activities towards breast cancer and myelocytic leukemia (Chan et 
al,, 2009; Yu et al.，2007). 
Neuroblastoma is a malignant embryonic tumour in which the proliferation 
is uncontrolled. Although the etiology of it is still not clearly understood, it is 
probably due to the uncoupling of cell proliferation and differentiation during the 
course of differentiation of neural crest cells. In fact, certain genes such as 
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MASH-1, Id-2 and MYCN have been shown to be located at the loci of genetic 
aberrations in neuroblastoma cells (Nakagawara, 2005). Therefore, in the 
development of a novel drug in the treatment of neuroblastoma, the first criterion 
would be its ability to inhibit the proliferation of neuroblastoma cells. In this 
chapter, the anti-proliferative effect of I3M and tryptanthrin on one murine 
neuroblastoma cell line and two human neuroblastoma cell lines was examined. 
The rationale for using cell lines from different species was to eliminate the 
possibility that the observed anti-proliferative effect of these two alkaloids on 
neuroblastoma cells is cell line- or species-specific. Doxorubicin, an anti-cancer 
drug commonly used in the treatment of various cancers including neuroblastoma, 
was also included in the anti-proliferation study as a positive control. Kinetic and 
reversibility studies of the anti-proliferative effect of these two alkaloids were 
conducted using the murine neuroblastoma Neuro-2a BU-1 cells. The direct 
cytotoxic effect of the alkaloids was examined on Neuro-2a BU-1 cells and 
normal cells from mice and rats. The colony-forming ability of Neuro-2a BU-1 
cells, which represents the in vitro tumorigenicity of the cells, was also examined 
(Hildebrand-Zanki and Kem, 1987). The cell cycle profile of alkaloid-treated 
Neuro-2a BU-1 cells was studied to determine if the alkaloids could arrest the 
neuroblastoma cells in a particular phase of the cell cycle. Finally, the effects of 
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3.2 Results 
3.2.1 Effects of indirubin-3'-oxime and tryptanthrin on the proliferation of 
human and murine neuroblastoma cells 
The anti-proliferative effect of I3M and tryptanthrin on neuroblastoma cells 
was measured using the tritiated-thymidine incorporation assay. Doxorubicin, a 
commonly used anti-cancer drug for neuroblastoma, was also included for 
comparison of the drug efficacy and potency. In this proliferation assay, 
tritiated-thymidine, a radioactive marker, is uptaken by viable cells during DNA 
replication. The more viable cells remained at the end of treatment, the more 
tritiated-thymidine could be incorporated into the DNA of the cells, and vice 
versa. As shown in Figure 3.1 to 3.6, I3M and tryptanthrin exhibited significant 
anti-proliferative effect on the murine neuroblastoma Neuro-2a BU-1 cells, 
human neuroblastoma LA-N-1 cells and SH-SY5Y cells with the estimated IC50 
values in the ^M range. Figure 3.7 to 3.9 show that the anti-proliferative effect of 
doxorubicin was much more potent than I3M and tryptanthrin for the three cell 
lines，and the IC50 values are within the nM range. The estimated IC50 value of 
tryptanthrin, I3M and doxorubicin on Neuro-2a BU-1 cells, LA-N-1 cells and 
SH-SY5Y cells are summarized in Table 3.1. Both I3M and tryptanthrin inhibited 
the proliferation of neuroblastoma cells in a dose-dependent manner. In addition, 
I3M appeared to be more potent than tryptanthrin in its anti-proliferative effect as 
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the IC50 value of I3M was found to be lower in all three cell lines when 
compared with that of tryptanthrin. It is interesting to note that doxorubicin, a 
conventional anti-cancer drug, was found to be more potent in inhibiting the 
proliferation of neuroblastoma cells. However, doxorubicin has been found to 
cause many side effects in patients due to its relative high cytotoxicity at its 
therapeutic dose. 
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Figure 3.1. Anti-proIiferative effect of tryptanthrin on murine 
neuroblastoma Neuro-2a BU-1 cells after 48 hour treatment. Neuro-2a BU-1 
cells (lQ4 cells/ml) were incubated with various concentrations (0-20 ^iM) of 
tryptanthrin at 37�C for 48 hours. Cultures were pulsed with 0.5 ^iCi of3H-TdR 
for 6 hours before harvest. Radioactivity (counts per minute (cpm)) was 
determined using a liquid scintillation counter. Results were expressed as % 
inhibition o f ^ - T d R incorporation with respect to the solvent-treated cells. Each 
point represents the mean 土 S.E. of quadruplicate cultures. The results shown are 
representative of 3 independent experiments. 
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Figure 3.2. Anti-proliferative effect of tryptanthrin on human 
neuroblastoma SH-SY5Y cells after 48 hour treatment. SH-SY5Y cells (10^ 
cells/ml) were incubated with various concentrations (0-50 ^iM) oftryptanthrin at 
3 7 T for 48 hours. Cultures were pulsed with 0.5 ^iCi of ^ - T d R for 6 hours 
before harvest. Radioactivity (cpm) was determined using a liquid scintillation 
counter. Results were expressed as % inhibition of ^ - T d R incorporation with 
respect to the solvent-treated cells. Each point represents the mean 士 S.E. of 
quadruplicate cultures. 
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Figure 3.3. Anti-proIiferative effect of tryptanthrin on human 
neuroblastoma LA-N-1 cells after 48 hour treatment. LA-N-1 cells (10^ 
cells/ml) were incubated with various concentrations (0-50 ^M) oftryptanthrin at 
3 7 T for 48 hours. Cultures were pulsed with 0.5 ^iCi of ^ - T d R for 6 hours 
before harvest. Radioactivity (cpm) was determined using a liquid scintillation 
counter. Results were expressed as % inhibition of ^ - T d R incorporation with 
respect to the solvent-treated cells. Each point represents the mean 土 S.E. of 
quadruplicate cultures. 
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Figure 3.4. Anti-proliferative effect of indirubin-3'-oxime (I3M) on murine 
neuroblastoma Neuo-2a BU-1 cells after 48 hour treatment. Neuro-2a BU-1 
cells (10^ cells/ml) were incubated with various concentrations (0-1.5 ^iM) of 
I3M at 37�C for 48 hours. Cultures were pulsed with 0.5 ^iCi of ^ - T d R for 6 
hours before harvest. Radioactivity (cpm) was determined using a liquid 
scintillation counter. Results were expressed as % inhibition of ^H-TdR 
incorporation with respect to the solvent-treated cells. Each point represents the 
mean 士 S.E. of quadruplicate cultures. 
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Figure 3.5. Anti-proliferative effect of indirubin-3'-oxime (I3M) on human 
neuroblastoma SH-SY5Y cells after 48 hour treatment. SH-SY5Y cells (10^ 
cells/ml) were incubated with various concentrations (0-20 [M) of I3M at 37°C 
for 48 hours. Cultures were pulsed with 0.5 ^iCi of ^ - T d R for 6 hours before 
harvest. Radioactivity (cpm) was determined using a liquid scintillation counter. 
Results were expressed as % inhibition of ^H-TdR incorporation with respect to 
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Figure 3.6. Anti-proliferative effect of indirubin-3'-oxime (I3M) on human 
neuroblastoma LA-N-1 cells after 48 hour treatment. LA-N-1 cells (10^ 
cells/ml) were incubated with various concentrations (0-20 ^iM) of I3M at 37°C 
for 48 hours. Cultures were pulsed with 0.5 ^Ci of ^ - T d R for 6 hours before 
harvest. Radioactivity (cpm) was determined using a liquid scintillation counter. 
Results were expressed as % inhibition of ^ - T d R incorporation with respect to 
the solvent-treated cells. Each point represents the mean 士 S.E. of quadruplicate 
cultures. 
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Figure 3.7. Anti-proIiferative effect of doxorubicin on murine 
neuroblastoma Neuro-2a BU-1 cells after 48 hour treatment. Neuro-2a BU-1 
cells (10^ cells/ml) were incubated with various concentrations (0-0.1 ^M) of 
doxorubicin at 3TC for 48 hours. Cultures were pulsed with 0.5 ^iCi of ^ - T d R 
for 6 hours before harvest. Radioactivity (cpm) was determined using a liquid 
scintillation counter. Results were expressed as % inhibition of ^ - T d R 
incorporation with respect to the solvent-treated cells. Each point represents the 
mean 士 S.E. of quadruplicate cultures. 
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Figure 3.8. Anti-proliferative effect of doxorubicin on human 
neuroblastoma SH-SY5Y cells after 48 hour treatment. SH-SY5Y cells (10^ 
cells/ml) were incubated with various concentrations (0-0.4 ^iM) of doxorubicin 
at 37�C for 48 hours. Cultures were pulsed with 0.5 )iCi of ^ - T d R for 6 hours 
before harvest. Radioactivity (cpm) was determined using a liquid scintillation 
counter. Results were expressed as % inhibition of ^H-TdR incorporation with 
respect to the solvent-treated cells. Each point represents the mean 土 S.E. of 
quadruplicate cultures. 
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Figure 3.9. Anti-proIiferative effect of doxorubicin on human 
neuroblastoma LA-N-1 cells after 48 hour treatment. LA-N-1 cells (10^ 
cells/ml) were incubated with various concentrations (0-0.5 ^M) of doxorubicin 
at 37�C for 48 hours. Cultures were pulsed with 0.5 ^iCi o f ^ - T d R for 6 hours 
before harvest. Radioactivity (cpm) was determined using a liquid scintillation 
counter. Results were expressed as % inhibition of ^ - T d R incorporation with 
respect to the solvent-treated cells. Each point represents the mean 土 S.E. of 
quadruplicate cultures. 
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Table 3.1. The estimated IC50 of three different drugs on the neuroblastoma 
cell lines after 48 hour treatment. 
^ X ~ Drug~~~ Indimbin-3'oxime Tryptanthrin Doxorubicin 
Cell l i n e ^ ^ IC50 value (^M) 
BU-1 0.45±0.10 1.25±0.43 0.012±0.004~~ 
SH-SY5Y 3 .8 i0 .15 11.15 + 1.00 0 .116i0 .002~~ 
L-AN-1 2 .9 t0 .81 14.33i0.58 0.078 土 0.004~~ 
IC50 value is the estimated concentration of the drug at which the proliferation of 
cells is inhibited by 50%. The estimated IC50 is expressed as the mean 士 S.E. o f3 
independent experiments. 
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3.2.2 Kinetic and reversibility studies of the anti-proliferative effect of 
indirubin-3'-oxime and tryptanthrin on the murine neuroblastoma 
Neuro-2a BU-1 cells 
Kinetic study was done by incubating the Neuro-2a BU-1 cells with either 
I3M or tryptanthrin for 12, 24, 36 and 48 hours. The growth inhibition was 
measured by [^]-thymidine incorporation assay. As shown in Figure 3.10 and 
3.11，I3M and tryptanthrin inhibited the growth of Neuro-2a BU-1 cells in a 
time-dependent manner. The kinetics study was also conducted using 
doxorubicin as a positive control (Figure 3.12). The kinetic study was repeated 
using DMSO which was used as the solvent for I3M and tryptanthrin, and no 
inhibitory effect on Neuro-2a BU-1 cell proliferation was found (Figure 3.13). 
Reversibility study was also carried out to demonstrate the ability of the 
drug-treated Neuro-2a BU-1 cells to revert the growth inhibition after removal of 
the drugs. For I3M, after incubation for 24 and 36 hours, I3M was removed and 
replaced by fresh assay medium and further incubated up to 48 hours. The 
growth inhibition was measured by the MTT reduction assay. Figure 3.14 shows 
that the growth inhibition at 24 and 36 hours was lower than the corresponding 
dose at 48 hours. Moreover, the longer the drug exposure time, the greater the 
degree of growth inhibition. Therefore, the growth inhibitory effect of I3M on 
Neuro-2a BU-1 cells was partially reversible. Similarly, Neuro-2a BU-1 cells 
- 1 0 7 -
Chapter 2 
were incubated with tryptanthrin for 24 and 48 hours followed by removal of 
drug. Figure 3.15 shows that the growth inhibition at different concentrations 
was nearly the same irrespective of the drug exposure time, therefore, the growth 
inhibition of tryptanthrin on Neuro-2a BU-1 cells was basically irreversible after 
exposure of the cells to the drugs for 24 hours or longer. 
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Figure 3.10. Kinetic study of anti-proliferative effect of tryptanthrin on 
murine neuroblastoma Neuro-2a BU-1 cells. Neuro-2a BU-1 cells (10^ 
cells/ml) were incubated with various concentrations (0-10 ^iM) oftryptanthrin at 
3 7 T for 12 and 24 hours. Cultures were pulsed with 0.5 ^iCi o f h - T d R for 6 
hours before harvest. Radioactivity (cpm) was determined using a liquid 
scintillation counter. Results were expressed as % inhibition of ^ - T d R 
incorporation with respect to the solvent-treated cells. Each point represents the 
mean 士 S.E. of quadruplicate cultures. 
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Figure 3.11. Kinetic study of anti-proliferative effect of indirubin-3'-oxime 
(I3M) on murine neuroblastoma BU-1 cells. BU-1 cells (10^ cells/ml) were 
incubated with various concentrations (0-1 ^iM) of I3M at 37°C for 24，36 and 48 
hours. Cultures were pulsed with 0.5 ^iCi of^H-TdR for 6 hours before harvest. 
Radioactivity (cpm) was determined using a liquid scintillation counter. Results 
were expressed as % inhibition of ^ - T d R incorporation with respect to the 
solvent-treated cells. Each point represents the mean 士 S.E. of quadruplicate 
cultures. 
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Figure 3.12. Kinetic study of anti-proliferative effect of doxorubicin on 
murine neuroblastoma Neuro-2a BU-1 ceIIs. Neuro-2a BU-1 cells (10^ 
cells/ml) were incubated with various concentrations (0-0.2 ^iM) of doxorubicin 
at 37�C for 24 to 72 hours. Cultures were pulsed with 0.5 ^iCi of ^ - T d R for 6 
hours before harvest. Radioactivity (cpm) was determined using a liquid 
scintillation counter. Results were expressed as % inhibition of ^ - T d R 
incorporation with respect to the solvent-treated cells. Each point represents the 
mean 士 S.E. of quadruplicate cultures. 
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Figure 3.13. Kinetic study of anti-proliferative effect of DMSO on murine 
neuroblastoma Neuro-2a BU-1 cells. Neuro-2a BU-1 cells (10^ cells/ml) were 
incubated with various concentrations (0-0.2 %) o fDMSO at 37°C for 24 to 72 
hours. Cultures were pulsed with 0.5 |iCi of ^ - T d R for 6 hours before harvest. 
Radioactivity (cpm) was determined using a liquid scintillation counter. Results 
were expressed as % inhibition of ^ - T d R incorporation with respect to the 
untreated cells. Each point represents the mean 士 S.E. of quadruplicate cultures. 
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Figure 3.14. Reversibility study on the growth-inhibitory effect of 
indirubin-3'-oxime (I3M) on the murine neuroblastoma Neuro-2a BU-1 cells. 
Neuro-2a BU-1 cells (7,500 cells/well) were cultured with various concentrations 
of I3M (0-1 ^iM) for 24，36 and 48 hours at 37�C. The medium with I3M was 
removed at the corresponding time points and the cells were washed. Fresh assay 
medium was replenished and the cells were incubated up to 48 hours. Cell 
survival was determined by the MTT reduction assay. Results were expressed as 
percentage of growth inhibition using the solvent-treated cells as a control. Each 
bar represents the mean 土 S.E.ofquadruplicatecultures. 
* Significantly different from the 48-hour treatment, p < 0.005 
** Significantly different from the 48-hour treatment, p < 0.001 
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Figure 3.15. Reversibility study on the growth-inhibitory effect of 
tryptanthrin on the murine neuroblastoma Neuro-2a BU-1 cells. Neuro-2a 
BU-1 cells (7,500 cells/well) were cultured with various concentrations of 
tryptanthrin (0-4 ^M) for 24，36 and 48 hours at 37�C. The medium with 
tryptanthrin was removed at the corresponding time points and the cells were 
washed. Fresh assay medium was replenished and the cells were incubated up to 
48 hours. Cell survival was determined by the MTT reduction assay. Results 
were expressed as percentage of growth inhibition using the solvent-treated cells 
as a control. Each bar represents the mean 土 S.E. ofquadmplicate cultures. 
* Significantly different from the 48-hour treatment, p < 0.05 
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3.2.3 Cytotoxic effect of indirubin-3'-oxime and tryptanthrin on the murine 
neuroblastoma Neuro-2a BU-1 cells 
The cytotoxicity of I3M and tryptanthrin on Neuro-2a BU-1 cells were 
examined by trypan blue exclusion assay. Viable cells with intact plasma 
membrane can exclude the vital dye (trypan blue) while dead cells with disrupted 
plasma membrane are stained by the dye as blue. Figure 3.16-3.19 show that I3M 
and tryptanthrin did not exhibit significant direct cytotoxic effect on the 
Neuro-2a BU-1 cells up to 72 hours of treatment. The viability of the cells 
remained high (>90%). Moreover, both I3M and tryptanthrin inhibited the 
proliferation of Neuro-2a BU-1 cells significantly. The doubling time of the 
Neuro-2a BU-1 cells in culture decreased from � 2 4 hours in solvent control to ~ 
36 hours at 0.4 ^M I3M and � 4 8 hours at 2 ^M tryptanthrin. 
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Figure 3.16. Effect of tryptanthrin on the viability of murine neuroblastoma 
Neuro-2a BU-1 cells. Neuro-2a BU-1 cells (7xl0^ cells/well) were incubated 
with various concentrations of tryptanthrin (0-2 fiM) or solvent control (0.02% 
DMSO) at 37�C for 24’ 48 and 72 hours. The cell viability was determined by 
trypan blue dye exclusion test by counting the cells under light microscopy. 
Results were expressed as mean percentage of viability 土 S.E. of triplicate 
cultures. 
- 1 1 6 -
Chapter 2 
12 p ^ 一 • • “ Solvent control - M - 0.5 ^M - ^ 1 d^VI ~ 0 ~ 2 ^M uT"" 
? 10 • I 
卜 ^^ ^^ ^^ ^^  i:^^^^^ 
0^—— 1 1 ‘ 
0 24 48 72 
incubation time (hours) 
Figure 3.17. Effect of tryptanthrin on the growth of murine neuroblastoma 
Neuro-2a BU-1 cells. Neuro-2a cells (7xl0^ cells/well) were incubated with 
various concentrations of tryptanthrin (0-2 ^M) or solvent control (0.02% DMSO) 
at 37�C for 24，48 and 72 hours. The number of viable cells was counted using 
light microscopy. Results were expressed as mean number of viable cells 士 S.E. 
of triplicate cultures. * Significantly different from the solvent control, p < 0.01 ** Significantly different from the solvent control, p < 0.001 
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Figure 3.18. Effect of indirubin-3'-oxime (I3M) on the viability of murine 
neuroblastoma Neuro-2a BU-1 cells. Neuro-2a cells (7xl0^ cells/well) were 
incubated with various concentrations of I3M (0-0.5 ^iM) or solvent control 
(0.02% DMSO) at 37�C for 24，48 and 72 hours. The cell viability was 
determined by trypan blue dye exclusion test by counting the cells under light 
microscopy. Results were expressed as mean percentage ofviable cells 土 S.E. of 
triplicate cultures in at least 3 independent experiments. 
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Figure 3.19. Effect of indirubin-3'oxime (I3M) on the viability of murine 
neuroblastoma Neuro-2a BU-1 cells. The cells (7xl0^ cells/well) were 
incubated with various concentrations of I3M (0-0.5 p.M) or solvent control 
(0.02% DMSO) at 37°C for 24，48 and 72 hours. The number ofviable cells was 
counted using light microscopy. Results were expressed as mean number of 
viable cells 土 S.E. of triplicate cultures. * 
Significantly different from the solvent control, p < 0.01 ** 
Significantly different from the solvent control, p < 0.001 
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3.2.4 Effects of indirubin-3'-oxime and tryptanthrin on the clonogenicity of 
the murine neuroblastoma Neuro-2a BU-1 cells 
Clonogenicity is the ability ofcells to form colonies in soft agar medium. In 
this study, the soft agar colony-forming assay was used to study the effect ofI3M 
and tryptanthrin on the clonogenicity of Neuro-2a BU-1 cells. It has been shown 
that the colony-forming ability of drug-treated tumour cells is related to their 
tumourigenicity in vitro (Freedman and Shin, 1974). Figure 3.20 shows that the 
colony-forming ability of Neuro-2a BU-1 cells was markedly reduced to 20% at 
0.4 i^M tryptanthrin. On the other hand, the colony-forming ability of Neuro-2a 
BU-1 cells was significantly reduced to 30% at 0.3 i^M I3M (Figure 3.21). The 
inhibition of clonogenicity ofNeuro-2a BU-1 cells by both I3M and tryptanthrin 
followed a dose-dependent fashion. 
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Figure 3.20. Effect of tryptanthrin on the colony-forming ability of murine 
neuroblastoma Neuro-2a BU-1 cells in soft agar. Neuro-2a BU-1 cells (5,000 
cells/well) were cultured in soft agar plate supplemented with culture medium with or 
without tryptanthrin (0-0.4 p,M) in a 6-well culture plate. The cells were incubated at 
37°C for 12 days. The total number of colonies was then counted using light microscopy 
and was expressed as the percentage colonies relative to the solvent-treated cells. Each 
bar represents the mean 士 S.E. of triplicate cultures. 
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Figure 3.21. Effect of indirubin-3'-oxime (I3M) on the colony-forming ability of 
murine neuroblastoma Neuro-2a BU-1 cells in soft agar. Neuro-2a BU-1 cells (5,000 
cells/well) were cultured in soft agar plate supplemented with culture medium with or 
without I3M (0-1 i^M) in a 6-well culture plate. The cells were incubated at 37°C for 12 
days. The total number of colonies was then counted using light microscopy and was 
expressed as the percentage colonies relative to the solvent-treated cells. Each bar 
represents the mean 士 S.E. of triplicate cultures. 
* Significantly different from the solvent control, p < 0.01 
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3.2.5 Cytotoxicity of indirubin-3'-oxime and tryptanthrin on primary cells 
In the development of a novel anti-cancer drug, it is important to determine 
its cytotoxicity on normal cells at the very beginning. Therapeutic index can be 
expressed by the LD50 value of a drug over the ED50 value. A drug with high 
therapeutic index means that it is potent in inhibiting the proliferation of cancer 
cells while exhibiting little cytotoxicity towards the normal cells. Therefore, 
candidates with a high therapeutic index are more likely to have potential in 
anti-cancer drug development, bi our present study, the cytotoxic effect of I3M 
and tryptanthrin was determined by using MTT reduction assay. In this assay, a 
water-soluble yellow tetrazolium salt was reduced by mitochondrial 
dehydrogenase in viable cells to form insoluble purple formazan. In this study, 
primary embryonic cortical neuronal cells from SD rats, peritoneal macrophages 
and bone marrow cells from BALB/c mice were chosen as the models of normal 
cells. The cortical neuronal cells represent the normal counterpart of 
neuroblastoma cells whereas the macrophages represent the normal blood cells 
that are found in different parts of the body and therefore inevitably encounter 
the anti-cancer drug. Bone marrow cells were included as bone and bone marrow 
are two most common sites of metastasis in aggressive neuroblastoma. Figure 
3.22 and 3.23 show the effects of tryptanthrin, I3M and doxorubicin on 
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embryonic cortical neuronal cells from SD rats. Tryptanthrin was demonstrated 
to exhibit non-significant cytotoxic effect on the cortical neuronal cells. However, 
I3M showed -20% cytotoxicity on the cortical neuronal cells at a concentration 
of 2 ^iM. Nevertheless, the concentration was much higher the estimated IC50 
value of I3M on Neuro-2a BU-1 cells (~ 0.4 ^M). The conventional drug 
doxorubicin showed cytotoxicity towards the neuronal cells at concentrations 
comparable to its effective doses on neuroblastoma cells (Figure 3.24). The 
potential cytotoxic effect of tryptanthrin and I3M on peritoneal macrophages and 
bone marrow cells from BALB/c mice was also examined. The results show that 
tryptanthrin and I3M did not exhibit significant cytotoxic effect on macrophages 
and bone marrow cells at 24-hour and 48-hour treatment. Negative % 
cytotoxicity observed would due to the growth stimulation or increased activity 
of mitochondrial dehydrogenase (Figure 3.25-3.28). 
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Figure 3.22. Effect of tryptanthrin on the survival of SD rat cortical 
neuronal cells in vitro. Primary cortical neuronal cells harvested from SD rats 
were cultured (10^ cells/ml) with various concentrations of tryptanthrin (0-4 |iM) 
for 24 and 48 hours at 37�C. ell survival was determined by the MTT reduction 
assay. Results were expressed as percentage of cytotoxicity relative to the 
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Figure 3.23. Effect of I3M on the survival of SD rat cortical neuronal cells in 
vitro. Primary cortical neuronal cells harvested from SD rats were cultured (10^ 
cells/ml) with various concentrations of I3M (0-2 |iM) for 24 and 48 hours at 
37T. Cell survival was determined by the MTT reduction assay. Results were 
expressed as percentage of cytotoxicity relative to the solvent-treated cells 
(control). Each point represents the mean 土 S.E. of quadruplicate cultures. 
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Figure 3.24. Effect of doxorubicin on the survival of SD rat cortical 
neuronal cells in vitro. Primary cortical neuronal cells harvested from SD rats 
were cultured (10^ cells/ml) with various concentrations of doxorubicin (0-0.4 
^iM) for 24 and 48 hours at 37�C. ell survival was determined by the MTT 
reduction assay. Results were expressed as percentage of cytotoxicity relative to 
the solvent-treated cells (control). Each point represents the mean 土 S.E. of 
quadruplicate cultures. 
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Figure 3.25. Effect of tryptanthrin on the survival of murine peritoneal 
macrophages in vitro. Thioglycollate-elicited peritoneal macrophages harvested 
from BALB/c mice were cultured (10^ cells/ml) with various concentrations of 
tryptanthrin (0-20 ^iM) for 24 and 48 hours at 37�C. ell survival was determined 
by the MTT reduction assay. Results were expressed as percentage of 
cytotoxicity using the solvent-treated cells as a control. Each point represents the 
mean 土 S.E. of quadruplicate cultures. 
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Figure 3.26. Effect of tryptanthrin on the survival of murine bone marrow 
cells in vitro. Bone marrow cells harvested from BALB/c mice were cultured 
(2xlO^cells/ml) with various concentrations of tryptanthrin (0-20 ^M) for 24 and 
48 hours at 37�C. ell survival was determined by the MTT reduction assay. 
Results were expressed as percentage of cytotoxicity using the solvent-treated 
cells as a control. Each point represents the mean 土 S.E. of quadruplicate 
cultures. 
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Figure 3.27. Effect of I3M on the survival of murine peritoneal macrophages 
in vitro, Thioglycollate-elicited peritoneal macrophages harvested from BALB/c 
mice and were cultured (2xl0^ cells/ml) with various concentrations ofI3M (0-2 
^iM) for 24 and 48 hours at 37T. Cell survival was determined by the MTT 
reduction assay. Results were expressed as percentage of cytotoxicity using the 
solvent-treated cells as a control. Each point represents the mean 土 S.E. of 
quadruplicate cultures. 
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Figure 3.28. Effect of I3M on the survival of murine bone marrow cells in 
vitro. Bone marrow cells harvested from BALB/c mice were cultured (2xl0^ 
cells/ml) with various concentrations of I3M (0-2 ^iM) for 24 and 48 hours at 
3TC. Cell survival was determined by the MTT reduction assay. Results were 
expressed as percentage of cytotoxicity using the solvent-treated cells as a 
control. Each point represents the mean 土 S.E. of quadruplicate cultures. 
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3.2.6 Effects of tryptanthrin on the cell cycle profile and expression of 
cycIins and cyciin-dependent kinases (CDKs) in the murine 
neuroblastoma Neuro-2a BU-1 cells 
Uncontrolled cell proliferation is a common feature in various types of 
cancers. It is believed that the critical checkpoints in Gi-S transition or G2-M 
progression are not functional and this may contribute to the uncontrolled 
proliferation in cancer cells (Sheer, 1996; McDonald and El-Deiry, 2000). 
Therefore, by examining the cell cycle profile of tryptanthrin-treated Neuro-2a 
BU-1 cells, the anti-proliferative activity of tryptanthrin may be explained. The 
cell cycle profile was studied by using flow cytometry with propidium iodide, a 
DNA staining dye. The DNA content in the cell population was detected and the 
cell cycle phase distribution of the cells can be determined. As shown in Figure 
3.29，the % cell population at the G2/M phase increased while that in S phase 
decreased significantly as the concentration of tryptanthrin was increased. After 
48-hour treatment, the Neuro-2a BU-1 cells were arrested at G2M phase in a 
dose-dependent manner. The G2/M phase arrest in Neuro-2a BU-1 cells could be 
observed as early as 24 hours after tryptanthrin treatment (Figure 3.30). 
The cell cycle progression is governed by cyclins and CDKs at different 
points in the cell cycle (Table 3.2). The protein expression of cyclins fluctuated 
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in a cyclical manner and thus controls the phase-phase transition. Therefore, the 
effects of tryptanthrin on the protein expression of cyclins and CDKs were also 
examined. Figure 3.31 shows that the expression of cyclin A, cyclin B1 and cdc2 
(CDK1) decreased significantly after the 48-hour treatment with tryptanthrin in a 
dose-dependent manner. 
3.2.7 Effect of indirubin-3'-oxime on the cell cycle profile in the murine 
neuroblastoma Neuro-2a BU-1 cells 
I3M has been shown to be a potent CDK inhibitor on CDKl/cyclin B 
complex and CDK2 in different cancer cell lines. Therefore, the effect of I3M on 
the cell cycle profile was examined. Figure 3.32 shows that I3M caused an 
increase in % cell population in Go/Gi phase with a concomitant decrease in S 
phase. Therefore, I3M arrested the Neuro-2a BU-1 cells in Go/Gi phase in a 
dose-dependent manner. 
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Figure 3.29. Effect of tryptanthrin on the cell cycle profile of murine 
neuroblastoma Neuro-2a BU-1 cells after 48 hour treatment. Neuro-2a BU-1 
cells (lC)5 cells/mL) were either incubated with solvent control (0.04% DMSO) or 
tryptanthrin at various concentrations for 24 hours. Treated cells (10^ cells) were 
fixed with ethanol and stained with PI staining buffer. (A) The fluorescence 
intensity of the stained cells was measured by using the FACSCanto flow 
cytometer. (B) Cell cycle distribution was analyzed by using RFIT analysis 
model of MODFIT program. Each bar represents the mean 土 S.E. in at least 3 
independent experiments. 
* Significantly different from the solvent control, p < 0.01 
** Significantly different from the solvent control, p < 0.001 
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Figure 3.30. Effect of tryptanthrin on the cell cycle distribution in G2/M 
phase of murine neuroblastoma Neuro-2a BU-1 cells. Neuro-2a BU-1 cells 
(105 cells/mL) were either incubated with solvent control (0.05% DMSO) or 
tryptanthrin at various concentrations for 24, 48 and 72 hours. Treated cells (10^ 
cells) were fixed with ethanol and stained with PI staining buffer. The 
fluorescence intensity of the stained cells was measured by using the FACSCanto 
flow cytometer. Cell cycle distribution was analyzed by using RFIT analysis 




Table 3.2. The regulatory roles of cyclins and CDKs in different phases 
of cell cycle. 
CDK Cyclin Cell cycle phase activity 
CDK4 Dl ,D2, D3 Gi phase 
CDK6 Dl ,D2, D3 Gi phase 
CDK2 E Gi/S phase transition 
CDK2 A S phase 
CDK1 (cdc2) A G2M phase transition 
CDK1 (cdc2) B Mitosis 
. • 
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Figure 3.31. Effect of tryptanthrin on the expression of cyclins and 
cyclin-dependent kinase (cdk) in the murine neuroblastoma Neuro-2a BU-1 
cells after 48 hour treatment. Neuro-2a BU-1 cells (10^ cells/ml) were either 
incubated with solvent control (0.04% DMSO) or with various concentrations 
(1-4 ^M) of tryptanthrin at 37�C for 48 hours. The proteins of each sample were 
extracted and semi-quantified by Westem blotting as described in the Material 
and Methods section. The extracted protein were resolved by SDS-
polyacrylamide gel electrophoresis and transferred onto PVDF membrane for 
probing with specific primary antibodies followed by horseradish 
peroxidase-conjugated secondary antibody. Then ECL detection assay was 
carried out in order to generate visible signal by exposing the membrane to X-ray 
films. (A) The representative protein bands on X-ray films were shown. (B) The 
relative intensity of each protein band was normalized with respect to P-actin and 
compared with the corresponding solvent control. Each bar represents the mean + 
S.E. in 3 independent experiments. 
* Significantly different from the solvent control, p < 0.01 
** Significantly different from the solvent control, p < 0.001 
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Figure 3.32. Effect of indirubin-3'-oxime (I3M) on the cell cycle profile of 
murine neuroblastoma Neuro-2a BU-1 cells after 24 hour treatment. 
Neuro-2a BU-1 cells (10^ cells/mL) were either incubated with solvent control 
(0.01% DMSO) or I3M at various concentrations for 24 hours. Treated cells (10^ 
cells) were fixed with ethanol and stained with PI staining buffer. (A) The 
fluorescence intensity of the stained cells was measured by using the FACSCanto 
flow cytometer. (B) Cell cycle distribution was analyzed by using RFIT analysis 
model of MODFIT program. Each bar represents the mean 土 S.E. in 3 
independent experiments. 
* Significantly different from the solvent control, p < 0.02 




The present study shows that both tryptanthrin and indirubin-3'-oxime (I3M) 
derived from Banlangen are potent alkaloids that were found to be effective in 
inhibiting the proliferation of the murine neuroblastoma Neuro-2a BU-1 cells as 
measured by the tritiated-thymidine incorporation assay. The estimated IC50 value 
of tryptanthrin was found to be around 1 i^M for the Neuro-2a BU-1 cells 
whereas it was around 10 i^M and 14 ^M for the human neuroblastoma 
SH-SY5Y and LA-N-1 cells respectively. The IC50values of tryptanthrin for the 
human neuroblastoma cells are 10 times higher than that of the murine 
neuroblastoma cells. The IC50 of I3M was found to be 0.43 i^M for the Neuro-2a 
BU-1 cells. Similarly, the IC50 values were 5 and 10 times higher for the LA-N-1 
cells (2.5 fiM) and SH-SY5Y cells (3.9 ^iM) respectively. It was demonstrated 
that although tryptanthrin and I3M exerted inhibitory effect on the cell 
proliferation of the three neuroblastoma cell lines, the murine neuroblastoma 
Neuro-2a BU-1 cells were found to be most sensitive to the growth-inhibitory 
activity of the two alkaloids. Therefore, the murine neuroblastoma Neuro-2a 
BU-1 cells were chosen as the cell model for further mechanistic studies in the 
later parts of the research project. The BU-1 subclone was originally derived 
from the Neuro-2a cell line. When compared to the parental Neuro-2a cell line, 
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the Neuro-2a BU-1 subclone is more homogeneous and the BU-1 subclone has 
been well characterized and widely used as a neuronal model for different 
mechanistic studies (Mak et al., 2000; 2001). In the anti-proliferation studies, 
doxorubicin, a conventional drug commonly used for the chemotherapy of 
neuroblastoma, was also included as a positive control for comparison of the 
potency o f the two alkaloids. The IC50 values of doxorubicin were less than 0.1 
^M in for the 3 neuroblastoma cell lines being tested. The results suggest that 
doxorubicin is a more potent drug in inhibiting the growth of neuroblastoma cells. 
However, new drugs are required to be developed due to the highly cytotoxic 
property of doxorubicin on normal cells, which leads to serious side effects in 
patients undergoing chemotherapy. 
The kinetic studies show that the IC50 values of tryptanthrin decreased from 
6 i^M at 12 hours to 1.5 i^M at 24 hours. Similarly, the IC50 values of I3M 
decreased with longer incubation time. It is clear that the inhibitory effect of 
tryptanthrin and I3M on the proliferation of Neuro-2a BU-1 cells increased in a 
time-dependent manner. In order to find out whether the inhibitory effect on the 
proliferation of the Neuro-2a BU-1 cells could be reversed, the drugs were 
removed at specific time points and further incubated with fresh complete RPMI 
medium. The reversibility study indicates that the longer the incubation time with 
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I3M, the lower the ability of the cells to recover their proliferative property. 
Therefore, the inhibitory effect of I3M on Neuro-2a BU-1 cells was partially 
reversible. On the other hand, the percentage growth inhibition by tryptanthrin 
was found to be more or less the same after 24，36 or 48 hours of drug exposure. 
It is clear that the inhibitory effect oftryptanthrin was nearly irreversible after 24 
hours ofdrug treatment. In other words, the anti-proliferative effect oftrytanthrin 
on Neuro-2a BU-1 cells may involve the commitment to some irreversible cell 
death pathways. The results imply that cytostatic mechanisms such as induction 
of cell differentiation and cytotoxic mechanisms such as induction of apoptosis 
may be involved in the alkaloids-induced growth inhibition in Neuro-2a BU-1 
cells. The underlying mechanisms of alkaloids-induced growth inhibition would 
be discussed in more details in Chapter 4 and 5. 
From the trypan blue exclusion assay, the doubling time of the Neuro-2a 
BU-1 cells was found to be increased after incubation with tryptanthrin or I3M. It 
agrees with the results from the tritiated-thymidine incorporation assay and the 
kinetic studies. Moreover, the inhibition was not due to direct cytotoxic effect ofthe 
alkaloids on the Neuro-2a BU-1 cells as the viability of cells remained higher than 
95% and showed no significant drop during the course of the assay. It can be 
postulated that induction of programmed cell death, cell cycle arrest or triggering of 
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cell differentiation may be the underlying mechanisms for the observed growth 
inhibition. Similarly, the results of soft agar colony-forming assay show that 
tryptanthrin and I3M could reduce the number of colonies by 80% and 70% at 0.4 
i^M and 1 i^M respectively, suggesting that the in vitro clonogenicity of the Neuro-2a 
BU-1 cells was suppressed in a dose-dependent manner. Earlier work had shown that 
the reduction of the colony-forming ability in vitro was highly correlated to the 
suppression in in vivo tumourigenicity (Freedman and Shin, 1974). In view ofthe 
potent anti-proliferative activity of tryptanthrin and I3M on neuroblastoma cells, and 
to explore their potential as drug candidates in treatment of neuroblastoma, it is 
important to determine their cytotoxicity on normal cells. For drugs commonly used 
in the chemotherapy of neuroblastoma, such as cisplatin, etoposide, doxorubicin, 
cyclophosphamide and vincristine, they are potent in killing both cancer cells and 
highly proliferating normal cells such as bone marrow cells and cells lining the 
mouth and intestines. This leads to many adverse side effects, e.g. loss of weight and 
appetite, diarrhea, vomiting, stomatitis, and impairments of kidneys, bladder, heart 
and nervous system (American Cancer Society, 2009). In our present study, MTT 
reduction assay was used to study the possible cytotoxic effect of tryptanthrin and 
I3M on normal cells. Our results show that tryptanthrin and I3M did not reduce the 
cell viability of the Neuro-2a BU-1 cells after 24 hours and 48 hours of treatment. 
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Moreover, no significant cytotoxicity was found in peritoneal macrophages and bone 
marrow cells from BALB/c mice up to 20 i^M tryptanthrin and 2 i^M I3M. The 
cytotoxicity oftryptanthrin and I3M on rat cortical neuronal cells was also minimal. 
Although there was around 20% cytotoxicity when the concentration ofI3M reached 
2 ^iM, this concentration was higher than concentration that effectively suppressed 
the proliferation of the Neuro-2a BU-1 cells. However, doxorubicin was shown to 
kill the cortical neuronal cells at concentrations comparable to those in inhibiting 
the proliferation of the neuroblastoma cells. Therefore, tryptanthrin and I3M 
have shown selectivity in the inhibiting the growth of neuroblastoma cells while 
sparing the normal cells. 
Living cells proliferate through DNA replication and mitosis with two gaps, 
known as Gi phase and G2 phase of cell cycle in between. The cell cycle 
progression is regulated by cyclins，CDKs and cyclin-dependent kinase inhibitors 
(CKIs) in cells. The protein levels of CDKs remain relatively stable while those 
of cyclins change in different phases under strict regulation of synthesis and 
degradation. The activated cyclin-CDK complexes will phosphorylate and 
activate substrates that are responsible for the phase-transitions in the cell cycle 
(Morgan, 1995). Table 3.2 summarized the corresponding CDKs and cyclins in 
different phases. Both normal and cancer cells proliferate as they actively 
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progress in the cell cycle. However, checkpoint dysfunctions are commonly 
found in cancer cells. They are characterized by the highly proliferative ability 
and uncontrolled cell cycle regulation (Vermeulen et al.’ 2003). 
Indirubin-3'-oxime (I3M) was reported to be a potent inhibitor of CDKs. 
The underlying mechanism was revealed by examining the crystal structure of 
CDK2-I3M complex. The electron density map showed that I3M bound to the 
ATP-binding site in CDK2 via van der Waal's interactions and hydrogen bonds 
between the backbone oxygen ofGlu81 of CDK2, backbone oxygen and nitrogen 
ofLeu83 and I3M (Hoessel et cd., 1999). Therefore, I3M competed with ATP for 
binding to the catalytic subunit of CDKs. In the present study, I3M was 
demonstrated to arrest the Neuro-2a BU-1 cells in Go/Gi phase in a 
dose-dependent manner with a 50% increase in the cell distributed in the Go/Gi 
phase at 1 ^M concentration. However, Hoessel et aL (1999) showed that almost 
all cell lines being studied were arrested in G2/M phase. The discrepancy with 
our findings with that ofHoessel et al (1999) remains unclear, it may due to the 
difference in cell cycle aberrations of the cell lines used and this awaits further 
investigations. The use of I3M as a small kinase inhibitor has an advantage over 
strategy targeting on the p53 pathway as I3M suppresses the proliferation of the 
Neuro-2a BU-1 cells by direct inhibition of the catalytic activity of CDKs such 
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as CDK2, 4 and 6. This direct mode of inhibition arrested the cell cycle of 
neuroblastoma cells with defective p53 pathway which is often targeted in the 
treatments of different cancers. 
Unlike I3M, tryptanthrin has not been reported to possess CDK inhibitory 
activity. In other words, any effect on the cell cycle profile of the Neuro-2a BU-1 
cells might be due to activities other than CDK inhibition, hi the present study, 
tryptanthrin was shown to arrest the Neuro-2a BU-1 cells in the G2/M phase with 
more than 30% increase in cell population at the G2M phase at 4 ^M 
concentration after a 48-h treatment. Previous studies in our laboratory had 
shown that the murine myeloid leukemia WEHI-3B JCS cells were arrested in 
the Go/Gi phase after 48-hour treatment. The mRNA levels of cyclin D2, D3, Cdk 
2, 4 and 6 genes were found to be down-regulated (Chan et al., 2009). In the 
present study, the effects of tryptanthrin on the expression of cyclins and CDK in 
Neuro-2a BU-1 cells were examined. The results of Westem blot analysis 
showed that the protein levels of cyclin A, cyclin B1 and cdc2 (CDK1) decreased 
by 3 to 5 fold at 4 fiM tryptanthrin. It has been well documented that CDK1 
forms complexes with cyclin A for promoting the cells into mitosis while it will 
complex with cyclin B for regulating the progression in mitosis. Since 
tryptanthrin reduced the protein expression level of the cyclin A and B1 as well 
- 1 4 8 -
Chapter 2 
as CDK1, and thus rendering less cyclin-CDK complexes formation. Therefore, 
the Neuro-2a BU-1 cells were arrested at the G2/M phase and could not progress 
properly into the mitotic phase. From the results obtained so far, it can be 
concluded that tryptanthrin and I3M potently inhibited the proliferation of the 
Neuro-2a BU-1 cells and arrested the cells in G j M phase and Go/Gi phase 
respectively. It would be worthy to further elucidate the underlying molecular 
mechanisms for the growth-inhibitory activity of these two alkaloids on the 
Neuro-2a BU-1 cells. 
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CHAPTER 4 
IN VITRO STUDIES ON THE 
APOPTOSIS-INDUCING EFFECT OF 
INDIRUBIN-3'-OXIME ON 
NEUROBLASTOMA CELLS 
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4.1 Introduction 
In the field of cell death research, "necrosis" is a term used to describe the 
cell death induced by noxious stimuli, resulting in irreversible disturbance of 
cellular homeostatic mechanism and the cells die in a way similar to autolysis in 
vitro. It was not until 1972，the term "apoptosis" was used to describe another 
mode ofcell death distinguished from necrosis in terms of cell death morphology 
(Kerr et al., 1972). Morphological changes during apoptosis include 
condensation of nucleus and cytoplasm, nuclear fragmentation, and formation of 
roughly spherical cytoplasmic fragments with intact membrane known as 
apoptotic bodies. It was believed that apoptosis worked complementary with 
mitosis to control the size of cell population in our body. Therefore, apoptosis 
would virtually occur in various tissues in a healthy subject e.g. (Kerr 1965, 1971; 
Prins and 0'Rahilly, 1997; Ucker et al., 1994). One of them is the adrenal cortex 
of normal embryonic rat under ACTH-deprivation (Wyllie et al., 1973). On the 
other hand, spontaneous apoptosis has also been found in untreated malignant 
cells e.g. basal cell carcinoma, testicular germ cell tumour, colon cancer and 
pancreatic cancer (Kerr and Searle, 1972; Mandoky et al.’ 2008; Meggiato et al., 
2000; Wang et al., 1996) Spontaneous regression is also frequently observed in a 
subtype of neuroblastoma. 
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Besides those morphological features described by Kerr et al. (1972), 
some biochemical and physiological changes have been demonstrated in 
apoptosis. Apoptosis is an ATP-driven process. The ATP level is high in apoptotic 
cells as ATP hydrolysis readily takes place to provide energy for the reactions in 
apoptosis (Lazebnik et cd., 1993; Nicotera and Leist, 1997). Extemalization of 
phosphatidylserine on plasma membrane is a feature in the early stage of 
apoptosis. It shows the "eat me" signal to adjacent cells or macrophages. It 
renders apoptosis to be physiological favorable over necrosis as a potential mode 
of cell death induced in chemotherapy since apoptotic bodies do not induce 
significant cytokine production and thus apoptosis does not cause inflammatory 
response (Fadok et al., 2000). Release of factors like cytochrome c and 
apoptosis-inducing factor (AIF) from mitochondria into cytoplasm or nucleus 
and the activation of caspase cascade are two other biochemical features of 
apoptosis (Green and Reed, 1998). Mono- and oligonucleosomal DNA fragments 
would be produced by non-random DNA fragmentation (Galluzzi et al., 2009). It 
contributes to the ladder pattern of DNA in agarose gel electrophoresis 
experiment. These hallmarks or important features of apoptosis can be observed 
from nematodes to humans as apoptosis is strictly regulated by a set of highly 
conserved genes (Danial and Korsmeyer, 2004). 
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Apoptosis can be initiated by different stimuli including death signal from 
the plasma membrane, DNA damage and proteolytic enzyme attack. Different 
stimuli initiate apoptosis through different pathways, namely extrinsic pathway 
and intrinsic pathway. The extrinsic pathway is initiated through the engagement 
of "death signal" molecules and death receptors while the intrinsic pathway is 
initiated in the mitochondria (Strasser et al., 1995). On the plasma membrane of 
cells, there are death receptors to receive "death signal" from the extracellular 
matrix. Death receptors such as Fas (CD95) belong to tumour-necrosis factor 
(TNF) receptor family. When FasL, TNF and TNF-related apoptosis inducing 
ligand (TRAIL) binds to their receptors, the death domain (DD) of the death 
receptors binds to an adaptor protein known as Fas-associated death domain 
(FADD). The complex recruits pro-caspase 8 in cytoplasm via death effector 
domains. The proximity in the complex allows dimerization and autocatalysis of 
pro-caspase 8 into active form (Nagata, 1994; Pitti et al., 1996) . In neurons, 
nerve growth factor (NGF) receptor p75, a member o fTNF receptor family, was 
found to induce apoptosis upon binding to NGF (Eggert et al., 2000). DNA 
damages such as genotoxic chemotherapy and radiation are two common factors 
which can initiate the intrinsic pathway. If the genome is extensively and 
irreversibly damaged, activation of transcription factor p53 would take place, 
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leading to up-regulation of pro-apoptotic and down-regulation of anti-apoptotic 
proteins o f the Bcl-2 family (Kastan et al., 1991; Krajewski et aL, 1994; Sun et 
al,, 1995). However, activation of p53 is not an essential process in some cells to 
undergo apoptosis (Marchenko et al., 2000). The Bcl-2 family proteins work in a 
switch-like manner, BH3-only proteins engage to pro-survival Bcl-2 proteins 
which lose their inhibitory effect on Bak and Bax (Willis et al., 2007). 
Cytoplasmic Bax monomers translocate to the outer mitochondrial membrane 
(OMM) where they undergo oligomerization (Green, 2005). Similarly, 
conformational change is induced in Bak on OMM to form oligomers. The 
oligomers punch "pores" and permeabilize OMM. However, the nature of 
"pores" still remains controversial (Kuwana et al., 2002; Martinou and Green, 
2001). Cytochrome c in mitochondria is released into the cytoplasm and induces 
conformational changes of Apaf-1. Pro-caspase 9 is recruited and oligomerized 
to form apoptosome (Acehan et aL, 2002). The extrinsic and intrinsic pathways 
of apoptosis indeed can work independently or in an interconnected manner. 
Active caspase 8 can cause the cleavage ofBid to form truncated Bid (tBid). The 
tBid binds to anti-apoptotic Bcl-2 family proteins and thus promotes the 
oligomerization of Bax and Bak (Willis et al., 2007). Both extrinsic and 
intrinsic pathways converge to the executioner caspase 3，6 and 7. Executioner 
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caspases degrade the cytoskeleton proteins and induce various morphological 
changes during apoptosis and activate caspase-activated DNases (CAD) to 
produce nucleosomal DNA fragments (Enari et al., 1998). 
In this study, DNA fragmentation was used as a marker for the induction 
of apoptosis by I3M. It was detected by DNA agarose gel electrophoresis and 
quantified by an ELISA kit. To further support the occurrence of apoptosis, 
morphological study on condensation of chromatin by Hoechst 33342 staining 
was also performed. After the confirmation of apoptosis induced by I3M, 
enzymatic activities ofcaspase 3，8 and 9 were examined to differentiate whether 
intrinsic and/or extrinsic pathway(s) might be involved. Meanwhile, the 
production of reactive oxygen species (ROS) which plays an important role in 
the mitochondrial pathway was also measured. Attempts had also been made to 
investigate the expression of Bcl-2 protein family in order to elucidate the 
underlying mechanism of I3M-induced apoptosis in the murine neuroblastoma 
Neuro-2a BU-1 cells. 
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4.2 Results 
4.2.1 Induction of DNA fragmentation in the indirubin-3'-oxime-treated 
murine neuroblastoma Neuro-2a BU-1 cells 
During apoptosis, DNA in apoptotic cells would be degraded following 
three patterns, they are single-strand DNA nicks, chromatin cleavage with the 
formation of large fragments with size of 50 to 300 kilo base-pair (kbp) and 
nucleosome fragments formation with size of 180 to 200 bp (Brown et al., 1993; 
Wyllie, 1980). The production ofnucleosome fragments during apoptosis can be 
detected as DNA ladders in DNA agarose gel electrophoresis (Wyllie, 1980). It is 
one of the hallmark characteristics in apoptosis. Figure 4.1 shows that DNA 
fragmentation was induced by I3M in the Neuro-2a BU-1 cells in a dose- and 
time-dependent manner. Recently, more sensitive ELISA kits have been 
developed by different commercial companies to detect the presence of DNA 
fragmentation. In this study, Cell Death ELISA^^^^ kit was used to detect the 
presence of DNA fragmentation and to quantify the apoptosis event in 
I3M-treated Neuro-2a BU-1 cells. In the ELISA assay, only the 
histone-complexed DNA fragments, i.e. mono- and oligonucleosomes, would be 
detected. Figure 4.2 shows that the enrichment factor, which is a quantitative 
measurement of DNA fragmentation, increased significantly in a dose-dependent 
manner. The DNA fragmentation was 25-fold higher in Neuro-2a BU-1 cells 
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Figure 4.1. Induction of DNA fragmentation in by indirubin-3'-oxime (I3M) 
in murine neuroblastoma Neuro-2a BU-1 cells. Neuro-2a BU-1 cells (10^ 
cells/ml) were treated with solvent control (0.01% DMSO) or different 
concentrations (0, 0.5, 0.75 and 1 ^iM) ofI3M at 37�C for 24 and 48 hours. DNA 
fragments were extracted and were resolved by agarose gel electrophoresis in 
parallel with 100 bp DNA marker (M) followed by ethidium bromide staining. 
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Figure 4.2. Induction of apoptosis in indirubin-3'-oxime (I3M)-treated 
murine neuroblastoma Neuro-2a BU-1 cells as measured by the Cell Death 
Detection ELISA. Neuro-2a BU-1 cells (7,500 cells/well) were cultured 
ovemight and treated with I3M (0-1 ^iM) in a 96-well culture plate for 16 hours. 
The released cytoplasmic mono- and oligo-nucleosomes were then quantified by 
Cell Death ELISA^^^^ kit according to the manufacturer's instructions. Each bar 
represents the mean 土 S.E. of triplicate cultures. 
* Significantly different from the solvent control, p < 0.002 
** Significantly different from the solvent control, p < 0.001 
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4.2.2 Induction of chromatin condensation in the indirubin-3'-oxime-treated 
murine neuroblastoma Neuro-2a BU-1 cells 
In apoptotic cells, condensation of nuclei can be observed and is one of the 
hallmarks for apoptosis. The nuclear condensation can be induced either in a 
caspase-dependent or caspase-independent manner. Cytoplasmic substrates of 
caspase 3 such as lamins and acinus are known to be involved in 
caspase-dependent nuclear condensation in apoptotic cells (Rao et al, 1996; 
Sahara et al., 1999). On the other hand, apoptosis-inducing factor (AIF) is 
believed to play a role in caspase-independent mechanism (Susin et al” 2000). 
Hoechst 33342 is a cell-permeable blue fluorescent bisbenzimide dye that 
selectively binds to AT-rich double-stranded (ds) DNA to give a fluorescence 
signal 2 times greater than the GC-rich dsDNA. Figure 4.3 clearly shows that 
chromatin was stained blue with a condensed conformation in treated groups as 
compared to the diffused form seen in the control group. 
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4.2.3 Induction of caspase activities in the indirubin-3'-oxime-treated 
murine neuroblastoma Neuro-2a BU-1 cells 
After the mode of cell death induced by I3M in Neuro-2a BU-1 cells was 
confirmed, attempts had been made to distinguish which pathway(s) of 
apoptosis might be involved. The initiation of apoptosis in both extrinsic and 
intrinsic pathways involves the initiator caspase 8 and caspase 9 respectively 
and converges in the activation of executioner caspase 3，6 and 7 in the caspase 
cascade. Caspases are a group of cysteine-dependent aspartate-specific 
proteases with a stringent specificity towards aspartate using cysteine side chain 
for catalyzing peptide bond cleavage. They present as zymogens in cells and are 
activated by limited proteolysis upon apoptosis stimuli (Eamshaw et al.’ 1999; 
Thomberry et al., 1997; Thomberry and Lazebnik, 1998). The involvement of 
caspases in I3M-induced apoptosis in Neuro-2a BU-1 cells was determined by 
the Cell Death ELISA^^^^ kit in the presence of a pan-caspase inhibitor 
(z-VAD-FMK). As shown in Figure 4.4，the enrichment factor was significantly 
lower in the co-treatment o f I3M (0.75 ^iM) and z-VAD-FMK (50 or 100 ^iM) 
when compared to the treatment with I3M (0.75 ^iM) alone. The activation of 
caspases induced by I3M was detected by using caspase-specific fluorogenic 
substrates, Ac-DEVD-AMC, Ac-IETD-AMC and Ac-LEHD-AMC for caspase 
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3，caspase 8 and caspase 9 respectively (Pennington and Thomberry, 1994). As 
shown in Figure 4.5, 4.6 and 4.7，the activity of caspase 3，caspase 8 and 
caspase 9 increased in a dose-dependent manner after 24-hour treatment with 
I3M in the Neuro-2a BU-1 cells. A kinetic study was also carried out for the 
activation of caspase 3 induced by I3M after 8 hours, 16 hours and 24 hours of 
treatment. Figure 4.8 shows that caspase 3 activation occurred as early as 8 
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Figure 4.4. Inhibition of apoptosis in indirubin-3'-oxime (I3M)-treated 
murine neuroblastoma Neuro-2a BU-1 cells as measured by the Cell Death 
Detection ELISA. Neuro-2a BU-1 cells (7,500 cells/well) were cultured 
ovemight and pretreated with either 50 |uM or 100 i^M z-VAD-FMK for 8 hours. 
Then, the cells were treated with I3M (0.75 ^iM) in a 96-well culture plate for 16 
hours. The released cytoplasmic mono- and oligo-nucleosomes were then 
quantified by the Cell Death ELISA^^^^ kit according to the manufacturer's 
instructions. Each bar represents the mean 土 S.E. of triplicate cultures. 
* Significantly different from the cells treated with 0.75 ^iM I3M alone, p <0.05 
** Significantly different from the cells treated with 0.75 ^iM I3M alone, 
p<0 .001 
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Figure 4.5. Effect of indirubin-3'-oxime (I3M) on the induction of caspase 3 
activity in murine neuroblastoma Neuro-2a BU-1 cells. Neuro-2a BU-1 cells 
(105 cells/ml) were either incubated with solvent control (0.01% DMSO) or 
treated with various concentrations of I3M (0-1 ^iM) at 37�C for 24 hours. 
Protein samples were extracted and the fluorogenic substrate of caspase 3 
(Ac-DEVD-AMC) was added with or without the caspase 3 specific inhibitor 
(Ac-DEVD-CHO). Fluorescence was then measured by a fluorescence plate 
reader using an excitation wavelength of 360 nm and an emission wavelength of 
465 nm. The caspase 3 activity was proportional to the AMC released from 
Ac-DEVD-AMC. The fluorescence units were quantified by comparing with the 
AMC standard curve. The results were expressed as the relative fluorescence 
intensity as compared to the solvent-treated group. Each bar represents the mean 
土 S.E. in triplicate cultures. 
* Significantly different from the solvent control, p < 0.001 
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Figure 4.6. Effect of indirubin-3'-oxime (I3M) on the induction of caspase 8 
activity in murine neuroblastoma Neuro-2a BU-1 cells. Neuro-2a BU-1 cells 
(105 cells/ml) were either incubated with solvent control (0.01% DMSO) or 
treated with various concentrations of I3M (0-1 ^iM) at 2>TC for 24 hours. 
Protein samples were extracted and the fluorogenic substrate of caspase 8 
(Ac-IETD-AMC) was added with or without the caspase 8 specific inhibitor 
(Ac-IETD-CHO). The fluorescence was then measured by a fluorescence plate 
reader using an excitation wavelength of 360 nm and an emission wavelength of 
465 nm. The caspase 8 activity was proportional to the AMC released from 
Ac-IETD-AMC. The fluorescence units were quantified by comparing with the 
AMC standard curve. The results were expressed as the relative fluorescence 
intensity as compared to the solvent-treated group in corresponding time points. 
Each bar represents the mean 土 S.E. in triplicate cultures. 
* Significantly different from the solvent control, p < 0.01 
** Significantly different from the solvent control, p < 0.001 
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Figure 4.7. Effect of indirubin-3'-oxime (I3M) on the induction of caspase 9 
activity in murine neuroblastoma Neuro-2a BU-1 cells. Neuro-2a BU-1 cells 
(105 cells/ml) were either incubated with solvent control (0.01% DMSO) or 
treated with various concentrations of I3M (0-1 ^iM) at 37°C for 24 hours. 
Protein samples were extracted and the fluorogenic substrate of caspase 9 
(Ac-LEHD-AMC) was added with or without the caspase-3 specific inhibitor 
(Ac-LEHD-CHO). The fluorescence was then measured by a fluorescence plate 
reader using an excitation wavelength of 360 nm and an emission wavelength of 
465 nm. The caspase 9 activity was proportional to the AMC released from 
Ac-LEHD-AMC. The fluorescence units were quantified by comparing with the 
AMC standard curve. The results were expressed as the relative fluorescence 
intensity as compared to the solvent-treated group in corresponding time points. 
Each bar represents the mean 土 S.E. in triplicate cultures. 
* Significantly different from the solvent control, p < 0.001 
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Figure 4.8. Kinetic study of the induction of caspase 3 activity in murine 
neuroblastoma Neuro-2a BU-1 cells by indirubin-3'-oxime (I3M). Neuro-2a 
BU-1 cells (10^ cells/ml) were either incubated with solvent control (0.01% 
DMSO) or treated with 1 ^M I3M at 37°C for 8，16 and 24 hours. Protein 
samples were extracted and the fluorogenic substrate of caspase 3 
(Ac-DEVD-AMC) was added with or without the caspase 3 specific inhibitor 
(Ac-DEVD-CHO). The fluorescence was then measured by a fluorescence plate 
reader using an excitation wavelength of 360 nm and an emission wavelength of 
465 nm. The caspase 3 activity was proportional to the AMC released from 
Ac-DEVD-AMC. The fluorescence units were quantified by comparing with the 
AMC standard curve. The results were expressed as the relative fluorescence 
intensity as compared to the solvent-treated group in corresponding time points. 
Each bar represents the mean 土 S.E. in triplicate cultures. 
* Significantly different from the solvent control, p < 0.001 
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4.2.4 Induction of reactive oxygen species (ROS) in the 
indirubin-3'-oxime-treated murine neuroblastoma Neuro-2a BU-1 cells 
Apoptosis may involve two distinct but interconnected pathways known as 
extrinsic pathway and intrinsic pathway. Mitochondria play a vital role in the 
initiation of the intrinsic pathway. It is believed that ROS are one of the 
mediators that initiate the biochemical changes in mitochondria upstream of the 
intrinsic pathway and lead to apoptosis eventually (Simon et al., 2000). In our 
study, the production of ROS in Neuro-2a BU-1 cells was examined after 
treatment with I3M at several time points, namely, 0.5, 1 and 4 hours. The ROS 
production in Neuro-2a BU-1 cells was measured by using flow cytometry with a 
fluorescence superoxide indicator called dihydroethidium (DHE). DHE would be 
oxidized by the ROS produced in Neuro-2a BU-1 cells and emitted blue 
fluorescence. As shown in Figure 4.9，I3M induced ROS production in Neuro-2a 
BU-1 cells in a time-dependent manner. The % of cells in region Ml increased 
by 16 fold after the 4-hour treatment compared to control. The pretreatment of 
the Neuro-2a BU-1 cells with 50 i^M vitamin E for an hour partially suppressed 
the ROS production. The assay was repeated using a longer incubation time. It 
was found that the ROS level was two-fold higher than the control after 24-hour 
treatment (Figure 4.10). Therefore, the results suggest that ROS may play a role 
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Figure 4.9. Effect of indirubin-3'-oxime (I3M) on the induction of ROS in 
murine neuroblastoma Neuro-2a BU-1 cells. Neuro-2a BU-1 cells (10^ cells/ml) 
were either incubated with solvent control (0.01% DMSO) or treated with 1 i^M 
I3M at 37°C for 24 hours. The induced cells were then stained with 
dihydroethidium (DHE) for 30 minutes and the fluorescence was measured by a 
FACSCanto flow cytometer. 
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Figure 4.10. Induction of ROS in murine neuroblastoma Neuro-2a BU-1 
cells after 24 hours of treatment with I3M. Neuro-2a BU-1 cells (10^ cells/ml) 
were either incubated with solvent control (0.01% DMSO) or treated with 1 \xM 
I3M at 37°C for 24 hours. (A) The induced cells were then stained with dihydroethidium (DHE) for 30 minutes and the fluorescence was measured by a FACSCanto flow cytometer. (B) The percentage of cells in region Ml wascalculat d using WinMDI version 2.9 and the results from 3 dependent assaywere plot ed as a bar cha t. Each b r r p nts th  mean 土 S.D. for 3 independent experiments. * Significantly differ from he solv nt con rol, p < 0.01 - 1 7 2 -
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4.2.5 Expression of pro-apoptotic and anti-apoptotic proteins in the 
indirubin-3'-oxime-treated murine neuroblastoma Neuro-2a BU-1 
cells 
The activation of the intrinsic pathway in apoptosis depends on a group of 
proteins called Bcl-2 protein family. The BCL-2 proto-oncogene was identified 
and located at the chromosomal breakpoint of t(14;18) bearing human follicular 
B cell lymphoma (Bakhshi et al., 1985; Cleary and Sklar,- 1985). Around 20 
Bcl-2 family members have been found in mammals and functionally they can be 
classified into anti-apoptotic and pro-apoptotic proteins. Upon stresses such as 
cytokine deprivation or intracellular damages, the intrinsic pathway is initiated. 
Pro-apoptotic subfamily BH3-only proteins, including Bik, Bad, Bid, Bim, Bmf, 
Hrk, Noxa and Puma, will inhibit the anti-apoptotic activity of Bcl-2-like 
subfamily proteins include Bcl-2, Bcl-XL, Bcl-w, Mcl-l, Al and Bcl-B. The 
engagement of BH3-only proteins to Bcl-2 proteins displaces the anti-apoptotic 
Bcl-2 proteins from Bax-like apoptotic proteins which would then be activated 
and permeabilize the outer membrane of mitochondria. In our study, the 
expression of Bcl-2 family proteins was studied by Westem blot analysis. Li 
I3M-induced apoptotic Neuro-2a BU-1 cells, whether a disruption in the balance 
between pro-apoptotic and anti-apoptotic proteins was examined. (Cory et al” 
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2003). Figure 4.11 shows that the expression of an anti-apoptotic protein Bcl-Xt 
was decreased in a dose-dependent manner and a 66% reduction in the 
expression of Bcl-XL was seen after 24 hours of treatment with 1 i^M I3M. 
Interestingly, the expression of a pro-apoptotic protein Bax was increased by 
1.59 fold at 0.5 ^M I3M. The expression of uncleaved Bid also decreased in a 
dose-dependent manner. In addition, the expression of the inhibitor of 
caspase-activated DNase (ICAD), a target protein of caspase 3, was found to be 
decreased in the I3M-treated Neuro-2a BU-1 cells. 
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Figure 4.11. Effect of indirubin-3'-oxime on the expression of 
apoptosis-related proteins in murine neuroblastoma Neuro-2a BU-1 cells 
after 24 hour treatment. 
Neuro-2a cells (10^ cells/ml) were either incubated with solvent control (0.01% 
DMSO) or with various concentrations (0.5-1 |iM) of I3M at ZTC for 24 hours. 
The proteins of each sample were extracted and semi-quantified by Westem 
blotting as described in the Material and Methods section. The extracted protein 
were resolved by SDS- polyacrylamide gel electrophoresis and transferred onto 
PVDF membrane for probing with specific primary antibodies followed by 
horseradish peroxidase-conjugated secondary antibody. Then ECL detection 
assay was carried out in order to generate visible signal by exposing the 
membrane to X-ray films. (A) The representative protein bands on X-ray films 
were shown. (B) The relative intensity of each protein band was normalized with 
respect to P_actin and compared with the corresponding solvent control. Each bar 
represents the mean 土 S.E. for 3 independent experiments. 
* Significantly different from the solvent control, p < 0.01 
** Significantly different from the solvent control, p < 0.005 
•** Significantly different from the solvent control, p < 0.001 
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4.3 Discussion 
Upon DNA damage, a strictly controlled programmed cell death mechanism 
called apoptosis will be initiated to remove cells with non-repairable DNA 
damage and genetic instability. Apoptosis can also be induced after serum 
removal in vitro or in the presence of death signals from the extracellular 
environment or internal stress. Apoptosis is coordinated by different protein 
regulators including multi-BH proteins, Bcl-2 protein family, BH3-only proteins, 
apoptogenic factors in mitochondria and caspases. The activation of caspase 
cascade leads to the activation of executioner caspase 3，6 and 7 which in tum, 
cleave cellular substrates, leading to irreversible commitment to cell death. One 
of the substrates of executioner caspases is nuclear DNA. The cleavage of DNA 
starts in early stage in a fashion of large-scale at AT-rich region, producing 
50-200 kb DNA. It is followed by the formation of oligonucleosomal DNA 
fragments which give the characteristic DNA ladder in agarose gel 
electrophoresis (Lagarkova et al., 1995). In the present study, the induction of 
DNA fragmentation by I3M was detected by agarose gel electrophoresis and it 
increased in a dose-and time-dependent manner. The induction of DNA 
fragmentation in the Neuro-2a BU-1 cells was also confirmed by the quantitative 
Cell Death ELISA^^^^ kit. There are two distinct mechanisms for apoptotic DNA 
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fragmentation. In caspase-dependent pathway, caspase-activated DNase (CAD) 
is involved. CAD is produced as a dimer with its inhibitor, inhibitor of CAD 
(ICAD) in the cytoplasm of healthy cells (Enari et al., 1998). However, under 
apoptotic stimuli, the caspase cascade would be initiated, leading to caspase 3 
and 7 activation. ICAD is cleaved by the caspases, releasing the active CAD 
(McIlroy et al., 1999). The active CAD is translocated into nucleus where they 
cut the DNA. In the caspase-independent pathway, Endonuclease G (EndoG) and 
Apoptosis-inducing factor (AIF) are translocated from mitochondria to nucleus 
for their action (Li et al., 2001). However, it was found that the release ofEndoG 
and AIF is abolished in isolated mitochondria and after treatment with a 
pan-caspase inhibitor z-VAD-FMK. (Amoult et al., 2003). Therefore, the release 
ofEndoG and AIF should be downstream ofcaspase activation. To certain extent, 
the DNA fragmentation triggered by AIF and EndoG is caspase-dependent. 
Apoptotic DNA fragmentation is often accompanied with nuclear condensation. 
In our study, the nuclei ofNeuro-2a BU-1 cells treated with I3M were examined 
under a fluorescence microscope after Hoechst 33342 staining. The nuclei of 
solvent-treated cells appeared round and stained dim-blue as chromatin diffusely 
spread within the nuclei. However, the nuclei of I3M-treated cells shrank and 
highly-brightened spots were observed due to chromatin condensation. Similar to 
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DNA fragmentation, nuclear condensation is regulated by CAD and AIF. It has 
been suggested that AIF causes peripheral chromatin condensation while CAD 
causes advanced chromatin condensation (Susin et al, 2000). Moreover, a 
protein called apoptotic chromatin condensation inducer in the nucleus (Acinus) 
was reported by Sahara et al (1999) to be an important factor in nuclear 
condensation during apoptosis other than CAD. Acinus is cleaved and activated 
by caspase 3 to form a 23kDa fragment (Acinus p23). However, nuclear 
condensation is not abrogated in Acinus-knockdown cells by inducible RNA 
interference (Joselin et al., 2006). Therefore, the role of Acinus in DNA 
fragmentation or chromatin condensation remains controversial. 
In view of the ability ofI3M to induce apoptosis in the Neuro-2a BU-l cells, 
the next step was to elucidate which regulators in the apoptotic pathway did I3M 
target. Before we go further into this, it is important to aware that some 
checkpoints in the apoptotic pathway of neuroblastoma are impaired, rendering 
its ability to evade from chemotherapy that targets on the apoptosis pathway. The 
impairments include inactivation of extrinsic pathway, high expression of 
anti-apoptotic Bcl-2 family proteins and an inhibitor of apoptosis protein (IAP), 
survivin, loss of neurotrophin receptor p73 and p53 inactivation (Dole et al., 
1995; O'Connor et al., 2000; Teitz et al., 2000; Pahlman and Hoehner, 1996). 
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Normal cells with intact extrinsic pathway of apoptosis would initiate the 
cell death process upon the ligation of ligands such as Fas ligands or TRAIL to 
the cell surface death receptors. The recruitment of pro-caspase 8 to the cytosolic 
death domain of the death receptor via an adaptor protein FADD would form the 
death-inducing signaling complex (DISC). It is followed by oligomerization of 
pro-caspase 8，leading to activation of caspase 8 through autoproteolysis. The 
activation of pro-caspase 8 is inhibited constitutively by FLICE-inhibitory 
protein (c-FLIP) and DISC-inhibitory PED/PEA-15 protein (Ricci-Vitiani et al” 
2004). However, in neuroblastoma cells the loss of caspase 8 and TRAIL 
receptor expression could be frequently found in cell lines and primary tumours. 
Silencing in the promoter CpG islands of CASP8 through hypermethylation 
could be found in neuroblastoma cells with no expression of caspase 8 and thus 
resistant to apoptotic stimuli through death receptors. Hypermethylation of CpG 
islands could also be located in genes encoding the TRAIL receptors. Therefore, 
demethylating agents such as 5-azacytidine was used to reverse this inherent 
deficiency. It was found that 5-azacytidine could reverse hypermethylation and 
caused re-expression of caspase 8. Thus, the sensitivity to death receptor- and 
drug-induced apoptosis was restored (Fulda et al.’ 2001). Li our present study, 
I3M induced caspase 8 activity after 24-hour treatment in a dose-dependent 
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manner. Although the expression of caspase 8 was not checked at the 
transcriptional level, it could be possible that I3M restored the activity of caspase 
8 by demethylation. Mirubin has been shown to be an inhibitor of STAT3 
signaling in breast and prostatic cancers in vitro CNam et al., 2005). One of the 
target genes downstream in the STAT3 pathway is DNA methyltransferase I gene 
(Zhang et al., 2006). Therefore, it could be postulated that I3M might inhibit the 
STAT3 pathway, leading to suppression of DNA methyltransferase expression 
and thus the hypermethylation in CASP8. Other possible mechanisms by which 
I3M induced caspase 8 activity include down-regulation of c-FLIP expression • 
and up-regulation of TRAIL receptors expression. Further investigations are 
required to elucidate these possible underlying mechanisms. 
The activation of caspase 8 leads to two downstream processes. One is 
cleavage of Bid to truncated Bid (tBid). Another is the activation of executioner 
caspase 3 in the caspase cascade. Our data clearly show that the caspase 3 
activity was enhanced in I3M-treated Neuro-2a BU-1 cells. The caspase 3 
activity increased � 8 0 fold at 1 [iM I3M after 24 hour treatment. It agreed with 
the results in DNA fragmentation and chromatin condensation that activation of 
caspase 3 leads to subsequent activation of CAD. The activation of caspase 3 
could be detected as early at 8 hours. It implied that I3M could initiate the 
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apoptotic pathway, probably by demethylation of CASP8, followed by activation 
of the caspase cascade. It was reported that activation of caspase 3 started at 6 
hours and peaked at 12 hours in 5-azacytidine-treated mouse thymus in vivo 
(Tochitani et al., 2010). The other fate ofcaspase 8 activation is cleavage ofBid. 
The cleavage of Bid in I3M-treated Neuro-2a BU-1 cells was revealed by the 
decreased expression of the protein band of Bid at 22 kDa in Western blot 
analysis. Our results are in line with others who showed that activation of 
caspase 8 and cleavage of Bid were followed by conformational change of Bax 
in I3M-treated human cervical HeLa cells (Shi and Shen, 2008). It is known that 
the pro-apoptotic Bid would be cleaved by active caspase 8 to form the active 
tBid which is a BH3-only protein. BH3-only proteins, such as tBid, Bim, Bad 
and Puma, will activate downstream Bax-like proteins (Bax, Bak and Bok) by 
two proposed mechanisms. In the direct activation model, tBid and Bim bound to 
Bax and Bak directly will initiate their oligomerization on the outer 
mitochondrial membrane, forming the mitochondrial permeability transition 
pores (PTP). Other BH3-only proteins, e.g. Bad, could not activate Bax or Bak 
directly. Instead, they bound to pro-survival proteins and displaced tBid and Bim 
from them (Letai et al., 2002). In the indirect activation model, however, all the 
BH3-only proteins can bind to pro-survival proteins only and thereby prevented 
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the engagement of pro-survival proteins to Bax or Bak (Willis et al,, 2007). 
In cancer cells, the proportion of pro-survival proteins usually outweighed 
the proportion of pro-apoptotic proteins (Adams and Cory, 2007) Pro-survival 
Bcl-2 proteins are highly expressed in neuroblastoma cell lines and primary 
tumours (Dole et al., 1995). The high level of Bcl-2 proteins sequestered 
BH3-only proteins, preventing the activation and conformational changes ofBax 
and Bak. Thus, the mitochondrial pathway in neuroblastoma would be impaired 
and the tumour cells become 
( 
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in I3M-induced apoptosis in the Neuro-2a BU-1 cells by tBid, which acts as a 
bridge between the extrinsic and the intrinsic pathways, the activity of caspase 9 
was then examined. Our results showed that I3M induced an increase in caspase 
9 activity in the Neuro-2a BU-1 cells after 24 hour treatment. It has been shown 
that caspase 9 is an apical caspase in the intrinsic pathway. Cytochrome c which 
released from mitochondria with depolarized outer membrane would bind to and 
induce a conformational change in the scaffold protein Apaf-1. Recruitment of 
pro-caspase 9 leads to the formation of apoptosome, which provides surfaces 
with catalytic organization of the active site. The activated caspase 9 would 
further activate the executioner caspase 3 and 7. 
Other than the cross-talk from death receptor signals via tBid, the intrinsic 
pathway could be initiated due to internal stresses such as ROS production. 
Reactive oxygen species (ROS) are a group ofhighly reactive short-lived entities, 
including hydroxyl ( OH), superoxide (O2.), alkoxyl (R0 ), peroxyl ( R 0 0 ), 
nitroxyl radical (NO ), hydrogen peroxide (H2O2), organic hydroperoxides 
(ROOH), hypochlorous acid (H0C1) etc. (Simon et al., 2000). ROS are mainly 
produced in two different intracellular sites, namely, mitochondria and cytoplasm. 
In the inner mitochondrial membrane, the electron transport chain is responsible 
for the generation of ATP as an energy source for various biological processes. 
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The complex I and complex III in the electron transport chain are the primary 
sites of superoxide anions generation. Hydrogen peroxide would also be formed 
subsequently (Beyer et al., 1992). The other site is NADPH oxidase found in 
cytoplasm. The balance of ROS production and their elimination is strictly 
controlled by reduced glutathione (GSH) and thioredoxin (Trx) 
non-enzymatically and by superoxide dismutase (SOD), catalase and peroxidase 
enzymatically. Although ROS have been documented for their capacity in 
oncogenesis due to their damaging effects on cellular protein, lipids and DNA, 
their role in apoptosis induction in malignant cells has also been studied 
extensively (Clerkin et al, 2008; Ramsey et al, 2004). It has been demonstrated 
that arterunate, an anti-malarial drug, can induce apoptosis by the induction of 
ROS in several human neuroblastoma cell lines (Michaelis et al, 2009). Diallyl 
disulfide, an oil-soluble molecule found in garlic, could induce apoptosis with 
Bcl-2 down-regulation, cytochrome c release and activation of caspase 9 and 3. 
There was an oxidative burst and the apoptosis depended on c-Jun NH2-terminal 
Kinase/c-Jun pathway (Filomeni et al., 2003). The ROS-dependent 
apoptosis-inducing activity of different chemicals has been demonstrated in 
various tumour cell lines (Watson et al., 1997; Wedi et al., 1999; Herrera et al., 
2001; Renschler，2004; Chowdhury et al., 2009). In our present study, the ROS 
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production in the Neuro-2a BU-1 cells was determined by using the fluorogenic 
dye called dihydroethidium. The fluorescence signal was measured by flow 
cytometry. In I3M-treated Neuro-2a BU-1 cells, the induction ofROS production 
could be detected as early as 30 minutes and it increased in a dose-dependent 
manner up to 4 hours. The level of intracellular ROS remained higher than the 
control till 24 hours. We postulated that the I3M-induced apoptosis is dependent 
on ROS which play a role in both extrinsic and intrinsic pathway. In the extrinsic 
pathway, followed by the activation ofFas, FasL could trigger a rapid generation 
of ROS from NADPH oxidase. In addition, ROS could mediate ubiquitination 
and degradation of FLIP by proteosome (Wang et al” 2007). These added 
together can activate caspase 8，which had been confirmed in our caspase activity 
assay. In the intrinsic pathway, as ROS are produced in mitochondria, higher 
concentrations of ROS could attack the inner mitochondrial membrane and 
mitochondrial DNA. ROS can also activate JNK which then translocated to the 
outer mitochondrial membrane for Bax or Bak activation and/or Bcl-2 and Bcl-x[ 
inhibition. It could result in the opening of the permeability transition pores. 
Furthermore, ROS could cause peroxidation of cardiolipin, a protein associated 
with cytochrome c in inner mitochondrial membrane. The cytochrome c can then 
dissociate and release into the cytosol (Petrosillo et al.’ 2003; Shidoji et al,, 
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1999.). The early production ofROS implies that the ROS may play a role in the 
activation of I3M-induced apoptosis instead of being the by-products produced 
during apoptosis. Moreover, the level of intracellular ROS peaked at 4 hours 
providing a support that the activation of caspase 3 as early as 8 hours after I3M 
treatment and this could be due to ROS production and activation. However, the 
causative relationship between the I3M-induced ROS production and the 
activation of caspase 8，caspase 9 and 3 remains unclear and this is an intriguing 
aspect that awaits further investigation. 
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CHAPTER 5 
STUDIES ON THE 
DIFFERENTIATION-INDUCING 
ACTIVITY OF TRYPTANTHRIN ON 
NEUROBLASTOMA CELLS 
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5.1 Introduction 
Neuroblastoma is a solid tumour developed during the embryonic stage 
from the sympathoadrenal lineage of neural crest. Neural crest is a transient 
embryonal structure between neural and non-neural ectoderm. During the 
development, cells migrate from neural tube to form other cell types. However, 
neuroblastoma can only be found in sympathetic ganglion and adrenal medulla 
but not in other types of cells. The uncoupling of cell proliferation and 
differentiation of neural crest cells has been long suggested to be the reason 
underlying neuroblastoma development OSfakagawara, 2005). Several genes that 
may cause neuroblastoma or to modulate its biology, including MASH1, Phox 2a, 
Phox 2b，MYCN, Id-2 and p73, have been identified and they function after cell 
fate determination and direct the cells to sympathetic differentiation (Lasorella et 
al., 2000; Ichimiya et al； 2001; Nakagawa et al., 2002). In primary and 
metastatic neuroblastomas, different cell types in different histologically 
differentiated stages could be found, e.g. ganglioneuroblastoma and 
ganglioneuroma (Shimada et al., 1984). In neuroblastoma cell lines, three 
subtypes of cells with distinct morphologic, biochemical and tumourigenic 
properties have been identified, they are neuroblastic cells (N-type), 
non-neuronal substrate-adherent cells (S-type) and cells with intermediate 
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phenotype (I-type). I-type cells could differentiate into N- or S-type cells under 
selective culture conditions (Rettig et al.’ 1987; Biedler et al., 1997). Maturation 
of neuroblastoma can also be induced by cytotoxic chemotherapy (McLaughlin 
and Urich, 1977，Raafe/ al., 1982). Apart from the neuroblastoma cases reported 
with clinical manifestations, incidences of neuroblastomas that were 
cytologically identical with typical malignant neuroblastoma but with 
microscopic size and no metastasis had also been found. The term “in situ 
neuroblastoma" was coined by Beckwith and Perrin (1963). The incidence rate of 
in situ neuroblastoma was reported to be 40 times higher than that of sporadic 
one. However, only a very minute portion of these would become clinically 
apparent. The underlying reasons might be that neuroblastoma cells differentiate 
into more differentiated form or become normal medulla. Degeneration of 
tumours had also been suggested. In fact, spontaneous regression of 
neuroblastoma could be found in stage 4s patients even no treatment was 
received (D'Angio et al., 1971; Maris et al, 2007). From the cell development of 
neuroblastoma to the identification of in situ neuroblastoma, it was strongly 
suggested that neuroblastoma had potential to differentiate into mature neurons 
and shed a light on the possibility treating neuroblastoma with 
differentiation-inducing agents. 
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Retinol or vitamin A commonly found in our diet plays an important role in 
normal neural crest development. Retinol is metabolized into all-trans retinoic 
acid (ATRA) in the human body. ATRA has been shown to inhibit cell growth 
and induce neurite extension and differentiation in cell culture systems 
(Abemayor and Sidell, 1989; Sidell, 1982). The mechanism behind is probably 
due to the down-regulation of MYCN transcription and expression and 
up-regulation of CDK inhibitor p27 preceding Gi phase arrest and differentiation. 
The success of ATRA in inducing the differentiation of neuroblastoma in vitro 
has led to the development of differentiation therapy for neuroblastoma patients. 
Nowadays, c/5-retin0ic acid (CRA) is included following the high-dose 
chemotherapy and stem cell transplantation in the standard therapy. The 3-year 
event-free survival rate in high-risk patients had been increased (Matthay et al, 
1999). Other than using CRA as a single agent, it has been used in combination 
with histone deacetylase inhibitor SAHA or a chimeric anti-disialoganglioside 
(GD2) antibody Ch 14.18 in phase I and phase III trials respectively (Fouladi et 
al, 2008; Wagner and Danks, 2009). 
Tryptanthrin, a quinazoline alkaloid, had been demonstrated by our group to 
possess differentiation-inducing activity towards murine myeloid leukemia 
WEHI-3B JCS cells (Chan et al., 2009). Tryptanthrin-treated WEHI-3B JCS 
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cells showed increased vacuolation, and cytoplasm to nucleus ratio. The 
nitroblue-tetrazolium (NBT) reducing ability of WEHI-3B JCS cells was also 
increased. These findings suggest that tryptanthrin can induce both 
morphological and functional differentiation in the myeloid leukemia cells (Chan 
et al., 2009). The differentiation-inducing activity of tryptanthrin had also been 
demonstrated in monocytic U-937 and promyelocytic HL-60 leukemia cells with 
differentiation to monocytes or macrophages (Kimoto et a/.,-2001). 
In the present study, the investigation on differentiation-inducing ability of 
tryptanthrin on the murine neuroblastoma Neuro-2a BU-1 cells was investigated 
by both morphological and functional criteria. The cell size and internal 
granularity were measured by analyzing the parameters forward scatter light 
(FSC) and side scatter light (SSC) respectively using flow cytometry. The 
morphological features of the cells were examined under a light microscope after 
Hemacolor® staining. The activity of acetylcholine esterase (AChE), a 
biochemical marker for neuronal cell differentiation, was determined in a 
colorimetric assay. Moreover, the protein expression of the cytoskeleton protein 
and differentiation regulators in neuronal cells was also measured by 
immunoblotting. 
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5.2 Results 
5.2.1 Effects of tryptanthrin on the cell size and cellular complexity of the 
murine neuroblastoma Neuro-2a BU-1 cells 
FSC light refers to the diffracted light at low angles relative to the incident 
light source in the flow cytometer. The signal depends on the cell surface area of 
the laser-stroke cells. SSC light refers to the reflected and refracted light at 
higher angles. The signal depends on the internal complexity of the cells, ]n a 
differentiated neuronal cell, the cell size increased as a result of the enlargement 
of cell body and elongation of neurites. The cytoplasm of a differentiated cell 
would possess more organelles or granules such as neurotransmitter vesicles and 
therefore it has higher internal complexity. By measuring these two parameters, 
the tryptanthrin-treated Neuro-2a BU-1 cells could be examined for the induction 
of differentiation. Briefly, Neuro-2a BU-1 cells were incubated with tryptanthrin 
(0-2 ^iM) for 48，72 and 96 hours. Figure 5.1 shows the plot ofSSC against FSC. 
It can be seen that the cell population mainly shifted from the lower left (LL) 
quadrant to the upper left (UL) quadrant with some shifts to the upper right (UR) 
quadrant. The percentage cell population in UL quadrant had a 10-fold and 
20-fold increase at 2 [iM after 48-hour and 72-hour treatment respectively 
compared to the solvent control. Maximum increases in FSC and SSC 
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Figure 5.1. Effect of tryptanthrin on the cell size and internal complexity of 
murine neuroblastoma Neuro-2a BU-1 cells. Neuro-2a BU-1 cells (10VmL) 
were seeded ovemight and treated with various concentrations of tryptanthrin 
(0-2 ^iM) and 0.02% DMSO (solvent control) up to 96 hours. The cells were 
harvested and resuspended in PBS. The cell size and internal complexity ofBU-1 
cells were analysed by flow cytometry (BD FACSCanto). The data were 
analyzed using WinMDI Ver.2.9 software. 
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5.2.2 Morphological studies on tryptanthrin-treated murine neuroblastoma 
Neuro-2a BU-1 cells 
In view of the changes in cell size and internal complexity of the 
tryptanthrin-treated Neuro-2a BU-1 cells, the morphology of the cells was further 
studied on adherent preparations of the cells under light microscopy. The 
Neuro-2a BU-1 cells are mostly adhered onto the surface of tissue culture flask. 
The cells are roughly-rounded and neuroblast-like in shape. Extension ofneurites 
is an indicator of morphological differentiation in neuronal cells (Wu et al., 
1998). In the present study, Neuro-2a BU-1 cells were treated with tryptanthrin 
(0-2 ^iM) for 48 hours. The cells were fixed and stained with Hemacolor® dye for 
the visualization of nucleus and cytoplasm. Figure 5.2 shows that the 
solvent-treated Neuro-2a BU-1 cells were small and round in shape. They had 
the phenotype of neuroblasts with some tiny neurite-like cytoplasmic processes. 
However, the tryptanthrin-treated cells were elongated and showed outgrowth of 
bipolar or multi-polar neurites. The cell size and the cell body were also enlarged. 
Also, the density of cells decreased as the concentration of tryptanthrin was 
increased. This observation was due to the fact that tryptanthrin inhibited the cell 
growth in a dose-dependent manner. Moreover, differentiation of the cells was 
accompanied with the loss of the proliferative ability of the cells. 
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Figure 5.2. Effect of tryptanthrin on the cell morphology of murine 
neuroblastoma Neuro-2a BU-1 cells after 48-hour treatment. Neuro-2a 
BU-1 cells (5,000/ well) were seeded ovemight in a 24-well tissue culture 
microplate and treated with various concentrations of tryptanthrin (0-2 ^iM) and 
0.02% DMSO (solvent control) for 48 hours. The cells were washed with PBS 
and then fixed. Hemacolor® stained Neuro-2a BU-1 cells were observed for 
morphological changes under a light microscope. The scale bars represent 20 or 
50 i^m and magnification is 200X. 
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5.2.3 Effect of tryptanthrin on the acetylcholine esterase (AChE) activity in 
the murine neuroblastoma Neuro-2a BU-1 cells 
Acetylcholine esterase (AChE) is an enzyme that hydrolyzes acetylcholine 
in the synaptic cleft to terminate the excitation. The activity of AChE would 
increase during neuronal differentiation from neuroblasts to the matured neuronal 
cells. Moroever，AChE activity was found to be increased in drug-induced 
differentiation o f the murine neuroblastoma cells (Harkins et al, 1972; Kates et 
al., 1971; Schubert and Jacob, 1970). Therefore, the activity of AChE can be 
used as a biochemical marker to assay for the differentiation of the 
tryptanthrin-treated Neuro-2a BU-1 cells. In this study, Neuro-2a BU-1 cells 
were incubated with tryptanthrin (0-2 ^iM) for 48 hours and the AChE activity 
was then measured by a colorimetric method. As shown in Figure 5.3，the AChE 
activity in the cells increased in a dose-dependent manner and around 1.3-fold 
increase was seen at 2 ^iM tryptanthrin. Therefore, the Neuro-2a BU-1 cells were 
functionally differentiated upon treatment with tryptanthrin. 
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Fig 4.3. Effect of tryptanthrin on acetylcholinesterase (AChE) activity in 
murine neuroblastoma Neuro-2a BU-1 cells. Neuro-2a BU-1 cells (10VmL) 
were seeded ovemight and treated with various concentration of tryptanthrin (0-2 
^M) and 0.02% DMSO (solvent control) for 48 hours. The total cell lysates were 
mixed with acetylthiocholine iodide (substrate) and 5,5'-dithio(bis)nitrobenzoic 
acid for colorimetric measurement at 412 nm. The representative data o fa t least 
3 independent experiments was shown. 
* Significantly different from the solvent control, p < 0.02 
** Significantly different from the solvent control, p < 0.001 
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5.2.4. Effects of tryptanthrin on the expression of tau protein and other 
mediators involved in the neuronal differentiation pathway 
During differentiation of neuronal cells, a neuronal microtubule-associated 
protein called tau is responsible for the polymerization and stabilization of 
microtubules for the elongation of axons. In the present study, the expression of 
tau protein in the tryptanthrin-treated Neuro-2a BU-1 cells was examined by 
Westem blotting technique. Multipple bands were obtained indicating different 
phosphorylated forms of tau (data not shown). Figure 5.4 shows that the protein 
expression of tau increased in a dose-dependent manner with 4.5 fold increase at 
2 i^M of tryptanthrin. 
c-Myc is an oncogenic transcription factor that dimerizes with Max and the 
complex binds to specific DNA sequences, and regulating the expression of 
target genes involved in cell cycle regulation. Previous studies had shown that 
c-Myc could suppress differentiation in various cell types both in vitro and in 
vivo (Brewer, 2000; Facchini, and Penn et al., 1998) and its expression was 
down-regulated after drug-induced differentiation in different cell models (Chang 
et al., 2000; Larsson et al, 1994). Figure 5.4 shows that the protein expression of 
c-Myc was down-regulated in a dose-dependent manner. The Ras protein, a small 
GTPase which interacts with different cytoplasmic signaling molecules, has also 
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shown to induce differentiation in different cell models (Guerrero et al., 1986; 
Noda et al., 1985). In this study, the expression of the Ras protein was also found 
to be up-regulated (Figure 5.4). The c-Jun protein is a transcription factor 
involves in neuronal differentiation. Figure 5.4 shows that the protein expression 
ofc-Jun was up-regulated in a dose-dependent manner. 
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Figure 5.4. Effect of tryptanthrin on the expression of differentiation-related 
proteins in murine neuroblastoma Neuro-2a BU-1 cells after 48h-hour 
treatment. Neuro-2a BU-1 cells (10^ cells/ml) were either incubated with 
solvent control (0.02% DMSO) or with various concentrations (0.5-2 ^iM) of 
tryptanthrin at 2>TC for 24 hours. The proteins of each sample were extracted and 
semi-quantified by Westem blotting as described in the Material and Methods 
section. The extracted protein were resolved by SDS-polyacrylamide gel 
electrophoresis and transferred onto PVDF membrane for probing with specific 
primary antibodies followed by horseradish peroxidase-conjugated secondary 
antibody. Then ECL detection assay was carried out in order to generate visible 
signal by exposing the membrane to X-ray films. (A) The representative protein 
bands on X-ray films were shown. (B) The relative intensity of each protein band 
was normalized with respect to p-actin and compared with the corresponding 
solvent control. Each bar represents the mean 土 S.E. in at least 3 independent 
experiments. 
* Significantly different from the solvent control, p < 0.05 
** Significantly different from the solvent control, p < 0.01 




As discussed in Chapter 3, tryptanthrin could inhibit the proliferation of the 
murine neuroblastoma Neuro-2a BU-1 cells in a dose-dependent manner. The 
cells were arrested in G2/M phase as early as 24 hours after treatment with 
tryptanthrin. We postulated that observed growth-inhibitory activity of 
tryptanthrin could be due to induction of apoptosis or differentiation. Therefore, 
in this chapter the differentiation-inducing activity of tryptanthrin was examined. 
Murine neuroblastoma Neuro-2a (BU-1 subclone) is a good cell model for the 
investigation of differentiation induced by tryptanthrin. The Neuro-2a cell line 
has been widely used as the model in neuronal cell differentiation studies. For 
example, the cell line was used as the model for the investigation of signaling 
pathways involved in neuronal differentiation after serum removal 
(Evangelopoulos et al., 2005). It was also used to demonstrate the induction of 
neuritogenesis by synthetic sialyl compounds (Tsuji et al, 1988). The subcloned 
Neuro-2a BU-1 cell line was used for the studies of the growth-inhibitory and 
neuronal differentiation-inducing activities of euxanthone, a compound isolated 
from the medicinal plant Polygala caudate (Mak et al； 2000; 2001). Moreover, 
previous work in our laboratory also showed that the soy isoflavones daidzein 
can inhibit the proliferation of the Neuro-2a BU-1 cells through modulation of 
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cell cycle regulation and triggering of neuronal cell apoptosis (Lo et al., 2007). 
The present study suggests that tryptanthrin could induce neuronal differentiation 
in the Neuro-2a BU-1 cells as evidenced by the increase in cell size and internal 
complexity. It is well documented that an increase of neuronal cell size and an 
extension of neurite length could be observed in neuronal cells after 
differentiation induction (Kojima et al., 1994; Tsokos et al., 1987). The 
formation of neurosecretory granules in differentiated human neuroblastoma cell 
lines was reported by Tsokos et al (1987). It is conceivable that the increased 
internal complexity or cellular granularity found in our study may be attributed to 
the formation of neurosecretory granules in tryptanthrin-induced differentiated 
Neuro-2a BU-1 cells and this awaits further investigation. After the preliminary 
study, more specific assays were used to confirm the differentiation-inducing 
activity of tryptanthrin. The morphological study after Hemacolor® staining 
clearly showed that the untreated Neuro-2a BU-1 cells with neuroblast-like 
phenotypes became flat and elongated in shape after treatment with tryptanthrin. 
The extension of either bipolar or multipolar neurites was also observed. Li the 
functional study, AChE was chosen as the biochemical marker for neuronal 
differentiation. It is well documented that the activity of AChE in Neuro-2a cells 
would increase after the induction of cholinergic neuron-like differentiation 
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(Kojima et al, 1994; Hasegawa et al, 2000). The present study showed that the 
activity ofAChE increased 1.3 fold at 2 i^M tryptanthrin. The activity peaked at 
48 hours and decreased thereafter (data not shown). Morphological study also 
showed that the neurites became shortened in length and more cells that were 
large, swollen and spherical in shape appeared after 72 hours of trytanthrin 
treatment (data not shown). It is possible that the differentiated cells may die 
following induction ofcell differentiation, though the mode ofcell death remains 
unclear and awaits further investigation. Nevertheless, tryptanthrin was capable 
of inducing morphological and functional differentiation in the murine 
neuroblastoma Neuro-2a BU-1 cells. 
Tau belongs to a group of microtubule-associated proteins that function in 
microtubule assembly and neurite polarization. It is highly expressed in neuronal 
cells but can also be found in other cell types. Its expression is closely related to 
the axonal outgrowth. An earlier study showed that the mRNA and protein 
expression of tau were increased by doxorubicin and okadaic acid in the human 
neuroblastoma SH-SY5Y cells (Uberti et al., 1997). m this study, the expression 
of the tau protein in tryptanthrin-treated Neuro-2a BU-1 cells was increased in a 
dose-dependent manner, indicating that axon development may be involved in 
the extension of neurites as seen in the morphological study. However, whether 
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the neurites sprouting from the differentiated Neuro-2a BU-1 cells are axons 
remains to be determined. As a preliminary study to examine the protein factors 
that may play a role in the tryptanthrin-induced differentiation, the protein 
expression ofan oncogenic transcription factor, c-Myc and a small GTPase ofthe 
Ras family, the Ras protein, was examined. 
Myc is a protooncogene that is commonly found to be deregulated in a 
variety of cancers. One of the examples is the amplification of N-Myc in 
aggressive neuroblastoma. Myc regulates various cellular processes including 
cell cycle progression, cell proliferation, differentiation, apoptosis and 
transformation. c-Myc protein is an oncogenic transcription factor that its 
down-regulation is accompanied by cell differentiation in human and murine 
neuroblastoma cell lines (Chang et al., 2000; Gonda and Metcalf, 1984; Chen et 
al” 1994; Larcher et aL, 1991). Recently, a group of scientists in Spain reported 
the possibility of cooperation between Myc and Ras in the abrogation of 
dexamethasone-induced differentiation in the pheochromocytoma UR61 cells 
(Vaque et al., 2008). Other than c-Myc, the Ras protein was also reported to be 
involved in neuronal cell differentiation. Three Ras proteins, namely H-Ras, 
K-Ras and N-Ras are found in mammals. They are small GTPases being 
activated by the cell surface G protein-coupled receptors. Moreover, they are also 
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found in Golgi and endosome. Ras works with MEK and ERK in a cascade 
through the activation of the Raf family kinases (McKay and Morrison, 2007). 
Ras activation during differentiation has been reported in pheochromocytoma 
cells and adipocytic precursor cells (Guerrero et al,, 1986; Noda et al,, 1985). 
According to Vaque and co-workers (2007)，c-Myc could inhibit Ras-mediated 
differentiation by preventing the up-regulation of c-Jun, which is a 
transcriptional factor involved in neuronal cell differentiation (Eriksson et al., 
2007). Our preliminary results show that tryptanthrin could down-regulate the 
expression of c-Myc. We hypothesize that this may release the suppression of 
c-Jun up-regulation from c-Myc and leads to up-regulation of Ras expression in 
the Neuro-2a BU-1 cells. To support this hypothesis, more experiments should be 




CONCLUSIONS AND FUTURE 
PERSPECTIVES 
- 2 0 9 -
Chapter 6 
Conclusions and Future Perspectives 
Tryptanthrin is a quinazoline alkaloid and indirubin-3'-oxime is an indole 
alkaloid derived from a traditional Chinese medicinal plant called Banlangen. 
They have been found to possess diverse pharmacological activities such as 
anti-cancer, anti-inflammatory and anti-microbial activities, hi the present study, 
both tryptanthrin and indirubin-3'-oxime have been shown to exert potent 
anti-proliferative effect on the murine neuroblastoma Neuro-2a BU-1 cells by 
distinctive action mechanisms. 
Indirubin-3'-oxime (I3M) was shown to inhibit the cell proliferation in the 
Neuro-2a BU-1 cells and two other human neuroblastoma cell lines. The 
doubling time of the Neuro-2a BU-1 cells was found to be increased by I3M, in 
other words, the cell proliferation was suppressed by I3M. However, the viability 
of I3M-treated cells remained high. Therefore, the growth-inhibitory effect of 
I3M on Neuro-2a BU-1 cells cannot be attributed to the direct cytotoxicity of the 
compound. In addition, I3M was also demonstrated to suppress the tumour cell 
clonogenicity in vitro. Moreover, the cytotoxicity of I3M on normal cells was 
found to be minimal at the concentrations which effectively suppress the 
proliferation of the neuroblastoma cells. On the other hand, doxorubicin exerted 
significant direct cytotoxicity on the normal cells. The results suggest that I3M 
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could be a potential candidate, either alone or in combination with some 
conventional drugs for treatment of neuroblastoma. Similarly, tryptanthrin could 
inhibit the proliferation ofNeuro-2a BU-1 cells and suppressed the tumour cell 
clonogenicity in vitro without killing the normal cells. It would also be 
interesting to examine whether there is synergistic effect on the proliferation of 
/ 
Neuro-2a BU-1 cells in the combination ofI3M with tryptanthrin or doxorubicin 
in the future studies. Investigation of the cell cycle profile of I3M-treated or 
tryptanthrin-treated Neuro-2a BU-1 cells showed two distinct patterns of cell 
cycle arrest. I3M arrested the Neuro-2a BU-1 cells in Go/Gi phase while 
tryptanthrin arrested the neuroblastoma cells in G2M phase. Mechanistic 
studies suggest that tryptanthrin-induced G2/M phase arrest was dependent on the 
down-regulation of cyclin A, cyclin B and CDK 1 which can form cyclin 
A/CDK1 and cyclin B/CDK1 complexes. The reduced expression of individual 
components ofthese complexes might lower the level of cyclin/CDK complexes 
which play an important role in G2-M phase transition and progression in mitosis. 
In the future, the protein expression of CDK inhibitors regulating G2M phase 
progression, including p21^'"^^'P\ p27^'^^ and p57^'P^ should be examined. Due 
to the time constraints, the molecular events involved in the I3M-induced Go/Gi 
phase arrest have not been examined in the present study. The inhibitory effect of 
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I3M on the CDK activities is well-documented (Hoessel et al., 1999). It would 
be interesting to see if I3M could also modulate the expression of Gi phase 
regulatory cyclins and CDKs in addition to targeting on the CDK activities. 
The I3M-treated Neuro-2a BU-1 cells appeared to be shrinkage in size when 
observed under the microscope (data not shown). It may be a typical 
morphological change seen in apoptotic cells. Therefore, the apoptosis-inducing 
effect of I3M on the Neuro-2a BU-1 cells was studied. The ability of I3M to 
induce apoptosis in Neuro-2a BU-1 cells was supported by the appearance of 
DNA fragmentation in agarose gel electrophoresis and the Cell Death ELISA^^^^ 
kit which provides a quantitative measurement on DNA fragmentation. The 
nuclear morphology was also changed in the I3M-treated Neuro-2a BU-1 cells. 
Chromatin condensation appeared as intense-fluorescent scattered spots inside 
the nuclei after Hoechst 33342 staining. The DNA fragmentation and chromatin 
condensation have been reported to follow either caspase-dependent (e.g. CAD) 
or independent (e.g. AIF) mechanisms which are worth to explore in 
I3M-induced apoptosis. For example, siRNA could be used to knockdown CAD 
and any changes in nuclear morphology and DNA fragmentation could be 
examined. Our preliminary results show that the expression of ICAD, a protein 
which can form dimer with CAD and thus keeps it in an inactive form, was 
. » 
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reduced and possibly cleaved in the I3M-treated Neuro-2a BU-1 cells as revealed 
by Western blot analysis. Moreover, our results suggest that the I3M-induced 
apoptosis may involve both the extrinsic and the intrinsic pathways. Activation 
ofcaspase 8 by I3M may be mediated through the re-expression of CASP8 which 
cleaves the Bid into tBid. The translocation of tBid to mitochondria may lead to 
the activation ofpro-apoptotic proteins like Bax or Bak. It would be ofinterest to 
examine the expression of caspase 8 at the transcriptional level in the 
I3M-treated cells in the future so as to test this hypothesis. The expression ofBax, 
a pro-apoptotic protein which can oligomerize to form pores on the outer 
mitochondrial membrane, was found to be increased, and the expression of 
Bcl-XL was decreased in I3M-treated Neuro-2a BU-1 cells. Therefore, I3M could 
reduce the inhibitory effect ofBcl -XL on the formation o fPTP that are composed 
of Bax. Other than the two proteins studied, other pro-apoptotic proteins such as 
Bad and Bak, and pro-survival proteins Bcl-2, Bcl-w and Mcl-l should be 
studied in the future. The effect of I3M on mitochondrial membrane potential 
should also be established using JC-1 staining in order to confirm the effect of 
I3M on the intrinsic apoptotic pathway. Moreover, the release of cytochrome c, 
EndoG and AIF into cytosol or nucleus should be investigated by examining 
their protein expression in mitochondrial fraction and cytosolic/nuclear fraction. 
• • 
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On the other hand, the activity of caspase 9，an initiator caspase in the intrinsic 
pathway, and the activity of caspase 3，an executioner caspase in the caspase 
cascade, were found to be increased in the I3M-treated Neuro-2a BU-1 cells. The 
role of caspase 3，8 and 9 activation in I3M-induced apoptosis could be 
confirmed by using caspase-specific inhibitors z-DEVD-FMK, z-IETD-FMK 
and z-LEHD-FMK for caspase 3，8 and 9 respectively in the DNA fragmentation 
or Cell Death ELISA^^^^ kit assays. -
In this study, an increased level ofintracellular ROS was induced by I3M in 
a time-dependent manner, probably either through an increase in ROS production 
or a decrease in antioxidant level inside the cells. Therefore, the intracellular 
levels of SOD and GSH should be measured in future work. It is believed that 
ROS are involved in the mitochondrial-dependent apoptotic pathway. However, 
whether the blockage of ROS production by pretreatment of the cells with 
superoxide dismutase (SOD) or N-acetylcysteine (NAC) would abrogate the 
I3M-induced apoptosis has not yet been determined. Besides, other ROS 
detection reagents such as 2',7'-dichlorodihydrofluorescein diacetate (H2DCFDA) 
could be used to detect the production of other ROS including hydroxyl ( OH), 
nitric oxide (NO.) and hydrogen peroxide (H2O2). 
Interesting enough, the apoptosis-inducing effect was not demonstrated by 
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treatment of Neuro-2a BU-1 cells with tryptanthrin. Instead, tryptanthrin 
triggered neuronal differentiation in the Neuro-2a BU-1 cells. The 
tryptanthrin-treated Neruo-2a BU-1 cells showed an increase in cell size and 
granularity as revealed by flow cytometric analysis. Moreover, tryptanthrin also 
induced morphological differentiation in the Neuro-2a BU-1 cells as shown by 
the enlarged cell body and the outgrowth of neurites. Functional differentiation 
was shown by the increase in the acetylcholine esterase activity in 
tryptanthrin-treated cells. The possible cytoplasmic cytoskeleton changes in 
differentiated Neuro-2a BU-1 cells were also investigated, and our results show 
that the expression of tau protein was increased in a dose-dependent manner. 
This implies that axonal growth might be involved in the neurite elongation. Di 
the future, the expression of MAP-2 and neurofilaments should be examined by 
confocal microscopy to check whether the neurites are dendrites or/and axons 
respectively. Moreover, the protein expression of c-Myc was found to be 
decreased whereas that of Ras was increased in tryptanthrin-treated Neuro-2a 
BU-1 cells. Both of these proteins are known to play a role in neuroblastoma 
differentiation. Recently, the differentiation in Neuro-2a cells by G alpha i/o 
pathway has been described by Ma'ayan et al (2009). The Ras/Raf/MEKVMAPK 
cascade is involved in the differentiation of Neuro-2a cells. It has been reported 
. • 
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that the protein expression of p53 would be down-regulated during 
differentiation of neuronal cells (MacCallum et al., 1996). Our preliminary 
results (data not shown) in Westem blot analysis showed that the expression of 
p53 in tryptanthrin-treated cells was decreased in a dose-dependent manner. It is 
worthy to investigate the role of p53 in tryptanthrin-induced neuronal 
differentiation and to explore other possible pathways that might be involved. 
Taken together, our present study shows that both I3M and tryptanthrin 
could inhibit the proliferation of the murine neuroblastoma Neuro-2a BU-1 cells 
in a dose- and time-dependent manner. Mechanistic studies indicate that I3M 
arrested the cells in Go/Gi phase and induced apoptosis of the neuroblastoma 
cells. Interestingly, tryptanthrin arrested the cells in G2fM phase and induced 
neuronal cell differentiation. Attempts should be made to investigate the 
relationship between the cell cycle arrest in different phases and the subsequent 
induction of apoptosis or differentiation. More detailed underlying mechanisms 
for the anti-tumour activities of Banlangen alkaloids in neuroblastoma cells 
should also be studied. Furthermore, other aspects of anti-cancer strategies, for 
example, anti-invasive, anti-metastatic and anti-angiogenic properties of these 
two alkaloids are also worthy of future investigations. In order to make the 
results more relevant to human clinical cases, human neuroblastoma cell lines 
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such as SH-SY5Y and LA-N-1 should be used as the models for in vitro and in 
vivo studies in future. By identifying the cellular and molecular mechanisms by 
which Banlangen alkaloids might modulate the proliferation, differentiation and 
apoptosis of neuroblastoma cells, it is hoped that novel and more effective 
therapeutic approaches for the treatments of some forms of neuroblastoma, based 
on inhibition of tumour cell proliferation, restoration of the neuronal cell 
differentiation and maturation processes, and induction of apoptotic cell death, 
can be developed with higher efficacy and minimal side effects. 
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